Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FUNGICIDAL HALOMETHYL KETONES, HYDRATES AND ENOL ETHERS
Document Type and Number:
WIPO Patent Application WO/2023/158602
Kind Code:
A1
Abstract:
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Inventors:
AKWABOAH DANIEL (US)
CHITTABOINA SRINIVAS (US)
MCMAHON TRAVIS CHANDLER (US)
FENG ZHENGAO (US)
WANG HENGBIN (US)
Application Number:
PCT/US2023/012882
Publication Date:
August 24, 2023
Filing Date:
February 13, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
FMC CORP (US)
International Classes:
C07D213/30; A01N43/54; A01N43/78; C07D213/46; C07D231/04; C07D231/12; C07D237/14; C07D237/22; C07D249/04; C07D261/08; C07D277/32; C07D405/12; C07D419/14
Domestic Patent References:
WO2022133114A12022-06-23
WO2021183707A22021-09-16
WO2020056090A12020-03-19
WO1992016527A11992-10-01
WO2020056090A12020-03-19
WO2021183707A22021-09-16
WO2018080859A12018-05-03
WO2018118781A12018-06-28
WO2018187553A12018-10-11
WO2019010192A12019-01-10
WO2003024222A12003-03-27
WO1991013546A11991-09-19
WO2008124092A22008-10-16
WO2014066120A12014-05-01
WO2020097012A12020-05-14
Foreign References:
EP3660007A12020-06-03
EP3428151A12019-01-16
US6350892B12002-02-26
US3060084A1962-10-23
US4172714A1979-10-30
US4144050A1979-03-13
US3920442A1975-11-18
DE3246493A11984-06-20
US5180587A1993-01-19
US5232701A1993-08-03
US5208030A1993-05-04
GB2095558A1982-10-06
US3299566A1967-01-24
US3235361A1966-02-15
US3309192A1967-03-14
US2891855A1959-06-23
US20080187553A12008-08-07
US6406690B12002-06-18
Other References:
PLAYER M R ET AL: "SYNTHESIS OF 2,7-DISUBSTITUTED-5,6-DIMETHYLPYRROLO- 2,3-D3?4-1,3-OXAZIN-4-ONES AS3ANTIFUNGAL AGENTS", JOURNAL OF HETEROCYCLIC CHEMISTRY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 31, no. 1, 1 January 1994 (1994-01-01), pages 209 - 214, XP000943939, ISSN: 0022-152X, DOI: 10.1002/JHET.5570310135
ERNEST L. ELIELSAMUEL H. WILEN: "Stereochemistry of Organic Compounds", JOHN WILEY & SONS, 1994
ORGANIC LETTERS, vol. 22, no. 17, 2006, pages 3745 - 3748
TETRAHEDRON, vol. 47, 1991, pages 3207 - 3258
CHEM. COMMUNICATIONS, vol. 49, no. 95, 2013, pages 11133 - 11148
MARCHSMITH: "March's Advanced Organic Chemistry", 2001, BRITISH CROP PROTECTION COUNCIL
BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 64, no. 9, 1991, pages 2730 - 2745
MAGNETIC RESONANCE IN CHEMISTRY, vol. 29, 1991, pages 675 - 678
"Comprehensive Heterocyclic Chemistry", vol. 4-6, 1984, PERGAMON PRESS, OXFORD
"Comprehensive Heterocyclic Chemistry II", vol. 2-4, 1996, PERGAMON PRESS, OXFORD
JOURNAL OF ORGANIC CHEMISTRY, vol. 52, no. 22, 1987, pages 5026 - 5030
CHEMICAL COMMUNICATIONS, vol. 49, no. 95, 2013, pages 11133 - 11148
JOURNAL OF FLUORINE CHEMISTRY, vol. 18, 1981, pages 117 - 129
"Journal of the Chemical Society", CHEMICAL COMMUNICATIONS, no. 2, 1989, pages 83 - 84
JOURNALOF FLUORINE CHEMISTRY, vol. 44, 1989, pages 377 - 394
ANGEW. CHEM., INT. ED., vol. 37, no. 6, 1998, pages 820 - 821
J. ORG. CHEM., vol. 64, 1999, pages 2873
CHEM. COMMUN., vol. 48, 2012, pages 9610
TETRAHEDRON, vol. 51, 1995, pages 2573 - 2584
TETRAHEDRON, vol. 70, 2014, pages 4668 - 4674
JOURNAL OF ORGANIC CHEMISTRY, vol. 52, 2013, pages 4171 - 4176
EUR. J. ORG. CHEM., vol. 2013, pages 3658 - 3661
"Master Organic Chemistry (Online", ON ACETALS AND HEMIACETALS, 28 May 2010 (2010-05-28), Retrieved from the Internet
"Preparative Organic Chemistry", 1972, WILEY, NEW YORK, pages: 381 - 387
NATURAL PRODUCT REPORTS, vol. 32, no. 4, 2015, pages 605 - 632
CHEMICAL SOCIETY REVIEW, vol. 38, 2009, pages 606 - 631
CHEMICAL SOCIETY REVIEW, vol. 00, 2014, pages 1 - 29
JOURNAL OF SAUDI CHEMICAL SOCIETY, vol. 16, 2012, pages 97 - 116
ORGANIC LETTERS, vol. 13, no. 12, 2011, pages 2988 - 2991
TETRAHEDRON, vol. 61, 2005, pages 10827 - 10852
HETEROCYCLES, vol. 40, 1995, pages 271 - 278
JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 8124 - 8134
JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1990, pages 2697 - 706
SYNTHESIS, vol. 5, 1989, pages 396 - 3977
J. CHEM. SOC., PERKIN TRANS., vol. 1, 1988, pages 1663 - 1668
TETRAHEDRON, vol. 44, 1988, pages 3025 - 3036
JOURNALOF ORGANIC CHEMISTRY, vol. 53, no. 6, 1988, pages 1323 - 1326
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, WILEY: NEW YORK
WATKINS ET AL.: "Handbook of Insecticide Dust Diluents and Carriers", 1950, DORLAND BOOKS
"annual American and International Editions", MCCUTCHEON'S DIVISION, THE MANUFACTURING CONFECTIONER PUBLISHING CO, article "McCutcheon's Emulsifiers and Detergents"
SISELYWOOD: "Encyclopedia of Surface Active Agents", 1964, CHEMICAL PUBL. CO., INC.
A. S. DAVIDSONB. MILWIDSKY: "Synthetic Detergents", 1987, JOHN WILEY AND SONS
CHEMICAL ENGINEERING, vol. 2, 4 December 1967 (1967-12-04), pages 147 - 48
"Perry's Chemical Engineer's Handbook,", 1963, MCGRAW-HILL, pages: 8 - 57
P. KOSTERS ET AL.: "Seed Treatment: Progress and Prospects,", BCPC MONGRAPH NO. 57, 1994
T. S. WOODS: "Pesticide Chemistry and Bioscience, The Food Environment Challenge", 1999, THE ROYAL SOCIETY OF CHEMISTRY, article "The Formulator's Toolbox - Product Forms for Modern Agriculture", pages: 120 - 133
KLINGMAN: "Weed Control as a Science", 1961, JOHN WILEY AND SONS, INC., pages: 81 - 96
HANCE ET AL.: "Weed Control Handbook", 1989, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD
"Developments in formulation technology", 2000, PJB PUBLICATIONS
K. H. KUCK ET AL.: "Modern Selective Fungicides - Properties, Applications and Mechanisms of Action", 1995, GUSTAV FISCHER VERLAG: NEW YORK, pages: 205 - 258
"The Pesticide Manual, 13th Edition", 2003, BRITISH CROP PROTECTION COUNCIL
Attorney, Agent or Firm:
STERNBERG, Charlene G. (US)
Download PDF:
View/Download PDF      PDF Help
Claims:
CLAIMS What is claimed is: 1. A compound selected from Formula 1, tautomers, N-oxides, and salts thereof, wherein T is selected from the group consisting of: wherein the bond extending to the left is attached to A; R1 is CF3, CHF2 or CCl3; W is O, S or NR3; R3 is H, cyano, nitro, C(=O)OH, benzyl, C1-C4 alkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, OR3a or NR3bR3c; R3a is H, benzyl, C1-C4 alkyl, C2-C4 alkylcarbonyl or C2-C4 haloalkylcarbonyl; R3b is H, C1-C4 alkyl, C2-C4 alkylcarbonyl or C2-C4 haloalkylcarbonyl; R3c is H or C1-C4 alkyl; or R3b and R3c are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; X is O, S or NR4a; Y is O, S or NR4b; R4a and R4b are each independently H, hydroxy or C1-C4 alkyl; R2a and R2b are each independently H, C1-C4 alkyl, C2-C4 alkenyl, C3-C15 trialkylsilyl or C3-C15 halotrialkylsilyl; or R2a and R2b are taken together with the atoms X and Y to which they are attached to form a 5- to 7-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 2 carbon atom ring members are independently selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy and C1-C2 haloalkoxy on carbon atom ring members; R2c is C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl or trifluoromethylsulfonyl, each optionally substituted with up 2 substituents independently selected from cyano, hydroxy, SC≡N and C1-C2 alkoxy; R2d is H, cyano, halogen or C1-C4 alkyl; when T is T-1 or T-2, then A is A1-A2-CR5aR5b, wherein A1 is connected to J, and CR5aR5b is connected to T; when T is T-3, then A is A1-A2, wherein A1 is connected to J, and A2 is connected to T; A1 is CR5aR5b, N(R6), O or S; A2 is a direct bond, CR5aR5b, N(R6), O or S; each R5a and R5b is independently H, cyano, hydroxy, halogen, C(=O)OCH3 or C1-C4 alkyl; each R6 is independently H, C(=O)H, cyano, C1-C4 alkyl or C2-C4 alkylcarbonyl; J is selected from the group consisting of: wherein the bond extending to the left is attached to L, and the bond extending to the right is attached to A; each R7 is independently F, Cl, I, Br, cyano, methyl, trifluoromethyl or methoxy; q is 0, 1, 2, 3 or 4; L is (CR8aR8b)n; each R8a and R8b is independently H, halogen, cyano, hydroxy, nitro, C1-C3 alkyl, C1- C3 haloalkyl, C1-C3 alkoxy or C1-C3 haloalkoxy; n is 0, 1, 2 or 3; G is phenyl is substituted with 1 to 3 substituents independently selected from R9 and optionally substituted with up to 3 substituents independently selected from R10; G is a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring is substituted with 1 to 3 substituents independently selected from R9 and optionally substituted with up to 3 substituents independently selected from R10; G is a 3- to 7-membered nonaromatic ring or an 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O)2, each ring is substituted with 1 to 3 substituents independently selected from R9 and optionally substituted with up to 3 substituents independently selected from R10; each R9 is independently -(CR11aR11b)mR9a, C(=O)NR12aR12b, C(R12e)=NR12f, C2- C6 alkyl(thiocarbonyl) or C2-C6 alkoxy(thiocarbonyl); each m is independently 1, 2 or 3; each R9a is independently C(=O)NR12cR12g, OC(=O)NR12cR12d or ONR12iR12j; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C3-C9 alkynylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C4-C9 cycloalkylalkylcarbonyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C9 cycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C8 cyanoalkoxy, C2-C8 alkylthioalkoxy, C2-C8 alkylsulfinylalkoxy, C2-C8 alkylsufonylalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C2-C8 alkylcarbonylthio, C3-C9 alkenylcarbonylthio, C3-C9 alkynylcarbonylthio, C5-C9 cycloalkylcarbonylthio, C2-C8 alkoxycarbonylthio, C2-C8 alkylaminocarbonylthio, C3-C9 dialkylaminocarbonylthio, C5-C9 cycloalkylalkylcarbonylthio, C2-C8 alkylcarbonylamino, C3-C9 alkenylcarbonylamino, C3-C9 alkynylcarbonylamino, C5-C10 cycloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C2-C8 alkylaminocarbonylamino, C3-C9 dialkylaminocarbonylamino, C5-C10 cycloalkylalkylcarbonylamino, C2-C8 alkenylthio, C2-C8 alkynylthio, C2-C8 alkylthioalkylthio, C4-C10 cycloalkylalkylthio, C2-C8 cyanoalkylthio, C2-C8 alkoxyalkylthio, C2-C8 alkylsulfinylalkylthio, C2-C8 alkylsufonylalkylthio, C3-C9 alkoxycarbonylalkylthio, C3-C9 alkylaminocarbonylalkylthio, C4-C10 dialkylaminocarbonylalkylthio, C3-C6 alkenyloxycarbonyl, C4-C10 cycloalkoxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl, C3-C9 alkoxycarbonylcarbonyl, C3-C8 trialkylsilylalkoxy or C3-C15 halotrialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R13; each R10 is independently cyano, halogen, hydroxy, nitro, -SH, SF5, CH(=O), C(=O)OH, NR14aR14b, C(=O)NR14aR14b, C(=O)C(=O)NR14aR14b, C(=S)NR14aR14b, C(R15)=NR16, N=CR17NR18aR18b or -U-V-Q; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloalkenyl, C1-C6 alkoxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C3-C7 cycloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 alkylaminosulfinyl, C2-C6 dialkylaminosulfinyl, C1-C6 alkylsulfonyloxy, C1-C6 alkylsulfonylamino, C2-C6 alkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C6 alkoxycarbonyl, C3-C6 alkenyloxycarbonyl, C3-C6 alkynyloxycarbonyl, C4-C7 cycloalkoxycarbonyl, C3-C6 alkoxycarbonylcarbonyl, C2-C6 alkylcarbonyloxy, C4-C7 cycloalkylcarbonyloxy, C2-C6 alkoxycarbonyloxy, C4-C7 cycloalkoxycarbonyloxy, C2-C6 alkylaminocarbonyloxy, C4-C7 cycloalkylaminocarbonyloxy, C2-C6 alkylcarbonylamino, C4-C7 cycloalkylcarbonylamino, C2-C6 alkoxycarbonylamino, C4-C7 cycloalkoxycarbonylamino, C2-C6 alkylaminocarbonylamino, C4-C7 cycloalkylaminocarbonylamino or C2-C6 dialkoxyphosphinyl, each optionally substituted with up to 3 substituents independently selected from R19; each R11a and R11b is independently H, halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C6 haloalkynyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C4 haloalkoxycarbonyl, C2-C4 alkylcarbonyloxy or C2-C4 haloalkylcarbonyloxy; or R11a and R11b are taken together with the carbon atom to which they are attached to form a 3-to 6-membered carbocyclic or heterocyclic ring, each ring containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O)2, each ring optionally substituted with up to 3 substituents independently selected from halogen and C1-C3 alkyl; each R12a is independently C1-C6 haloalkoxy, C1-C6 hydroxyalkoxy, C2-C6 cyanoalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C3-C8 cycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C6 alkoxyalkoxy, C3-C8 trialkylsilyloxy and C3-C15 halotrialkylsilyloxy; or phenyl-CH2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen, C1-C3 alkyl and C1-C3 haloalkyl; each R12b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C3-C8 dialkylaminoalkyl or C4-C10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C3-C15 trialkylsilyl or C3-C15 halotrialkylsilyl; each R12c is independently H, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, C2-C4 alkylthioalkyl, C2-C4 alkylsulfinylalkyl, C2-C4 alkylsulfonylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C5 alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-C5 alkylaminocarbonyl or C3-C5 dialkylaminocarbonyl; each R12d is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylcarbonyl, C2-C6 alkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C3-C8 dialkylaminoalkyl or C4-C10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C3-C15 trialkylsilyl and C3-C15 halotrialkylsilyl; or R12c and R12d are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C1-C3 alkyl; each R12e is independently NH2, C2-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C5-C10 alkylcycloalkylalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy, C4-C10 cycloalkylalkoxy, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthio, C1-C6 haloalkylthio, C2-C6 alkylthioalkyl, C1-C6 alkylsulfinyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C3-C8 dialkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C3-C8 alkylcarbonyl or C2-C8 haloalkylcarbonyl; each R12f is independently hydroxy or NR20aR20b; or C1-C6 alkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C4-C10 cycloalkylalkoxy, C2-C4 alkylcarbonyloxy, C2-C5 alkoxycarbonyloxy, C2-C5 alkylaminocarbonyloxy or C3-C5 dialkylaminocarbonyloxy, each optionally substituted with up to 3 substituents independently selected from cyano, halogen, hydroxy and C(=O)OH; each R12g is H, cyano, hydroxy, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C2-C4 alkoxyalkyl, C2-C4 haloalkoxyalkyl, C1-C4 alkylsulfonyl or C1-C4 haloalkylsulfonyl; each R12i and R12j is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C2-C4 alkylcarbonyl or C2-C4 haloalkylcarbonyl; or R12i and R12j are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O)2, each ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R13 is independently -C(=O)OH, halogen, cyano, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl or C3-C6 cycloalkyl; each R14a is independently H, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C2-C4 haloalkynyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, C2-C4 alkylthioalkyl, C2-C4 alkylsulfinylalkyl, C2-C4 alkylsulfonylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C5 alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-C5 alkylaminocarbonyl or C3-C5 dialkylaminocarbonyl; each R14b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 hydroxyalkyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C3-C8 dialkylaminoalkyl or C4-C10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C3-C15 trialkylsilyl and C3-C15 halotrialkylsilyl; or R14a and R14b are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C1-C3 alkyl; each R15 is independently H, cyano, halogen, methyl, methoxy, methylthio or methoxycarbonyl; each R16 is independently hydroxy or NR20aR20b; or C1-C4 alkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C2-C4 alkylcarbonyloxy, C2-C5 alkoxycarbonyloxy, C2-C5 alkylaminocarbonyloxy or C3-C5 dialkylaminocarbonyloxy, each optionally substituted with up to 1 substituent selected from cyano, halogen, hydroxy and C(=O)OH; each R17 is independently H, methyl, methoxy or methylthio; each R18a and R18b is independently H or C1-C4 alkyl; each R19 is independently amino, cyano, halogen, hydroxy, nitro, -SH, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkoxyalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C5 alkoxycarbonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C5 alkylaminocarbonyl, C3-C5 dialkylaminocarbonyl, C3-C5 alkylthioalkylcarbonyl, C3-C15 trialkylsily, C3-C15 halotrialkylsilyl, C(R21)=NOR22 or C(R23)=NR24; each U is independently a direct bond, C(=O)O, C(=O)N(R25) or C(=S)N(R26), wherein the atom to the left is connected to G, and the atom to the right is connected to V; each V is independently a direct bond; or C1-C6 alkylene, C2-C6 alkenylene, C3-C6 alkynylene, C3-C6 cycloalkylene or C3-C6 cycloalkenylene, wherein up to 1 carbon atom is C(=O), each optionally substituted with up to 3 substituents independently selected from halogen, cyano, nitro, hydroxy, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy and C1-C2 haloalkoxy; each Q is independently phenyl or phenoxy, each optionally substituted with up to 2 substituents independently selected from R27; or each Q is independently a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R27; or each Q is independently a 3- to 7-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O)2, each ring optionally substituted with up to 2 substituents independently selected from R27; each R20a is independently H, C1-C4 alkyl or C2-C4 alkylcarbonyl; each R20b is independently H, cyano, C1-C5 alkyl, C2-C5 alkylcarbonyl, C2-C5 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C5 alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-C5 alkylaminocarbonyl or C3-C5 dialkylaminocarbonyl; or R20a and R20b are taken together to form a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; each R21 and R23 is independently H, cyano, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl or C1-C3 alkoxy; or phenyl optionally substituted with up to 2 substituents independently selected from halogen and C1-C3 alkyl; each R22 is independently H, C1-C5 alkyl, C1-C5 haloalkyl, C2-C5 alkenyl, C2-C5 haloalkenyl, C2-C5 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C5 alkylcarbonyl or C2-C5 alkoxycarbonyl; or each R22 is phenyl optionally substituted with up to 2 substituents independently selected halogen and C1-C3 alkyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and C1-C3 alkyl; each R24 is independently H, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C4 alkoxy, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; each R25 and R26 is independently H, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C4 alkoxycarbonyl or C2-C4 haloalkoxycarbonyl; each R27 is independently halogen, cyano, hydroxy, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C1-C4 alkoxy, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; Z is a direct bond, O, S(=O)p, N(R28), C(=O), C(=O)N(R28), NR28C(=O), N(R28)C(=O)N(R28), N(R28)C(=S)N(R28), OC(=O)N(R28), N(R28)C(=O)O, S(O)2N(R28), N(R28)S(=O)2 or N(R28)S(O)2N(R28), wherein the atom to the right is connected to L; each R28 is independently H, C1-C3 alkyl, C1-C3 alkoxy, C2-C3 alkylcarbonyl or C2-C3 alkoxycarbonyl; and p is 0, 1 or 2; provided that: (a) when A1 is N(R6), O or S, then A2 is a direct bond or CR5aR5b; and (a) when A2 is N(R6), O or S; then A1 is CR5aR5b. 2. A compound Claim 1 wherein T is T-2 or T-3; R1 is CF3; X is O; Y is O; R2a and R2b are each independently H or C1-C2 alkyl; or R2a and R2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members; R2c is methyl or ethyl; R2d is H or methyl; A1 is CR5aR5b or O; A2 is a direct bond, CR5aR5b or O; each R5a and R5b is independently H or methyl; J is J-1, J-6 or J-14; each R7 is independently F, Cl or methyl; q is 0, 1 or 2; each R8a and R8b is independently H, halogen or methyl; n is 0, 1 or 2; G is selected from the group consisting of: , wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3; and y is 0, 1, 2 or 3; each R9 is independently -(CR11aR11b)mR9a, C(=O)NR12aR12b, C(R12e)=NR12f or C2-C4 alkoxy(thiocarbonyl); each m is independently 1 or 2; each R9a is independently OC(=O)NR12cR12d; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C3-C9 alkynylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C4-C9 cycloalkylalkylcarbonyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C4-C10 cycloalkylalkoxy, C2-C8 cyanoalkoxy, C2-C8 alkylsufonylalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C2-C8 alkylcarbonylthio, C2-C8 alkylcarbonylamino, C3-C9 alkenylcarbonylamino, C3-C9 alkynylcarbonylamino, C5-C10 cycloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C3-C6 alkenyloxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl, C3-C9 alkoxycarbonylcarbonyl or C3-C8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R13; each R10 is is independently halogen, C(=O)NR14aR14b or -U-V-Q; or C2-C5 alkoxycarbonyl, C3-C5 alkenyloxycarbonyl, C3-C5 alkynyloxycarbonyl or C4-C6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R19; each R11a and R11b is independently H, methyl, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl or C2-C3 haloalkoxycarbonyl; each R12a is independently C1-C6 haloalkoxy, C1-C6 hydroxyalkoxy, C2-C6 cyanoalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy or C4-C8 cycloalkylalkoxy; or phenyl-CH2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; each R12b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl or C3-C8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; each R12c is independently H, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C5 alkoxycarbonyl, C2-C5 alkylaminocarbonyl or C3-C5 dialkylaminocarbonyl; each R12d is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl or C3-C8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; or R12c and R12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R12e is independently C2-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkoxy, C1-C6 haloalkoxy, C4-C5 cycloalkylalkoxy or C2-C6 alkoxyalkyl; each R12f is independently C1-C4 alkoxy, C2-C4 alkenyloxy, C4-C6 cycloalkylalkoxy, C2-C4 alkylcarbonyloxy or C2-C5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R13 is independently halogen, cyano, C2-C4 alkenyl, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio, C1-C4 alkylsufonyl or C3-C6 cycloalkyl; each R14a is independently H, C1-C2 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; each R14b is independently H, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropylmethyl or C2- C4 alkoxyalkyl; or R14a and R14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R19 is independently cyano, halogen, C1-C2 alkyl, C1-C2 haloalkyl, C3-C6 cycloalkyl, C1-C2 alkoxy, C1-C2 haloalkoxy, C2-C3 alkylcarbonyl, C2-C3 haloalkylcarbonyl or C2-C3 alkoxycarbonyl; each U is independently a direct bond, C(=O)O or C(=O)N(R25); each V is independently a direct bond; or C1-C3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C1-C2 alkyl, C1-C2 alkoxy and C1-C2 haloalkoxy; each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R27; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R27; each R25 is independently H, cyano, hydroxy or C1-C2 alkyl; each R27 is independently halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 alkoxy; and Z is a direct bond, O, NH, C(=O), C(=O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O)2NH, NHS(=O)2 or NHS(=O)2NH. 3. A compound of Claim 2 wherein R2a and R2b are each independently H or methyl; or R2a and R2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member; A1 is O; A2 is a direct bond, CH2 or O; J is J-1; q is 0; each R8a and R8b is independently H or methyl; n is 0 or 1; G is G-1, G-3, G-12 or G-13; x is 1 or 2; y is 0 or 1; each R9a is independently OC(=O)NR12cR12d; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C3-C9 alkynylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C4-C9 cycloalkylalkylcarbonyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C4-C10 cycloalkylalkoxy, C2-C8 cyanoalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C2-C8 alkylcarbonylamino, C3-C9 alkenylcarbonylamino, C3-C9 alkynylcarbonylamino, C2-C8 alkoxycarbonylamino, C3-C6 alkenyloxycarbonyl or C3-C9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R13; R10 is halogen, C(=O)NR14aR14b; or C2-C5 alkoxycarbonyl, C3-C5 alkenyloxycarbonyl, C3-C5 alkynyloxycarbonyl or C4-C6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R19; each R11a and R11b is independently H, methyl or C2-C3 alkoxycarbonyl; each R12a is independently C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C2-C4 alkynyloxy or C4-C6 cycloalkylalkoxy; or phenyl-CH2O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R12b is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C2-C4 alkynyl, C3-C5 cycloalkyl, C4-C6 cycloalkylalkyl, C2-C4 alkoxyalkyl, C2-C4 haloalkoxyalkyl, C2-C4 alkylaminoalkyl or C3-C5 dialkylaminoalkyl; each R12c is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl or C2-C5 alkoxycarbonyl; each R12d is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C3-C5 cycloalkyl, C4-C6 cycloalkylalkyl, C2-C4 alkoxyalkyl, C2-C4 haloalkoxyalkyl, C2-C4 alkylaminoalkyl or C3-C5 dialkylaminoalkyl; each R12e is independently C2-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkenyl, C2-C4 alkoxy, C1-C3 haloalkoxy or C4-C5 cycloalkylalkoxy; each R12f is independently C1-C4 alkoxy, C2-C4 alkenyloxy or C4-C6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R13 is independently halogen, cyano, C2-C4 alkenyl, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio or C3-C5 cycloalkyl; R14a is H or C1-C2 alkyl; R14b is H, C1-C2 alkyl, C1-C2 haloalkyl or cyclopropylmethyl; each R19 is independently halogen; and Z is a direct bond, O, NH or C(=O). 4. A compound of Claim 3 wherein R2a and R2b are each H; or R2a and R2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R2c is ethyl; R2d is H; A2 is a direct bond; each R8a and R8b is H; n is 1; G is G-12; x is 1; y is 0; R9 is -CH2R9a, -CH2CH2R9a, C(=O)NR12aR12b, C(R12e)=NR12f or C2-C4 alkoxy(thiocarbonyl); R9a is OC(=O)NR12cR12d; or C2-C6 alkylcarbonyloxy, C3-C6 alkenylcarbonyloxy, C4- C6 cycloalkylcarbonyloxy, C2-C6 alkoxycarbonyloxy or C3-C6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R13; R12a is C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C4-C6 cycloalkylalkoxy or phenyl-CH2O; R12b is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C3-C5 cycloalkyl, C4-C6 cycloalkylalkyl or C2-C4 alkoxyalkyl; R12c is H, C1-C3 alkyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl or C2-C5 alkoxycarbonyl; R12d is H, C1-C3 alkyl, C1-C3 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C3-C5 cycloalkyl, C4-C6 cycloalkylalkyl or C2-C4 alkoxyalkyl; R12e is C2-C3 alkyl, C2-C4 alkoxy, C1-C3 haloalkoxy or C4-C5 cycloalkylalkoxy; R12f is C1-C4 alkoxy, C2-C4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R13 is independently halogen, cyano, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio or C3-C5 cycloalkyl; and Z is a direct bond. 5. A compound of Claim 4 wherein T is T-3; R9 is -CH2R9a, C(=O)NR12aR12b or C2-C4 alkoxy(thiocarbonyl); R9a is OC(=O)NR12cR12d; or C2-C6 alkylcarbonyloxy, C3-C6 alkenylcarbonyloxy, C4-C6 cycloalkylcarbonyloxy, C2-C6 alkoxycarbonyloxy or C3-C6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R13; R12a is C2-C4 alkenyloxy, C2-C4 haloalkenyloxy, C4-C5 cycloalkylalkoxy or phenyl-CH2O; R12b is H, C1-C2 alkyl or C1-C2 haloalkyl; R12c is H or C1-C3 alkoxy; R12d is H, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropylmethyl or C2-C4 alkoxyalkyl; and each R13 is independently Br, Cl, F, cyano, methoxy, C2-C4 alkoxycarbonyl, C1-C2 alkylthio or cyclopropyl. 6. A compound of Claim 5 wherein G is G-12 connected at the 1-position to Z and the 4-position is connected to R9; or G is G-12 connected at the 1-position to Z and the 3-position is connected to R9; or G is G-12 connected at the 1-position to Z and the 5-position is connected to R9; R9 is -CH2R9a; R9a is OC(=O)NR12cR12d; or C2-C6 alkylcarbonyloxy or C2-C6 alkoxycarbonyloxy each optionally substituted with up to 1 substituent selected from R13; R12c is methoxy; R12d is H, methyl or cyclopropylmethyl; and R13 is Br, Cl, F, cyano, methoxy, CH3OC(=O), CH3S or cyclopropyl. 7. A compound of Claim 1 wherein T is T-2 or T-3; R1 is CF3; X is O; Y is O; R2a and R2b are each H; or R2a and R2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R2c is methyl or ethyl; R2d is H; A1 is O; A2 is a direct bond; each R5a and R5b is H; J is J-1, J-6 or J-14; each R7 is F; q is 0, 1 or 2; each R8a and R8b is H; n is 1 or 2; G is selected from the group consisting of:

, wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring; x is 1; and y is 0 or 1; R9 is -(CR11aR11b)mR9a, C(=O)NR12aR12b, C(R12e)=NR12f or C2-C4 alkoxy(thiocarbonyl); m is 1; R9a is OC(=O)NR12cR12d; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C3- C9 alkynylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C4-C9 cycloalkylalkylcarbonyloxy, C2-C8 alkenyloxy, C2- C8 alkynyloxy, C3-C9 cycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C8 cyanoalkoxy, C2-C8 alkylsufonylalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C2-C8 alkylcarbonylthio, C2-C8 alkylcarbonylamino, C3-C9 alkenylcarbonylamino, C3-C9 alkynylcarbonylamino, C5-C10 cycloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C3-C6 alkenyloxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl, C3-C9 alkoxycarbonylcarbonyl or C3-C8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R13; R10 is halogen or C2-C3 alkoxycarbonyl; each R11a and R11b is independently H, methyl or C2-C3 alkoxycarbonyl; R12a is C1-C6 haloalkoxy, C1-C6 hydroxyalkoxy, C2-C6 cyanoalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C4-C8 cycloalkylalkoxy or C2-C6 alkoxyalkoxy; or phenyl-CH2O, the phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; R12b is H, C1-C2 alkyl or C1-C2 haloalkyl; R12c is H, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl, C2-C5 alkoxycarbonyl, C2-C5 alkylaminocarbonyl or C3-C5 dialkylaminocarbonyl; R12d is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C2-C6 cyanoalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 halocycloalkylalkyl, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl or C3-C8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl; or R12c and R12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; R12e is C2-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkoxy, C1-C6 haloalkoxy, C4-C5 cycloalkylalkoxy or C2-C6 alkoxyalkyl; R12f is C1-C4 alkoxy, C2-C4 alkenyloxy, C4-C6 cycloalkylalkoxy, C2-C4 alkylcarbonyloxy or C2-C5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R13 is independently halogen, cyano, C2-C4 alkenyl, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio, C1-C4 alkylsufonyl or C3-C6 cycloalkyl; and Z is a direct bond, O, NH or C(=O. 8. A compound of Claim 7 wherein R2c is ethyl; J is J-1; n is 1; G is G-12 or G-20; y is 0; R9a is OC(=O)NR12cR12d; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C3-C9 alkynylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C4-C9 cycloalkylalkylcarbonyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C9 cycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C8 cyanoalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C2-C8 alkylcarbonylthio, C2-C8 alkylcarbonylamino, C5-C10 cycloalkylcarbonylamino, C2-C8 alkoxycarbonylamino, C3-C6 alkenyloxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl or C3-C9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R13; each R11a and R11b is independently H or EtOC(=O); R12a is C1-C6 haloalkoxy, C2-C6 cyanoalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C4-C8 cycloalkylalkoxy or C2-C6 alkoxyalkoxy; R12b is H or methyl; R12c is C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C1-C5 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C4-C7 cycloalkylcarbonyl or C2-C5 alkoxycarbonyl; R12d is H or methyl; R12e is C2-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkenyl, C2-C4 alkoxy, C1-C3 haloalkoxy or C4-C5 cycloalkylalkoxy; R12f is C1-C4 alkoxy, C2-C4 alkenyloxy, C4-C6 cycloalkylalkoxy or C2-C4 alkylcarbonyloxy; each R13 is independently halogen, cyano, C1-C4 alkoxy, C2-C4 alkoxycarbonyl, C1-C4 alkylthio or C3-C5 cycloalkyl; and Z is a direct bond; 9. A compound of Claim 8 wherein T is T-3; q is 0; G is G-12; R9a is OC(=O)NR12cR12d; or C2-C8 alkylcarbonyloxy, C3-C9 alkenylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C8 alkoxycarbonyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C9 cycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C8 alkoxycarbonylalkoxy, C3-C9 alkoxycarbonylcarbonyloxy, C3-C6 alkenyloxycarbonyl or C3-C9 alkoxycarbonylcarbonyl, each optionally substituted with up to 2 substituents independently selected from R13; each R11a and R11b is H; R12a is C1-C6 haloalkoxy, C2-C6 cyanoalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C4-C8 cycloalkylalkoxy or C2-C6 alkoxyalkoxy; R12c is C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C4-C5 cycloalkylcarbonyl or C2-C5 alkoxycarbonyl; R12e is C2-C3 alkoxy, C1-C3 haloalkoxy or C4-C5 cycloalkylalkoxy; R12f is C1-C4 alkoxy, C2-C4 alkenyloxy or C4-C5 cycloalkylalkoxy; and R13 is Br, Cl, F, cyano, methoxy, C2-C4 alkoxycarbonyl, C1-C2 alkylthio or cyclopropyl. 10. A compound of Claim 9 wherein R9 is -(CR11aR11b)mR9a, C(=O)NR12aR12b or C(R12e)=NR12f; R9a is OC(=O)NR12cR12d; or C2-C6 alkylcarbonyloxy, C4-C9 cycloalkylcarbonyloxy, C2-C6 alkoxycarbonyloxy, C2-C6 alkenyloxy, C2-C6 alkynyloxy, C4-C10 cycloalkylalkoxy, C2-C6 alkoxycarbonylalkoxy or C3-C6 alkenyloxycarbonyl, each optionally substituted with up to 2 substituents independently selected from R13; R12a is C1-C6 haloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy or C4-C8 cycloalkylalkoxy; R12b is H; R12c is C1-C3 alkyl, C1-C3 alkoxy, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl or C2-C5 alkoxycarbonyl; R12e is ethoxy; R12f is C1-C4 alkoxy; and R13 is Br, Cl, F, cyano, methoxy, CH3OC(=O), CH3S or cyclopropyl. 11. A compound of Claim 1 which is selected from the group: O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1- yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate; (Z)-(1-(4-((2-ethoxy-3,3,3-trifluoroprop-1-en-1-yl)oxy)benzyl)-1H-pyrazol-4- yl)methyl methoxy(methyl)carbamate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl propanoate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl acetate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 2-methoxyacetate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 3-methylbutanoate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 2-methylpentanoate; 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N- (phenylmethoxy)-1H-pyrazole-4-carboxamide; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 3,3,3-trifluoropropanoate; 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N- (2,2,2-trifluoroethoxy)-1H-pyrazole-4-carboxamide; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 3-methylbutanoate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 2,2-dimethylpropanoate; 1-[[1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl] 2-methyl ethanedioate; [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl 3-(methylthio)propanoate; and 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H- pyrazol-4-yl]methyl methyl carbonate. 12. A fungicidal composition comprising (a) a compound of Claim 1; and (b) at least one other fungicide. 13. A fungicidal composition comprising (a) a compound of Claim 1; and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. 14. A method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Claim 1.
Description:
TITLE FUNGICIDAL HALOMETHYL KETONES, HYDRATES AND ENOL ETHERS FIELD OF THE INVENTION This invention relates to certain halomethyl ketones, hydrates and enol ethers, their N-oxides and salts, and to mixtures and compositions comprising such halomethyl ketones, hydrates and enol ethers and methods for using such derivatives and their mixtures and compositions as fungicides. BACKGROUND OF THE INVENTION The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds which are more effective, less costly, less toxic, environmentally safer or have different sites of action. PCT Patent Publication WO 2020/056090 WO 2021/183707 discloses halomethyl ketones and hydrates derivatives and their use in fungicidal compositions. SUMMARY OF THE INVENTION This invention is directed to compounds of Formula 1 (including all stereoisomers), tautomers, N-oxides, hydrates (and solvates thereof), and salts thereof: wherein T is selected from the group consisting of: wherein the bond extending to the left is attached to A; R 1 is CF 3 , CHF 2 or CCl 3 ; W is O, S or NR 3 ; R 3 is H, cyano, nitro, C(=O)OH, benzyl, C 1 -C 4 alkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, OR 3a or NR 3b R 3c ; R 3a is H, benzyl, C 1 -C 4 alkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 haloalkylcarbonyl; R 3b is H, C 1 -C 4 alkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 haloalkylcarbonyl; R 3c is H or C 1 -C 4 alkyl; or R 3b and R 3c are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; X is O, S or NR 4a ; Y is O, S or NR 4b ; R 4a and R 4b are each independently H, hydroxy or C 1 -C 4 alkyl; R 2a and R 2b are each independently H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 3 -C 15 trialkylsilyl or C 3 -C 15 halotrialkylsilyl; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5- to 7-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 2 carbon atom ring members are independently selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy on carbon atom ring members; R 2c is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl or trifluoromethylsulfonyl, each optionally substituted with up 2 substituents independently selected from cyano, hydroxy, SC≡N and C 1 -C 2 alkoxy; R 2d is H, cyano, halogen or C 1 -C 4 alkyl; when T is T-1 or T-2, then A is A 1 -A 2 -CR 5a R 5b , wherein A 1 is connected to J, and CR 5a R 5b is connected to T; when T is T-3, then A is A 1 -A 2 , wherein A 1 is connected to J, and A 2 is connected to T; A 1 is CR 5a R 5b , N(R 6 ), O or S; A 2 is a direct bond, CR 5a R 5b , N(R 6 ), O or S; each R 5a and R 5b is independently H, cyano, hydroxy, halogen, C(=O)OCH 3 or C 1 -C 4 alkyl; each R 6 is independently H, C(=O)H, cyano, C 1 -C 4 alkyl or C 2 -C 4 alkylcarbonyl; J is selected from the group consisting of:

wherein the bond extending to the left is attached to L, and the bond extending to the right is attached to A; each R 7 is independently F, Cl, I, Br, cyano, methyl, trifluoromethyl or methoxy; q is 0, 1, 2, 3 or 4; L is (CR 8a R 8b ) n ; each R 8a and R 8b is independently H, halogen, cyano, hydroxy, nitro, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy or C 1 -C 3 haloalkoxy; n is 0, 1, 2 or 3; G is phenyl is substituted with 1 to 3 substituents independently selected from R 9 and optionally substituted with up to 3 substituents independently selected from R 10 ; G is a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring is substituted with 1 to 3 substituents independently selected from R 9 and optionally substituted with up to 3 substituents independently selected from R 10 ; G is a 3- to 7-membered nonaromatic ring or an 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) 2 , each ring is substituted with 1 to 3 substituents independently selected from R 9 and optionally substituted with up to 3 substituents independently selected from R 10 ; each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f , C 2 -C 6 alkyl(thiocarbonyl) or C 2 -C 6 alkoxy(thiocarbonyl); each m is independently 1, 2 or 3; each R 9a is independently C(=O)NR 12c R 12g , OC(=O)NR 12c R 12d or ONR 12i R 12j ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylthioalkoxy, C 2 -C 8 alkylsulfinylalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 3 -C 9 alkenylcarbonylthio, C 3 -C 9 alkynylcarbonylthio, C 5 -C 9 cycloalkylcarbonylthio, C 2 - C 8 alkoxycarbonylthio, C 2 -C 8 alkylaminocarbonylthio, C 3 -C 9 dialkylaminocarbonylthio, C 5 -C 9 cycloalkylalkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 2 -C 8 alkylaminocarbonylamino, C 3 -C 9 dialkylaminocarbonylamino, C 5 -C 10 cycloalkylalkylcarbonylamino, C 2 -C 8 alkenylthio, C 2 -C 8 alkynylthio, C 2 -C 8 alkylthioalkylthio, C 4 -C 10 cycloalkylalkylthio, C 2 -C 8 cyanoalkylthio, C 2 -C 8 alkoxyalkylthio, C 2 -C 8 alkylsulfinylalkylthio, C 2 -C 8 alkylsufonylalkylthio, C 3 -C 9 alkoxycarbonylalkylthio, C 3 -C 9 alkylaminocarbonylalkylthio, C 4 -C 10 dialkylaminocarbonylalkylthio, C 3 -C 6 alkenyloxycarbonyl, C 4 -C 10 cycloalkoxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl, C 3 -C 8 trialkylsilylalkoxy or C 3 -C 15 halotrialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 ; each R 10 is independently cyano, halogen, hydroxy, nitro, -SH, SF 5 , CH(=O), C(=O)OH, NR 14a R 14b , C(=O)NR 14a R 14b , C(=O)C(=O)NR 14a R 14b , C(=S)NR 14a R 14b , C(R 15 )=NR 16 , N=CR 17 NR 18a R 18b or -U-V-Q; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 3 -C 7 cycloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfinyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylaminosulfinyl, C 2 -C 6 dialkylaminosulfinyl, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 alkylsulfonylamino, C 2 -C 6 alkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 3 -C 6 alkenyloxycarbonyl, C 3 -C 6 alkynyloxycarbonyl, C 4 -C 7 cycloalkoxycarbonyl, C 3 -C 6 alkoxycarbonylcarbonyl, C 2 -C 6 alkylcarbonyloxy, C 4 -C 7 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy, C 4 -C 7 cycloalkoxycarbonyloxy, C 2 -C 6 alkylaminocarbonyloxy, C 4 -C 7 cycloalkylaminocarbonyloxy, C 2 -C 6 alkylcarbonylamino, C 4 -C 7 cycloalkylcarbonylamino, C 2 -C 6 alkoxycarbonylamino, C 4 -C 7 cycloalkoxycarbonylamino, C 2 -C 6 alkylaminocarbonylamino, C 4 -C 7 cycloalkylaminocarbonylamino or C 2 -C 6 dialkoxyphosphinyl, each optionally substituted with up to 3 substituents independently selected from R 19 ; each R 11a and R 11b is independently H, halogen, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 2 -C 4 haloalkoxycarbonyl, C 2 -C 4 alkylcarbonyloxy or C 2 -C 4 haloalkylcarbonyloxy; or R 11a and R 11b are taken together with the carbon atom to which they are attached to form a 3-to 6-membered carbocyclic or heterocyclic ring, each ring containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) 2 , each ring optionally substituted with up to 3 substituents independently selected from halogen and C 1 -C 3 alkyl; each R 12a is independently C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy, C 3 -C 8 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 6 alkoxyalkoxy, C 3 -C 8 trialkylsilyloxy and C 3 -C 15 halotrialkylsilyloxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen, C 1 -C 3 alkyl and C 1 -C 3 haloalkyl; each R 12b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 6 -C 14 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 4 -C 10 cycloalkoxyalkyl, C 3 -C 8 alkoxyalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfinylalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl, C 2 -C 6 haloalkylaminoalkyl, C 3 -C 8 dialkylaminoalkyl or C 4 -C 10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 3 -C 15 trialkylsilyl or C 3 -C 15 halotrialkylsilyl; each R 12c is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, C 2 -C 4 alkylthioalkyl, C 2 -C 4 alkylsulfinylalkyl, C 2 -C 4 alkylsulfonylalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkoxycarbonylalkyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; each R 12d is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 6 -C 14 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 4 -C 10 cycloalkoxyalkyl, C 3 -C 8 alkoxyalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfinylalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylcarbonyl, C 2 -C 6 alkylaminoalkyl, C 2 -C 6 haloalkylaminoalkyl, C 3 -C 8 dialkylaminoalkyl or C 4 -C 10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 3 -C 15 trialkylsilyl and C 3 -C 15 halotrialkylsilyl; or R 12c and R 12d are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C 1 -C 3 alkyl; each R 12e is independently NH 2 , C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 4 -C 10 cycloalkoxyalkyl, C 3 -C 8 alkoxyalkoxyalkyl, C 2 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 2 -C 6 alkylthioalkyl, C 1 -C 6 alkylsulfinyl, C 2 -C 6 alkylsulfinylalkyl, C 2 -C 6 alkylsulfonyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl, C 2 -C 6 haloalkylaminoalkyl, C 3 -C 8 dialkylaminoalkyl, C 4 -C 10 cycloalkylaminoalkyl, C 3 -C 8 alkylcarbonyl or C 2 -C 8 haloalkylcarbonyl; each R 12f is independently hydroxy or NR 20a R 20b ; or C 1 -C 6 alkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy, C 2 -C 5 alkoxycarbonyloxy, C 2 -C 5 alkylaminocarbonyloxy or C 3 -C 5 dialkylaminocarbonyloxy, each optionally substituted with up to 3 substituents independently selected from cyano, halogen, hydroxy and C(=O)OH; each R 12g is H, cyano, hydroxy, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl, C 1 -C 5 alkoxy, C 1 -C 5 haloalkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 1 -C 4 alkylsulfonyl or C 1 -C 4 haloalkylsulfonyl; each R 12i and R 12j is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 haloalkylcarbonyl; or R 12i and R 12j are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) 2 , each ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R 13 is independently -C(=O)OH, halogen, cyano, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl or C 3 -C 6 cycloalkyl; each R 14a is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, C 2 -C 4 alkylthioalkyl, C 2 -C 4 alkylsulfinylalkyl, C 2 -C 4 alkylsulfonylalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkoxycarbonylalkyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; each R 14b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 6 -C 14 cycloalkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 4 -C 10 cycloalkoxyalkyl, C 3 -C 8 alkoxyalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfinylalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl, C 2 -C 6 haloalkylaminoalkyl, C 3 -C 8 dialkylaminoalkyl or C 4 -C 10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, C 3 -C 15 trialkylsilyl and C 3 -C 15 halotrialkylsilyl; or R 14a and R 14b are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C 1 -C 3 alkyl; each R 15 is independently H, cyano, halogen, methyl, methoxy, methylthio or methoxycarbonyl; each R 16 is independently hydroxy or NR 20a R 20b ; or C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 alkynyloxy, C 2 -C 4 alkylcarbonyloxy, C 2 -C 5 alkoxycarbonyloxy, C 2 -C 5 alkylaminocarbonyloxy or C 3 -C 5 dialkylaminocarbonyloxy, each optionally substituted with up to 1 substituent selected from cyano, halogen, hydroxy and C(=O)OH; each R 17 is independently H, methyl, methoxy or methylthio; each R 18a and R 18b is independently H or C 1 -C 4 alkyl; each R 19 is independently amino, cyano, halogen, hydroxy, nitro, -SH, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 2 -C 4 alkoxyalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylsulfonyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 1 -C 6 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 5 alkylaminocarbonyl, C 3 -C 5 dialkylaminocarbonyl, C 3 -C 5 alkylthioalkylcarbonyl, C 3 -C 15 trialkylsily, C 3 -C 15 halotrialkylsilyl, C(R 21 )=NOR 22 or C(R 23 )=NR 24 ; each U is independently a direct bond, C(=O)O, C(=O)N(R 25 ) or C(=S)N(R 26 ), wherein the atom to the left is connected to G, and the atom to the right is connected to V; each V is independently a direct bond; or C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 3 -C 6 alkynylene, C 3 -C 6 cycloalkylene or C 3 -C 6 cycloalkenylene, wherein up to 1 carbon atom is C(=O), each optionally substituted with up to 3 substituents independently selected from halogen, cyano, nitro, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy; each Q is independently phenyl or phenoxy, each optionally substituted with up to 2 substituents independently selected from R 27 ; or each Q is independently a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R 27 ; or each Q is independently a 3- to 7-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) 2 , each ring optionally substituted with up to 2 substituents independently selected from R 27 ; each R 20a is independently H, C 1 -C 4 alkyl or C 2 -C 4 alkylcarbonyl; each R 20b is independently H, cyano, C 1 -C 5 alkyl, C 2 -C 5 alkylcarbonyl, C 2 -C 5 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkoxycarbonylalkyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; or R 20a and R 20b are taken together to form a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; each R 21 and R 23 is independently H, cyano, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl or C 1 -C 3 alkoxy; or phenyl optionally substituted with up to 2 substituents independently selected from halogen and C 1 -C 3 alkyl; each R 22 is independently H, C 1 -C 5 alkyl, C 1 -C 5 haloalkyl, C 2 -C 5 alkenyl, C 2 -C 5 haloalkenyl, C 2 -C 5 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 2 -C 5 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; or each R 22 is phenyl optionally substituted with up to 2 substituents independently selected halogen and C 1 -C 3 alkyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and C 1 -C 3 alkyl; each R 24 is independently H, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; each R 25 and R 26 is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -C 4 alkoxycarbonyl or C 2 -C 4 haloalkoxycarbonyl; each R 27 is independently halogen, cyano, hydroxy, nitro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; Z is a direct bond, O, S(=O)p, N(R 28 ), C(=O), C(=O)N(R 28 ), NR 28 C(=O), N(R 28 )C(=O)N(R 28 ), N(R 28 )C(=S)N(R 28 ), OC(=O)N(R 28 ), N(R 28 )C(=O)O, S(O) 2 N(R 28 ), N(R 28 )S(=O) 2 or N(R 28 )S(O) 2 N(R 28 ), wherein the atom to the right is connected to L; each R 28 is independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 3 alkylcarbonyl or C 2 -C 3 alkoxycarbonyl; and p is 0, 1 or 2; provided that: (a) when A 1 is N(R 6 ), O or S, then A 2 is a direct bond or CR 5a R 5b ; and (b) when A 2 is N(R 6 ), O or S; then A 1 is CR 5a R 5b . More particularly, this invention pertains to a compound of Formula 1 (including all stereoisomers), an N-oxide or a salt thereof. This invention also relates to a fungicidal composition comprising (a) a compound of the invention (i.e. in a fungicidally effective amount); and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. This invention also relates to a fungicidal composition comprising (a) a compound of the invention; and (b) at least one other fungicide (e.g., at least one other fungicide having a different site of action). This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of the invention (e.g., as a composition described herein). This invention also relates to a composition comprising a compound of Formula 1, an N-oxide, or a salt thereof, and at least one invertebrate pest control compound or agent. DETAILS OF THE INVENTION As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains,” “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole. The transitional phrase “consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”. Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms “consisting essentially of” or “consisting of.” Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular. The term “agronomic” refers to the production of field crops such as for food and fiber and includes the growth of maize or corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye and rice), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (e.g., berries and cherries) and other specialty crops (e.g., canola, sunflower and olives). The term “nonagronomic” refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications. The term “crop vigor” refers to rate of growth or biomass accumulation of a crop plant. An “increase in vigor” refers to an increase in growth or biomass accumulation in a crop plant relative to an untreated control crop plant. The term “crop yield” refers to the return on crop material, in terms of both quantity and quality, obtained after harvesting a crop plant. An “increase in crop yield” refers to an increase in crop yield relative to an untreated control crop plant. The term “biologically effective amount” refers to the amount of a biologically active compound (e.g., a compound of Formula 1 or a mixture with at least one other fungicidal compound) sufficient to produce the desired biological effect when applied to (i.e. contacted with) a fungus to be controlled or its environment, or to a plant, the seed from which the plant is grown, or the locus of the plant (e.g., growth medium) to protect the plant from injury by the fungal disease or for other desired effect (e.g., increasing plant vigor). As referred to in the present disclosure and claims, “plant” includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds. As referred to herein, the term “seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed. As referred to herein, the term “broadleaf” used either alone or in words such as “broadleaf crop” means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons. As referred to in this disclosure, the terms “fungal pathogen” and “fungal plant pathogen” include pathogens in the Ascomycota, Basidiomycota and Zygomycota phyla, and the fungal-like Oomycota class that are the causal agents of a broad spectrum of plant diseases of economic importance, affecting ornamental, turf, vegetable, field, cereal and fruit crops. In the context of this disclosure, “protecting a plant from disease” or “control of a plant disease” includes preventative action (interruption of the fungal cycle of infection, colonization, symptom development and spore production) and/or curative action (inhibition of colonization of plant host tissues). As used herein, the term “mode of action” (MOA) is as define by the Fungicide Resistance Action Committee (FRAC), and is used to distinguish fungicides according to their biochemical mode of action in the biosynthetic pathways of plant pathogens, and their resistance risk. FRAC-defined modes of actions include (A) nucleic acids metabolism, (B) cytoskeleton and motor protein, (C) respiration, (D) amino acids and protein synthesis, (E) signal transduction, (F) lipid synthesis or transport and membrane integrity or function, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis, (I) melanin synthesis in cell wall, (P) host plant defense induction, (U) unknown mode of action, (M) chemicals with multi-site activity and (BM) biologicals with multiple modes of action. Each mode of action (i.e. letters A through BM) contain one or more subgroups (e.g., A includes subgroups A1, A2, A3 and A4) based either on individual validated target sites of action, or in cases where the precise target site is unknown, based on cross resistance profiles within a group or in relation to other groups. Each of these subgroups (e.g., A1, A2, A3 and A4) is assigned a FRAC code which is a number and/or letter. For example, the FRAC code for subgroup A1 is 4. Additional information on target sites and FRAC codes can be obtained from publicly available databases maintained, for example, by FRAC. As used herein, the term “cross resistance” refers to the phenomenon that occurs when a pathogen develops resistance to one fungicide and simultaneously becomes resistant to one or more other fungicides. These other fungicides are typically, but not always, in the same chemical class or have the same target site of action, or can be detoxified by the same mechanism. In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain and branched alkyl, such as, methyl, ethyl, n-propyl, i-propyl, and the different butyl, pentyl and hexyl isomers. “Alkenyl” includes straight- chain and branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. “Alkynyl” includes straight-chain and branched alkynes such as ethynyl, 1-propynyl, 2-propynyl, and the different butynyl, pentynyl and hexynyl isomers. “Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkylene” denotes a straight-chain or branched alkanediyl. Examples of “alkylene” include CH 2 , CH 2 CH 2 , CH(CH 3 ), CH 2 CH 2 CH 2 , CH 2 CH(CH 3 ), and the different butylene isomers. “Alkenylene” denotes a straight-chain or branched alkenediyl containing one olefinic bond. Examples of “alkenylene” include CH=CH, CH 2 CH=CH, CH=C(CH 3 ) and the different butenylene isomers. “Alkynylene” denotes a straight-chain or branched alkynediyl containing one triple bond. Examples of “alkynylene” include CH 2 C≡C, C≡CCH 2 , and the different butynylene, pentynylene or hexynylene isomers. The term “cycloalkylene” denotes a cycloalkanediyl ring. Examples of “cycloalkylene” include cyclobutanediyl, cyclopentanediyl and cyclohexanediyl. The term “cycloalkenylene” denotes a cycloalkenediyl ring containing one olefinic bond. Examples of “cycloalkenylene” include cyclopropenediyl and cyclopentenediyl. “Alkoxy” includes, for example, methoxy, ethoxy, n-propyloxy, i-propyloxy, and the different butoxy, pentoxy and hexyloxy isomers. “Alkenyloxy” includes straight-chain and branched alkenyl attached to and linked through an oxygen atom. Examples of “alkenyloxy” include H 2 C=CHCH 2 O and CH 3 CH=CHCH 2 O. “Alkynyloxy” includes straight-chain and branched alkynyl attached to and linked through an oxygen atom. Examples of “alkynyloxy” include HC ≡CCH 2 O and CH 3 C ≡CCH 2 O. The term “alkylthio” includes straight-chain and branched alkylthio moieties such as methylthio, ethylthio, and the different propylthio and butylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include CH 3 S(=O), CH 3 CH 2 S(=O), CH 3 CH 2 CH 2 S(=O), (CH 3 ) 2 CHS(=O), and the different butylsulfinyl isomers. Examples of “alkylsulfonyl” include CH 3 S(=O) 2 , CH 3 CH 2 S(=O) 2 , CH 3 CH 2 CH 2 S(=O) 2 , (CH 3 ) 2 CHS(=O) 2 , and the different butylsulfonyl isomers. The term “alkenylthio” includes straight-chain and branched alkenyl attached to and linked through a sulfur atom. Examples of “alkenylthio” include H 2 C=CHCH 2 S and CH 3 CH=CHCH 2 S. “Alkenylsulfinyl” includes both enantiomers of an alkenylsulfinyl group. Examples of “alkenylsulfinyl” include H 2 C=CHCH 2 S(=O), CH 3 CH=CHCH 2 S(=O), (CH 3 ) 2 C=CHCH 2 S(=O). Examples of “alkenylsulfonyl” include CH 3 CH=CHS(=O) 2 , (CH 3 ) 2 C=CHCH 2 S(=O) 2 . The tern “alkynylthio” includes straight-chain and branched alkynyl attached to and linked through a sulfur atom. Examples of “alkynylthio” include HC ≡CCH 2 S and CH 3 C ≡CCH 2 S. “Alkynylsulfinyl” includes both enantiomers of an alkynylsulfinyl group. Examples of “alkynylsulfinyl” include HC≡CCH 2 S(=O) and CH 3 C≡CCH 2 S(=O). Examples of “alkynylsulfonyl” include CH 3 C≡CS(=O) 2 and CH 3 C≡CCH 2 S(=O) 2 . The term “alkoxyalkylthio” includes straight-chain and branched alkoxyalkyl moieties attached to and linked through a sulfur such as CH 3 OCH 2 CS and CH 3 CH 2 CH 2 OCH 2 CH 2 S. “Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of “alkylthioalkyl” include CH 3 SCH 2 , CH 3 SCH 2 CH 2 , CH 3 CH 2 SCH 2 , CH 3 CH 2 CH 2 SCH 2 and CH 3 CH 2 SCH 2 CH 2 ; “alkylsulfinylalkyl” and “alkylsulfonylalkyl” include the corresponding sulfoxides and sulfones, respectively. “Alkylthioalkylthio” denotes alkylthio substitution on an alkylthio group. Examples of “alkylthioalkylthio” include CH 3 SCH 2 S, CH 3 SCH 2 CH 2 S, CH 3 CH 2 SCH 2 S, CH 3 CH 2 CH 2 SCH 2 S and CH 3 CH 2 SCH 2 CH 2 S. The term “alkylsufonylalkylthio” denotes alkylsufonyl substitution on alkylthio group. Examples of “alkylsufonylalkylthio” include CH 3 S(=O) 2 CH 2 S, CH 3 S(=O) 2 CH 2 CH 2 S and CH 3 CH 2 S(=O) 2 CH 2 CH 2 S. The term “alkylthioalkoxy” denotes alkylthio substitution on an alkoxy group. Examples of “alkylthioalkoxy” include CH 3 SCH 2 O, CH 3 SCH 2 CH 2 O, CH 3 CH 2 SCH 2 O, CH 3 CH 2 CH 2 SCH 2 O and CH 3 CH 2 SCH 2 CH 2 O. “Alkylsulfinylalkoxy” and “alkylsulfonylalkoxy” include the corresponding sulfoxides and sulfones, respectively. Examples of “alkylsulfinylalkoxy” include CH 3 CH 2 (CH 3 )S(=O)CH 2 O and CH 3 S(=O)CH 2 O. Examples of “alkylsulfonylalkoxy” include CH 3 CH 2 CH 2 S(=O) 2 CH 2 CH 2 O and (CH 3 ) 2 CHS(=O) 2 CH 2 O. The term “alkylthioalkylcarbonyl” denotes a straight-chain or branched alkylthioalkyl group bonded to a C(=O) moiety. Examples of “alkylthioalkylcarbonyl” include CH 3 SCH 2 C(=O), CH 3 SCH 2 CH 2 C(=O), CH 3 CH 2 SCH 2 C(=O) and CH 3 CH 2 SCH 2 CH 2 C(=O). “(Alkylthio)carbonyl” denotes a straight-chain or branched alkylthio group bonded to a C(=O) moiety. Examples of “(alkylthio)carbonyl” include CH 3 SC(=O), CH 3 CH 2 CH 2 SC(=O) and (CH 3 ) 2 CHSC(=O). The terms “(alkenylthio)carbonyl” and “(alkynylthio)carbonyl” are likewise defined. Examples of “(alkenylthio)carbonyl” include H 2 C=CHCH 2 SC(=O) and CH 3 CH 2 CH=CHSC(=O). Examples of “(alkynylthio)carbonyl” include HC ≡CCH 2 SC(=O) and CH 3 C ≡CCH 2 SC(=O). “Alkyl(thiocarbonyl)” denotes a straight-chain or branched alkyl group bonded to a C(=S) moiety. Examples of “alkyl(thiocarbonyl)” include CH 3 CH 2 C(=S), CH 3 CH 2 CH 2 C(=S) and (CH 3 ) 2 CHCH 2 C(=S). The terms “alkenyl(thiocarbonyl)” and “alkynyl(thiocarbonyl)” are likewise defined. Examples of “alkenyl(thiocarbonyl)” include H 2 C=CHCH 2 CH 2 C(=S) and CH 3 CH 2 CH=CHC(=S). Examples of “alkynyl(thiocarbonyl)” include HC ≡CCH 2 CH 2 C(=S) and CH 3 C ≡CCH 2 C(=S). “Alkoxy(thiocarbonyl)” denotes a straight-chain or branched alkoxy group bonded to a C(=S) moiety. Examples of “alkoxy(thiocarbonyl)” include CH 3 CH 2 OC(=S), CH 3 CH 2 CH 2 OC(=S) and (CH 3 ) 2 CHCH 2 OC(=S). “Alkylamino(thiocarbonyl)” denotes a straight-chain or branched alkylamino group bonded to a C(=S) moiety. Examples of “alkylamino(thiocarbonyl)” include CH 3 NHC(=S), CH 3 CH 2 CH 2 NHC(=S) and (CH 3 ) 2 CHNHC(=S). The terms “alkenylamino(thiocarbonyl)” and “alkynylamino(thiocarbonyl)” are likewise defined. Examples of “alkenylamino(thiocarbonyl)” include H 2 C=CHCH 2 CH 2 NHC(=S) and CH 3 CH 2 CH=CHNHC(=S). Examples of “alkynylamino(thiocarbonyl)” include HC ≡CCH 2 CH 2 NHC(=S) and CH 3 C ≡CCH 2 NHC(=S). “(Alkylthio)carbonylamino” denotes a straight-chain or branched alkylthio group bonded to a C(=O)NH moiety. Examples of “(alkylthio)carbonylamino” include CH 3 CH 2 SC(=O)NH, CH 3 CH 2 CH 2 SC(=O)NH and (CH 3 ) 2 CHSC(=O)NH. The terms “(alkenylthio)carbonylamino” and “(alkynylthio)carbonylamino” are likewise defined. Examples of “(alkenylthio)carbonylamino include H 2 C=CHCH 2 SC(=O)NH and CH 3 CH=CHSC(=O)NH. Examples of “(alkynylthio)carbonylamino” include HC ≡CCH 2 CH 2 SC(=O)NH and CH 3 C ≡CCH 2 CH 2 SC(=O)NH. “Alkylamino” includes an NH radical substituted with a straight-chain or branched alkyl group. Examples of “alkylamino” include CH 3 CH 2 NH, CH 3 CH 2 CH 2 NH, and (CH 3 ) 2 CHCH 2 NH. Examples of “dialkylamino” include (CH 3 ) 2 N, (CH 3 CH 2 CH 2 ) 2 N and CH 3 CH 2 (CH 3 )N. “Alkylaminoalkyl” denotes alkylamino substitution on alkyl. Examples of “alkylaminoalkyl” include CH 3 NHCH 2 , CH 3 NHCH 2 CH 2 , CH 3 CH 2 NHCH 2 , CH 3 CH 2 CH 2 CH 2 NHCH 2 and CH 3 CH 2 NHCH 2 CH 2 . “Alkylcarbonyl” denotes a straight-chain or branched alkyl group bonded to a C(=O) moiety. Examples of “alkylcarbonyl” include CH 3 C(=O), CH 3 CH 2 CH 2 C(=O) and (CH 3 ) 2 CHC(=O). The terms “alkenylcarbonyl” and “alkynylcarbonyl” are likewise defined. Examples of “alkenylcarbonyl” include H 2 C=CHCH 2 C(=O) and CH 3 CH 2 CH=CHC(=O). Examples of “alkynylcarbonyl” include HC ≡CCH 2 C(=O) and CH 3 C ≡CCH 2 C(=O). “Alkoxycarbonyl” includes a C(=O) moiety substituted with a straight-chain or branched alkoxy group. Examples of “alkoxycarbonyl” include CH 3 OC(=O), CH 3 CH 2 OC(=O), CH 3 CH 2 CH 2 OC(=O) and (CH 3 ) 2 CHOC(=O). The terms “alkenyloxycarbonyl” and “alkynyloxycarbonyl” are likewise defined. Examples of “alkenyloxycarbonyl” include H 2 C=CHCH 2 OC(=O) and CH 3 CH 2 CH=CHOC(=O). Examples of “alkynyloxycarbonyl” include HC ≡CCH 2 OC(=O) and CH 3 C ≡CCH 2 OC(=O). The term “alkoxycarbonylalkoxy” denotes a straight-chain or branched alkoxycarbonyl substitution on an alkoxy group. Examples of “alkoxycarbonylalkoxy” include CH 3 CH 2 OC(=O)CH 2 CH 2 O and CH 3 CH 2 (CH 3 )OC(=O)CH 2 O. The term “alkoxycarbonylcarbonyl” denotes a straight-chain or branched alkoxy group bonded to a C(=O)C(=O) moiety. Examples of “alkoxycarbonylcarbonyl” include CH 3 CH 2 OC(=O)C(=O) and CH 3 CH(CH 3 )OC(=O)C(=O). The term “alkoxycarbonylcarbonyloxy” denotes a straight-chain or branched alkoxy group bonded to a C(=O)C(=O)O moiety. Examples of “alkoxycarbonylcarbonyloxy” include CH 3 OC(=O)C(=O)O and CH 3 CH 2 OC(=O)C(=O)O. “Alkylaminocarbonyl” denotes a straight-chain or branched alkyl group bonded to a NHC(=O) moiety. Examples of “alkylaminocarbonyl” include CH 3 NHC(=O), CH 3 CH 2 NHC(=O), CH 3 CH 2 CH 2 NHC(=O) and (CH 3 ) 2 CHNHC(=O). The terms “alkenylaminocarbonyl” and “alkynylaminocarbonyl” are likewise defined. Examples of “alkenylaminocarbonyl” include H 2 C=CHCH 2 NHC(=O) and (CH 3 ) 2 C=CHCH 2 NHC(=O). Examples of “alkynylaminocarbonyl” include CH 3 C≡CNHC(=O) and CH 3 C≡CCH 2 NHC(=O). Examples of “dialkylaminocarbonyl” include (CH 3 ) 2 N(=O), (CH 3 CH 2 ) 2 NC(=O), CH 3 CH 2 (CH 3 )NC(=O), (CH 3 ) 2 CH(CH 3 )NC(=O) and CH 3 CH 2 CH 2 (CH 3 )NC(=O). The term “alkylcarbonylamino” denotes a straight-chain or branched alkyl group bonded to a C(=O)NH moiety. Examples of “alkylcarbonylamino” include CH 3 CH 2 C(=O)NH and CH 3 CH 2 CH 2 C(=O)NH. The terms “alkenylcarbonylamino” and “alkynylcarbonylamino” are likewise defined. Examples of “alkenylcarbonylamino” include H 2 C=CHCH 2 C(=O)NH and (CH 3 ) 2 C=CHCH 2 C(=O)NH. Examples of “alkynylcarbonylamino” include CH 3 C≡CCH(CH 3 )C(=O)NH and HC≡CCH 2 CH 2 C(=O)NH. The term “alkoxycarbonylamino” denotes alkoxy bonded to a C(=O)NH moiety. Examples of “alkoxycarbonylamino” include CH 3 OC(=O)NH and CH 3 CH 2 OC(=O)NH. The term “alkylaminocarbonylamino” denotes a straight-chain or branched alkyl group bonded to a NHC(=O)NH moiety. Examples of “alkylaminocarbonylamino” include CH 3 CH 2 NHC(=O)NH and (CH 3 CH 2 ) 2 CH 2 NHC(=O)NH. The terms “alkenylaminocarbonylamino” and “alkynylaminocarbonylamino” are likewise defined. Examples of “alkenylaminocarbonylamino” include H 2 C=CHCH 2 NHC(=O)NH and (CH 3 ) 2 C=CHCH 2 NHC(=O)NH. Examples of “alkynylaminocarbonylamino” include CH 3 C≡CCH(CH 3 )NHC(=O)NH and HC≡CCH 2 CH 2 NHC(=O)NH. “Alkylsulfonylamino” denotes an NH radical substituted with alkylsulfonyl. Examples of “alkylsulfonylamino” include CH 3 CH 2 S(=O) 2 NH and (CH 3 ) 2 CHS(=O) 2 NH. The terms “alkenylsulfonylamino” and “alkynylsulfonylamino” are likewise defined. Examples of “alkenylsulfonylamino” include H 2 C=CHCH 2 CH 2 S(=O) 2 NH and (CH 3 ) 2 C=CHCH 2 S(=O) 2 NH. Examples of “alkynylsulfonylamino” include CH 3 C≡CCH(CH 3 )S(=O) 2 NH and HC≡CCH 2 CH 2 S(=O) 2 NH. The term “alkylsulfonyloxy” denotes an alkylsulfonyl group bonded to an oxygen atom. Examples of “alkylsulfonyloxy” include CH 3 S(=O) 2 O, CH 3 CH 2 S(=O) 2 O, CH 3 CH 2 CH 2 S(=O) 2 O, (CH 3 ) 2 CHS(=O) 2 O, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers. “Alkylaminosulfonyl” denotes a straight-chain or branched alkyl group bonded to a NHS(=O) 2 moiety. Examples of “alkylaminosulfonyl” include CH 3 CH 2 NHS(=O) 2 and (CH 3 ) 2 CHNHS(=O) 2 . The terms “alkenylaminosulfonyl” and “alkynylaminosulfonyl” are likewise defined. Examples of “alkenylaminosulfonyl” include H 2 C=CHCH 2 CH 2 NHS(=O) 2 and (CH 3 ) 2 C=CHCH 2 NHS(=O) 2 . Examples of “alkynylaminosulfonyl” include CH 3 C≡CCH(CH 3 )NHS(=O) 2 and HC≡CCH 2 CH 2 NHS(=O) 2 . “Alkylaminosulfonylamino” denotes a straight-chain or branched alkyl group bonded to a NHS(=O) 2 NH moiety. Examples of “alkylaminosulfonylamino” include CH 3 CH 2 NHS(=O) 2 NH and (CH 3 ) 2 CHNHS(=O) 2 NH. The terms “alkenylaminosulfonylamino” and “alkynylaminosulfonylamino” are likewise defined. Examples of “alkenylaminosulfonylamino” include H 2 C=CHCH 2 CH 2 NHS(=O) 2 NH and (CH 3 ) 2 C=CHCH 2 NHS(=O) 2 NH. Examples of “alkynylaminosulfonylamino” include CH 3 C≡CCH(CH 3 )NHS(=O) 2 NH and HC≡CCH 2 CH 2 NHS(=O) 2 NH. “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH 3 OCH 2 , CH 3 OCH 2 CH 2 , CH 3 CH 2 OCH 2 , CH 3 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 . “Alkoxyalkoxy” denotes alkoxy substitution on another alkoxy moiety. “Alkoxyalkoxyalkyl” denotes alkoxyalkoxy substitution on alkyl. Examples of “alkoxyalkoxyalkyl” include CH 3 OCH 2 OCH 2 , CH 3 OCH 2 OCH 2 CH 2 and CH 3 CH 2 OCH 2 OCH 2 . The term “alkylcarbonyloxy” denotes a straight-chain or branched alkyl bonded to a C(=O)O moiety. Examples of “alkylcarbonyloxy” include CH 3 CH 2 C(=O)O and (CH 3 ) 2 CHC(=O)O. The terms “alkenylcarbonyloxy” and “alkynylcarbonyloxy” are likewise defined. Examples of “alkenylcarbonyloxy” include H 2 C=CHCH 2 CH 2 C(=O)O and (CH 3 ) 2 C=CHCH 2 C(=O)O. Examples of “alkynylcarbonyloxy” include CH 3 C≡CCH(CH 3 )C(=O)O and HC≡CCH 2 CH 2 C(=O)O. The term “alkoxycarbonyloxy” denotes a straight-chain or branched alkoxy group bonded to a C(=O)O moiety. Examples of “alkoxycarbonyloxy” include CH 3 CH 2 CH 2 OC(=O)O and (CH 3 ) 2 CHOC(=O)O. The term “alkoxycarbonylalkyl” denotes alkoxycarbonyl substitution on alkyl. Examples of “alkoxycarbonylalkyl” include CH 3 CH 2 OC(=O)CH 2 , (CH 3 ) 2 CHOC(=O)CH 2 and CH 3 OC(=O)CH 2 CH 2 . The term “alkylaminocarbonyloxy” denotes a straight-chain or branched alkylaminocarbonyl attached to and linked through an oxygen atom. Examples of “alkylaminocarbonyloxy” include (CH 3 ) 2 CHCH 2 NHC(=O)O and CH 3 CH 2 NHC(=O)O. The terms “alkenylaminocarbonyloxy” and “alkynylaminocarbonyloxy” are likewise defined. The term “alkylcarbonylthio” denotes a straight-chain or branched alkyl group bonded to a C(=O)S moiety. Examples of “alkylcarbonylthio” include CH 3 CH 2 C(=O)S and CH 3 CH 2 CH 2 C(=O)S. The term “alkenylcarbonylthio” denotes a straight-chain or branched alkenyl group bonded to a C(=O)S moiety. Examples of “alkenylcarbonylthio” include CH 3 CH=CHC(=O)S and CH 2 =CHCH 2 C(=O)S. “Alkynylcarbonylthio” denotes a straight-chain or branched alkynyl group bonded to a C(=O)S moiety. Examples of “alkynylcarbonylthio” include include CH 3 C≡CCH(CH 3 )C(=O)S and HC≡CCH 2 CH 2 C(=O)S. The term “alkoxycarbonylthio” denotes a straight-chain or branched alkoxy group bonded to a C(=O)S moiety. Examples of “alkoxycarbonylthio” include CH 3 CH 2 OC(=O)S and CH 3 CH 2 CH 2 OC(=O)S. The term “alkylaminocarbonylthio” denotes an alkyl group attached to and linked through a NHC(=O)S moiety. Examples of “alkylaminocarbonylthio” include CH 3 CH 2 NHC(=O)S and (CH 3 ) 2 CHCH 2 NHC(=O)S. Examples of “dialkylaminocarbonylthio” include (CH 3 CH 2 ) 2 NC(=O)S and CH 3 CH 2 N(CH 3 )C(=O)S. “Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to a straight-chain or branched alkyl group. The term “alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, i-propylcyclobutyl, methylcyclopentyl and methylcyclohexyl. “Alkylcycloalkylalkyl” denotes alkylcycloalkyl substitution on alkyl. Examples of “alkylcycloalkylalkyl” include methylcyclohexylmethyl and ethylcycloproylmethyl. “Cycloalkenyl” includes groups such as cyclopentenyl and cyclohexenyl as well as groups with more than one double bond such as 1,3- or 1,4-cyclohexadienyl. The term “cycloalkylcycloalkyl” denotes cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members. Examples of cycloalkylcycloalkyl include cyclopropylcyclopropyl (such as 1,1'- bicyclopropyl-1-yl, 1,1'-bicyclopropyl-2-yl), cyclohexylcyclopentyl (such as 4- cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as 1,1'-bicyclohexyl-1-yl), and the different cis- and trans-cycloalkylcycloalkyl isomers, (such as (1R,2S)-1,1'-bicyclopropyl-2-yl and (1R,2R)-1,1'-bicyclopropyl-2-yl). The term “cycloalkoxy” denotes cycloalkyl attached to and linked through an oxygen atom including, for example, cyclopentyloxy and cyclohexyloxy. The term “cycloalkoxyalkyl” denotes cycloalkoxy substitution on an alkyl moiety. Examples of “cycloalkoxyalkyl” include cyclopropyloxymethyl, cyclopentyloxyethyl, and other cycloalkoxy groups bonded to a straight-chain or branched alkyl moiety. The term “cycloalkylaminoalkyl” denotes cycloalkylamino substitution on an alkyl group. Examples of “cycloalkylaminoalkyl” include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to a straight-chain or branched alkyl group. “Cycloalkylcarbonyl” denotes cycloalkyl bonded to a C(=O) group including, for example, cyclopropylcarbonyl and cyclopentylcarbonyl. “Cycloalkylcarbonyloxy” denotes cycloalkylcarbonyl attached to and linked through an oxygen atom. Examples of “cycloalkylcarbonyloxy” include cyclohexylcarbonyloxy and cyclopentylcarbonyloxy. The term “cycloalkoxycarbonyl” means cycloalkoxy bonded to a C(=O) group, for example, cyclopropyloxycarbonyl and cyclopentyloxycarbonyl. “Cycloalkylaminocarbonylamino” denotes cycloalkylamino bonded to a C(=O)NH group, for example, cyclopentylaminocarbonyl- amino and cyclohexylaminocarbonylamino. “Cycloalkylaminocarbonyloxy” denotes cycloalkylamino bonded to a C(=O)O group, for example, cyclopentylaminocarbonyloxy and cyclohexylaminocarbonyloxy. The term “halogen”, either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include CF 3 , ClCH 2 , CF 3 CH 2 and CF 3 CCl2. The terms “haloalkenyl”, “haloalkynyl” “haloalkoxy”, “haloalkylsulfonyl”, “halocycloalkyl”, and the like, are defined analogously to the term “haloalkyl”. Examples of “haloalkenyl” include Cl2C=CHCH 2 and CF 3 CH 2 CH=CHCH 2 . Examples of “haloalkynyl” include HC ≡CCHCl, CF 3 C ≡C, CCl 3 C ≡C and FCH 2 C ≡CCH 2 . Examples of “haloalkoxy” include CF 3 O, CCl 3 CH 2 O, F 2 CHCH 2 CH 2 O and CF 3 CH 2 O. Examples of “haloalkylsulfonyl” include CF 3 S(=O) 2 , CCl 3 S(=O) 2 , CF 3 CH 2 S(=O) 2 and CF 3 CF 2 S(=O) 2 . Examples of “halocycloalkyl” include 2-chlorocyclopropyl, 2-fluorocyclobutyl, 3-bromocyclopentyl and 4-chorocyclohexyl. “Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH 2 , NCCH 2 CH 2 and CH 3 CH(CN)CH 2 . “Cyanoalkoxy” denotes an alkoxy group substituted with one cyano group. Examples of “cyanoalkoxy” include NCCH 2 O, NCCH 2 CH 2 O and CH 3 CH(CN)CH 2 O. “Cyanoalkylthio” denotes an alkylthio group substituted with one cyano group. Examples of “cyanoalkylthio” include NCCH 2 S, NCCH 2 CH 2 S and CH 3 CH(CN)CH 2 S. “Hydroxyalkyl” denotes an alkyl group substituted with one hydroxy group. Examples of “hydroxyalkyl” include HOCH 2 CH 2 , CH 3 CH 2 (OH)CH and HOCH 2 CH 2 CH 2 CH 2 . “Trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. The term “halotrialkylsilyl” is likewise defined. Examples of “halotrialkylsilyl” include trifluormethylsilyl and trichloromethylsilyl. “Trialkylsilyloxy” denotes a trialkylsilyl group attached to and linked through an oxygen atom, such as trimethylsilyloxy, triethylsilyloxy and tert-butyldimethylsilyloxy. The total number of carbon atoms in a substituent group is indicated by the “C i -C j ” prefix where i and j are numbers from 1 to 15. For example, C 1 -C 4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C2 alkoxyalkyl designates CH 3 OCH 2 ; C3 alkoxyalkyl designates, for example, CH 3 CH(OCH 3 ), CH 3 OCH 2 CH 2 or CH 3 CH 2 OCH 2 ; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 3 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 . Generally when a molecular fragment (i.e. radical) is denoted by a series of atom symbols (e.g., C, H, N, O and S) the implicit point or points of attachment will be easily recognized by those skilled in the art. In some instances herein, particularly when alternative points of attachment are possible, the point or points of attachment may be explicitly indicated by a hyphen (“-”). The term “unsubstituted” in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1. The term “optionally substituted” means that the number of substituents can be zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) ranges from 1 to 3. As used herein, the term “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted.” The number of optional substituents may be restricted by an expressed limitation. For example, the phrase “optionally substituted with up to 3 substituents independently selected from R 10” means that 0, 1, 2 or 3 substituents can be present (if the number of potential connection points allows). When a range specified for the number of substituents (e.g., y being an integer from 0 to 3 in Exhibit A) exceeds the number of positions available for substituents on a ring (e.g., 1 position available for (R 10 ) y on G-7 in Exhibit A), the actual higher end of the range is recognized to be the number of available positions. When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can vary (e.g., (R 10 ) y in Exhibit A wherein y is 1 to 3), then said substituents are independently selected from the group of defined substituents, unless otherwise indicated. When a variable group is shown to be optionally attached to a position, for example (R 10 ) y in Exhibit A wherein x may be 0, then hydrogen may be at the position even if not recited in the definition of the variable group. The dotted line in rings depicted in the present description (e.g., the rings G-44, G-45, G-48 and G-49 shown in Exhibit A) represents that the bond indicated can be a single bond or double bond. Naming of substituents in the present disclosure uses recognized terminology providing conciseness in precisely conveying to those skilled in the art the chemical structure. For sake of conciseness, locant descriptors may be omitted. Unless otherwise indicated, a “ring” or “ring system” as a component of Formula 1 (e.g., G) is carbocyclic or heterocyclic. The term “ring system” denotes two or more connected rings. The term “spirocyclic ring system” denotes a ring system consisting of two rings connected at a single atom (so the rings have a single atom in common). The term “bicyclic ring system” denotes a ring system consisting of two rings sharing two or more common atoms. In a “fused bicyclic ring system” the common atoms are adjacent, and therefore the rings share two adjacent atoms and a bond connecting them. The term “ring member” refers to an atom (e.g., C, O, N or S) or other moiety (e.g., C(=O), C(=S), S(=O) and S(=O) 2 ) forming the backbone of a ring or ring system. The term “aromatic” indicates that each of the ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and that (4n + 2) π electrons, where n is a positive integer, are associated with the ring to comply with Hückel’s rule The term “carbocyclic ring” denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Hückel’s rule, then said ring is also called an “aromatic ring”. “Saturated carbocyclic” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms. As used herein, the term “partially unsaturated ring" or "partially unsaturated heterocycle” refers to a ring which contains unsaturated ring atoms and one or more double bonds but is not aromatic. The terms “heterocyclic ring” or “heterocycle” denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated heterocyclic ring satisfies Hückel’s rule, then said ring is also called a “heteroaromatic ring” or aromatic heterocyclic ring. “Saturated heterocyclic ring” refers to a heterocyclic ring containing only single bonds between ring members. Unless otherwise indicated, heterocyclic rings and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen atom by replacement of a hydrogen on said carbon or nitrogen atom. Compounds of this invention can exist as one or more stereoisomers. Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis- and trans-isomers (also known as geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, 1994. Compounds of this invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form. For example, when T is T-3, then Formula 1 compounds contain at least one double bond and the configuration of substituents about that double bond can be (Z) or (E) (cis or trans), or a mixture thereof. In the context of the present disclosure and claims, a wavy bond (e.g., as shown in the T-3 moiety in the Summary of the Invention) indicates a single bond which is linked to an adjacent double bond wherein the geometry about the adjacent double bond is either (Z)-configuration (syn-isomer or cis-isomer) or (E)-configuration (anti-isomer or trans-isomer), or a mixture thereof. That is, a wavy bond represents an unspecified (Z)- or (E)- (cis- or trans-) isomer, or mixture thereof. In addition, the compounds of the present invention can contain one or more chiral centers and therefore exist in enantiomeric and diastereomeric forms. Unless the structural formula or the language of this application specifically designate a particular cis- or trans-isomer, or a configuration of a chiral center, the scope of the present invention is intended to cover all such isomers per se, as well as mixtures of cis- and trans-isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well. This invention also includes compounds of Formula 1 wherein one stereoisomer is enriched relative to the other stereoisomer(s). Of note are compounds of Formula 1 wherein T is T-3 and the substituents attached to the double bond in the T-3 moiety are in a predominately (Z)- configuration, or predominately an (E)-configuration. The ratio of the (Z)- to (E)-isomers in any compounds of Formula 1, whether produced stereoselectivity or non-stereoselectivity, may take on a broad range of values. For example, compounds of Formula 1 may comprise from about 10 to 90 percent by weight of the (Z)-isomer to about 90 to 10 percent by weight of the (E)-isomer. In other embodiments, Formula 1 compounds may contain from about 15 to 85 percent by weight of the (Z)-isomer and about 85 to 15 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 25 to 75 percent by weight of the (Z)-isomer and about 75 to 25 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 35 to 65 percent by weight of the (Z)-isomer and about 65 to 35 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 45 to 55 percent by weight of the (Z)-isomer and about 55 to 45 percent by weight of the (E)-isomer. These percentages by weight are based on the total weight of the composition, and it will be understood that the sum of the weight percent of the (Z)- isomer and the (E)-isomer is 100 weight percent. In other words, compounds of Formula 1 might contain 65 percent by weight of the (Z)-isomer and 35 percent by weight of the (E)-isomer, or vice versa. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1. When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess (“ee”), which is defined as (2x-1) ^100%, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers). Preferably the compositions of this invention have at least a 50% enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer. Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about an amide bond (e.g., C(=O)-N) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others. This invention comprises all stereoisomers, conformational isomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds. One skilled in the art will appreciate that not all nitrogen containing heterocycles can form N-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form N-oxides. One skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18-20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol.43, pp 149-161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, vol. 9, pp 285-291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, vol.22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press. One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1, N-oxides, and agriculturally suitable salts, and solvates thereof. Compounds selected from Formula 1, stereoisomers, tautomers, N-oxides, and salts thereof, typically exist in more than one form, and Formula 1 thus includes all crystalline and non- crystalline forms of the compounds that Formula 1 represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1. Preparation and isolation of a particular polymorph of a compound represented by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., Polymorphism in the Pharmaceutical Industry, Wiley-VCH, Weinheim, 2006. One skilled in the art recognizes that compounds of Formula 1 can exist as mixtures of ketonic and solvated forms (e.g., hemiketals, ketals and hydrates) and each are independently interconvertible and agriculturally active. For example, ketones of Formula 11 (i.e. compounds of Formula 1 wherein T is T-1) may exist in equilibrium with their corresponding hydrates of Formula 12 (i.e. compounds of Formula 1 wherein T is T-2, and R 2a X and R 2b Y are both OH). In cases where the ketone group is in close proximity to an electron-withdrawing group, such as when R 1 is a trifluoromethyl group, the equilibrium typically favors the hydrate form. This invention comprises all ketonic and solvated forms of Formula 1 compounds, and mixtures thereof in all proportions. Unless otherwise indicated, reference to a compound by one tautomer description is to be considered to include all tautomers. Additionally, some of the unsaturated rings and ring systems depicted in Exhibit A can have an arrangement of single and double bonds between ring members different from that depicted. Such differing arrangements of bonds for a particular arrangement of ring atoms correspond to different tautomers. For these unsaturated rings and ring systems, the particular tautomer depicted is to be considered representative of all the tautomers possible for the arrangement of ring atoms shown. Embodiments of the present invention as described in the Summary of the Invention include those described below. In the following Embodiments, Formula 1 includes stereoisomers, N-oxides, and salts thereof, and reference to “a compound of Formula 1” includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments. Embodiment 1. A compound of Formula 1 wherein T is T-1. Embodiment 2. A compound of Formula 1 wherein T is T-2 or T-3. Embodiment 3. A compound of Embodiment 2 wherein T is T-2. Embodiment 4. A compound of Embodiment 2 wherein T is T-3. Embodiment 5. A compound of Formula 1 or any one of Embodiments 1 through 4 wherein R 1 is CF 3 . Embodiment 6. A compound of Formula 1 or any one of Embodiments 1 through 5 wherein W is O or S. Embodiment 7. A compound of Embodiment 6 wherein W is O. Embodiment 8. A compound of Formula 1 or any one of Embodiments 1 through 5 wherein W is NR 3 . Embodiment 9. A compound of Formula 1 or any one of Embodiments 1 through 8 wherein R 3 is H, cyano, C(=O)OH, C 1 -C 2 alkyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl, OR 3a or NR 3b R 3c . Embodiment 10. A compound of Embodiment 9 wherein R 3 is H, cyano, C 1 -C 2 alkyl or OR 3a . Embodiment 11. A compound of Embodiment 10 wherein R 3 is H, cyano or OR 3a . Embodiment 12. A compound of Formula 1 or any one of Embodiments 1 through 11 wherein R 3a is H, C 1 -C 2 alkyl, C 2 -C 3 alkylcarbonyl or C 2 -C 3 haloalkylcarbonyl. Embodiment 13. A compound of Embodiment 12 wherein R 3a is H. Embodiment 14. A compound of Formula 1 or any one of Embodiments 1 through 13 wherein when R 3b is separate (i.e. not taken together with R 3c to form a ring), then R 3b is H, C 1 -C 3 alkyl, C 2 -C 3 alkylcarbonyl or C 2 -C 3 haloalkylcarbonyl. Embodiment 15. A compound of Embodiment 14 wherein R 3b is H or methyl. Embodiment 16. A compound of Formula 1 or any one of Embodiments 1 through 15 wherein when R 3c is separate (i.e. not taken together with R 3b to form a ring), then R 3c is H or C 1 -C 2 alkyl. Embodiment 17. A compound of Embodiment 16 wherein R 3c is H or methyl. Embodiment 18. A compound of Formula 1 or any one of Embodiments 1 through 17 wherein X is O or NR 4a . Embodiment 19. A compound of Formula 1 or any one of Embodiments 1 through 17 wherein X is O, S, NH or NOH. Embodiment 20. A compound of Embodiment 19 wherein X is O or NOH. Embodiment 21. A compound of Embodiment 20 wherein X is O. Embodiment 22. A compound of Formula 1 or any one of Embodiments 1 through 21 wherein Y is O or NR 4b . Embodiment 23. A compound of Formula 1 or any one of Embodiments 1 through 21 wherein Y is O, S, NH or NOH. Embodiment 24. A compound of Embodiment 23 wherein Y is O or NOH. Embodiment 25. A compound of Embodiment 24 wherein Y is O. Embodiment 26. A compound of Formula 1 or any one of Embodiments 1 through 25 wherein R 4a and R 4b are each independently H, hydroxy or C 1 -C 2 alkyl. Embodiment 27. A compound of Embodiment 26 wherein R 4a and R 4b are each independently H, hydroxy or methyl. Embodiment 28. A compound of Formula 1 or any one of Embodiments 1 through 27 wherein when R 2a and R 2b are separate (i.e. not taken together to form a ring), then R 2a and R 2b are each independently H, C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 3 -C 15 trialkylsilyl or C 3 -C 15 halotrialkylsilyl. Embodiment 29. A compound of Embodiment 28 wherein R 2a and R 2b are each independently H, C 1 -C 3 alkyl, C 2 -C 3 alkenyl, trimethylsilyl or halotrimethylsilyl. Embodiment 30. A compound of Embodiment 29 wherein R 2a and R 2b are each independently H, C 1 -C 2 alkyl, trimethylsilyl or halotrimethylsilyl. Embodiment 31. A compound of Embodiment 30 wherein R 2a and R 2b are each independently H or C 1 -C 2 alkyl. Embodiment 32. A compound of Embodiment 31 wherein R 2a and R 2b are each independently H or methyl. Embodiment 33. A compound of Embodiment 32 wherein R 2a and R 2b are each H. Embodiment 34. A compound of Formula 1 or any one of Embodiments 1 through 33 wherein when R 2a and R 2b are taken together to form a ring (i.e. not separate), then R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members. Embodiment 35. A compound of Embodiment 34 wherein R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is C(=O), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members. Embodiment 36. A compound of Embodiment 35 wherein R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl and methoxy on carbon atom ring members. Embodiment 37. A compound of Embodiment 36 wherein R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member. Embodiment 38. A compound of Embodiment 37 wherein R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms. Embodiment 39. A compound of Formula 1 or any one of Embodiments 1 through 38 wherein R 2c is C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, C 2 -C 3 alkynyl or C 2 -C 3 haloalkynyl, each optionally substituted with up 1 substituent selected from cyano, hydroxy, SC≡N and C 1 -C 2 alkoxy. Embodiment 40. A compound of Embodiment 39 wherein R 2c is C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, C 2 -C 3 alkynyl or C 2 -C 3 haloalkynyl, each optionally substituted with up 1 substituent selected from cyano and methoxy. Embodiment 41. A compound of Embodiment 40 wherein R 2c is C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl or C 2 -C 3 alkynyl. Embodiment 42. A compound of Embodiment 41 wherein R 2c is C 1 -C 2 alkyl, C 2 -C 3 alkenyl or C 2 -C 3 alkynyl. Embodiment 43. A compound of Embodiment 42 wherein R 2c is methyl or ethyl. Embodiment 44. A compound of Embodiment 43 wherein R 2c is ethyl. Embodiment 45. A compound of Formula 1 or any one of Embodiments 1 through 44 wherein R 2d is H, cyano, halogen or C 1 -C 2 alkyl. Embodiment 46. A compound of Embodiment 45 wherein R 2d is H, cyano, Cl, F or methyl. Embodiment 47. A compound of Embodiment 46 wherein R 2d is H or methyl. Embodiment 48. A compound of Embodiment 47 wherein R 2d is H. Embodiment 49. A compound of Formula 1 or any one of Embodiments 1 through 48 wherein A 1 is CH 2 , NH, O or S. Embodiment 50. A compound of Formula 1 or any one of Embodiments 1 through 48 wherein A 1 is CR 5a R 5b , O or S. Embodiment 51. A compound of Embodiment 50 wherein A 1 is CR 5a R 5b or O. Embodiment 52. A compound of Embodiment 51 wherein A 1 is CR 5a R 5b . Embodiment 53. A compound of Embodiment 51 wherein A 1 is O. Embodiment 54. A compound of Formula 1 or any one of Embodiments 1 through 53 wherein A 1 is N(R 6 ). Embodiment 55. A compound of Formula 1 or any one of Embodiments 1 through 54 wherein A 2 is a direct bond, CH 2 , NH, O or S. Embodiment 56. A compound of Formula 1 or any one of Embodiments 1 through 54 wherein A 2 is a direct bond, CR 5a R 5b , O or S. Embodiment 57. A compound of Embodiment 56 wherein A 2 is a direct bond, CR 5a R 5b or O. Embodiment 58. A compound of Embodiment 57 wherein A 2 is a direct bond, CH 2 or O. Embodiment 58a. A compound of Embodiment 58 wherein A 2 is a direct bond or CH 2 . Embodiment 59. A compound of Embodiment 58 wherein A 2 is a direct bond or O. Embodiment 60. A compound of Embodiment 59 wherein A 2 is a direct bond. Embodiment 61. A compound of Formula 1 or any one of Embodiments 1 through 60 wherein A 2 is N(R 6 ). Embodiment 62. A compound of Formula 1 or any one of Embodiments 1 through 61 wherein when A is A 1 -A 2 -CR 5a R 5b , then A 1 -A 2 -CR 5a R 5b is selected from OCH 2 , OCH(Me), CH(OH)CH 2 , CH 2 CH 2 , SCH 2 , OCF 2 and CH 2 OCH 2 . Embodiment 63. A compound of Embodiment 62 wherein A 1 -A 2 -CR 5a R 5b is selected from OCH 2 , OCH(Me) and CH 2 CH 2 . Embodiment 64. A compound of Embodiment 63 wherein A 1 -A 2 -CR 5a R 5b is selected from OCH 2 and CH 2 CH 2 . Embodiment 65. A compound of Embodiment 64 wherein A 1 -A 2 -CR 5a R 5b is OCH 2 . Embodiment 66. A compound of Formula 1 or any one of Embodiments 1 through 65 wherein when A is A 1 -A 2 , then A 1 -A 2 is selected from O, CH 2 , OCH 2 and CH 2 O. Embodiment 67. A compound of Embodiment 66 wherein A 1 -A 2 is selected from O, CH 2 and CH 2 O. Embodiment 68. A compound of Embodiment 67 wherein A 1 -A 2 is selected from O and CH 2 . Embodiment 69. A compound of Embodiment 68 wherein A 1 -A 2 is O. Embodiment 70. A compound of Formula 1 or any one of Embodiments 1 through 69 wherein each R 5a and R 5b is independently H, cyano, hydroxy, Br, Cl, F or methyl. Embodiment 71. A compound of Embodiment 70 wherein each R 5a and R 5b is independently H, cyano hydroxy or methyl. Embodiment 72. A compound of Embodiment 71 wherein each R 5a and R 5b is independently H or methyl. Embodiment 73. A compound of Embodiment 72 wherein each R 5a and R 5b is H. Embodiment 74. A compound of Formula 1 or any one of Embodiments 1 through 73 wherein each R 6 is independently H, C 1 -C 2 alkyl or C 2 -C 3 alkylcarbonyl. Embodiment 75. A compound of Embodiment 74 wherein each R 6 is each independently H or C 1 -C 2 alkyl. Embodiment 76. A compound of Embodiment 75 wherein each R 6 is each H. Embodiment 77. A compound of Formula 1 or any one of Embodiments 1 through 76 wherein J is J-1 through J-3, J-6 through J-10, J-14 or J-15. Embodiment 77a. A compound of Embodiment 77 wherein J is J-1 through J-3, J-6 through J-10 or J-14. Embodiment 78. A compound of Embodiment 77a wherein J is J-1, J-2, J-3, J-6 or J-14. Embodiment 79. A compound of Embodiment 78 wherein J is J-1, J-6 or J-14. Embodiment 80. A compound of Embodiment 79 wherein J is J-1 or J-6. Embodiment 81. A compound of Embodiment 79 wherein J is J-14. Embodiment 82. A compound of Embodiment 80 wherein J is J-1. Embodiment 83. A compound of Embodiment 80 wherein J is J-6. Embodiment 84. A compound of Formula 1 or any one of Embodiments 1 through 83 wherein each R 7 is independently F, Cl or methyl. Embodiment 85. A compound of Embodiment 84 wherein each R 7 is independently F or Cl. Embodiment 86. A compound of Embodiment 84 wherein each R 7 is independently F or methyl. Embodiment 87. A compound of Embodiment 86 wherein each R 7 is F. Embodiment 88. A compound of Formula 1 or any one of Embodiments 1 through 87 wherein q is 0, 1 or 2. Embodiment 88a. A compound of Embodiment 88 wherein q is 1 or 2. Embodiment 88b. A compound of Embodiment 88a wherein q is 2. Embodiment 89. A compound of Embodiment 88 wherein q is 0 or 1. Embodiment 90. A compound of Embodiment 89 wherein q is 1. Embodiment 91. A compound of Embodiment 89 wherein q is 0. Embodiment 92. A compound of Formula 1 or any one of Embodiments 1 through 91 wherein each R 8a and R 8b is independently H, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy or C 1 -C 3 haloalkoxy. Embodiment 93. A compound of Embodiment 92 wherein each R 8a and R 8b is independently H, halogen, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl. Embodiment 94. A compound of Embodiment 93 wherein each R 8a and R 8b is independently H, halogen or methyl. Embodiment 95. A compound of Embodiment 94 wherein each R 8a and R 8b is independently H or methyl. Embodiment 96. A compound of Embodiment 95 wherein each R 8a and R 8b is H. Embodiment 97. A compound of Formula 1 or any one of Embodiments 1 through 96 wherein n is 0, 1 or 2. Embodiment 97a. A compound of Embodiment 97 wherein n is 1 or 2. Embodiment 97b. A compound of Embodiment 97a wherein n is 2. Embodiment 98. A compound of Embodiment 97 wherein n is 0 or 1. Embodiment 99. A compound of Embodiment 98 wherein n is 1. Embodiment 100. A compound of Embodiment 98 wherein n is 0. Embodiment 101. A compound of Formula 1 or any one of Embodiments 1 through 100 wherein L is a direct bond, CH 2 , CH(Me) or CH 2 CH 2 . Embodiment 102. A compound of Embodiment 101 wherein L is a direct bond, CH 2 or CH 2 CH 2 . Embodiment 103. A compound of Embodiment 102 wherein L is a direct bond or CH 2 . Embodiment 104. A compound of Embodiment 103 wherein L is CH 2 . Embodiment 105. A compound of Embodiment 103 wherein L is a direct bond. Embodiment 106. A compound of Formula 1 or any one of Embodiments 1 through 105 wherein G is selected from G-1 through G-118 as shown in Exhibit A. Exhibit A

wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3 and y is 0, 1, 2 or 3. Embodiment 107. A compound of Embodiment 106 wherein G is G-1 through G-16, G-20, G-22 through G-30, G-36 through G-42, G-54 through G-60, G-85, G-86, G-108, G-110 or G-111. Embodiment 107a. A compound of Embodiment 107 wherein G is G-20. Embodiment 107b. A compound of Embodiment 106 wherein G is G-1, G-12, G-20, G-103 and G-104. Embodiment 108. A compound of Embodiment 107 wherein G is G-1 through G-16, G-22, G-24, G-25, G-26, G-28, G-29, G-30, G-36, G-37, G-38, G-41, G-42, G-54, G-57, G-58, G-59, G-60, G-85, G-86, G-108, G-110 or G-111. Embodiment 109. A compound of Embodiment 108 wherein G is G-1 through G-13, G-22, G-24, G-25, G-26, G-28, G-29, G-41, G-42, G-54, G-57, G-58, G-59 or G-60. Embodiment 110. A compound of Embodiment 109 wherein G is G-1, G-2, G-3, G-7, G-8, G-9, G-10, G-12, G-13, G-22, G-29, G-42, G-54 or G-58. Embodiment 111. A compound of Embodiment 110 wherein G is G-1, G-3, G-12, G-13, G-22 or G-42. Embodiment 112. A compound of Embodiment 111 wherein G is G-1, G-3, G-12 or G-13. Embodiment 113. A compound of Embodiment 112 wherein G is G-1, G-12 or G-13. Embodiment 114. A compound of Embodiment 112 wherein G is G-1. Embodiment 115. A compound of Embodiment 112 wherein G is G-3. Embodiment 116. A compound of Embodiment 112 wherein G is G-12. Embodiment 117. A compound of Embodiment 112 wherein G is G-13. Embodiment 118. A compound of Embodiment 114 wherein the 2-position of G-1 is connected to Z and the 4-position is connected to R 9 . Embodiment 119. A compound of Embodiment 114 wherein the 2-position of G-1 is connected to Z and the 5-position is connected to R 9 . Embodiment 120. A compound of Embodiment 115 wherein the 1-position of G-3 is connected to Z and the 4-position is connected to R 9 . Embodiment 121. A compound of Embodiment 116 wherein the 1-position of G-12 is connected to Z and the 4-position is connected to R 9 . Embodiment 122. A compound of Embodiment 116 wherein the 1-position of G-12 is connected to Z and the 3-position is connected to R 9 . Embodiment 123. A compound of Embodiment 116 wherein the 1-position of G-12 is connected to Z, the 3-position is connected to R 9 and the 5-position is connected to R 10 . Embodiment 124. A compound of Embodiment 116 wherein the 1-position of G-12 is connected to Z and the 5-position is connected to R 9 . Embodiment 125. A compound of Embodiment 117 wherein the 1-position of G-13 is connected to Z and the 4-position is connected to R 9 . Embodiment 126. A compound of Embodiment 117 wherein the 1-position of G-13 is connected to Z and the 5-position is connected to R 9 . Embodiment 127. A compound of any one of Embodiments 106 through 126 wherein x is 1 or 2. Embodiment 128. A compound of Embodiment 127 wherein x is 1. Embodiment 129. A compound of Embodiment 127 wherein x is 2. Embodiment 130. A compound of any one of Embodiments 106 through 129 wherein y is 0, 1 or 2. Embodiment 131. A compound of Embodiment 130 wherein y is 0 or 1. Embodiment 132. A compound of Embodiment 131 wherein y is 0. Embodiment 133. A compound of Formula 1 or any one of Embodiments 1 through 132 wherein each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl). Embodiment 133a. A compound of Embodiment 133 wherein each R 9 is independently -CH 2 R 9a , -CH 2 CH 2 R 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl). Embodiment 133b. A compound of Embodiment 133a wherein each R 9 is independently -CH 2 R 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl). Embodiment 133c. A compound of Embodiment 133b wherein each R 9 is independently -CH 2 R 9a , C(=O)NR 12a R 12b or C(R 12e )=NR 12f . Embodiment 134. A compound of Embodiment 133 wherein each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b or C 2 -C 4 alkoxy(thiocarbonyl). Embodiment 135. A compound of Embodiment 134 wherein each R 9 is independently C 2 -C 4 alkoxy(thiocarbonyl). Embodiment 135a. A compound of Embodiment 134 wherein each R 9 is independently -(CR 11a R 11b )mR 9a . Embodiment 135b. A compound of Embodiment 135a wherein each R 9 is independently -CH 2 R 9a . Embodiment 136. A compound of Embodiment 134 wherein each R 9 is independently C(=O)NR 12a R 12b . Embodiment 137. A compound of Formula 1 or any one of Embodiments 1 through 132 wherein each R 9 is independently C(R 12e )=NR 12f . Embodiment 138. A compound of Formula 1 or any one of Embodiments 1 through 135 wherein each m is independently 1 or 2. Embodiment 138a. A compound of Embodiment 138 wherein each m is 1. Embodiment 139. A compound of Formula 1 or any one of Embodiments 1 through 138a wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl or C 3 -C 8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 140. A compound of Embodiment 139 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 141. A compound of Embodiment 140 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 2 -C 8 alkynyloxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 142. A compound of Embodiment 141 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy, C 2 -C 6 alkoxycarbonylalkoxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 143. A compound of Embodiment 142 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 143a. A compound of Embodiment 143 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 . Embodiment 143b. A compound of Embodiment 143a wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R 13 . Embodiment 144. A compound of Embodiment 143 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 144a. A compound of Embodiment 144 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 . Embodiment 145. A compound of Embodiment 144 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R 13 . Embodiment 146. A compound of Embodiment 145 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R 13 . Embodiment 147. A compound of Embodiment 146 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 4 alkylcarbonyloxy or C 2 -C 4 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R 13 . Embodiment 147a. A compound of Embodiment 146 wherein each R 9a is independently OC(=O)NR 12c R 12d , C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy. Embodiment 147b. A compound of Embodiment 147a wherein each R 9a is independently OC(=O)NR 12c R 12d . Embodiment 147c. A compound of Embodiment 147a wherein each R 9a is independently C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy. Embodiment 148. A compound of Formula 1 or any one of Embodiments 1 through 138a wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl or C 3 -C 8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 . Embodiment 148a. A compound of Embodiment 148 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R 13 . Embodiment 148b. A compound of Embodiment 148a wherein each R 9a is independently R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 3 -C 6 alkenyloxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R 13 . Embodiment 149. A compound of Embodiment 148b wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy or C 3 -C 9 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R 13 . Embodiment 150. A compound of Embodiment 149 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 2 -C 8 alkenyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy or C 3 -C 9 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R 13 . Embodiment 151. A compound of Embodiment 150 wherein each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy or C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R 13 . Embodiment 151a. A compound of Embodiment 151 wherein each R 9a is independently OC(=O)NR 12c R 12d , C 2 -C 8 alkylcarbonyloxy or C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy. Embodiment 151b. A compound of Embodiment 151a wherein each R 9a is independently OC(=O)NR 12c R 12d , C 2 -C 4 alkylcarbonyloxy or C 4 -C 5 cycloalkylcarbonyloxy, C 2 -C 4 alkoxycarbonyloxy. Embodiment 152. A compound of Formula 1 or any one of Embodiments 1 through 151 wherein each R 10 is independently cyano, halogen, NR 14a R 14b , C(=O)NR 14a R 14b , C(R 15 )=NR 16 , N=CR 17 NR 18a R 18b or -U-V-Q; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 alkylsulfonylamino, C 2 -C 6 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 3 -C 6 alkenyloxycarbonyl, C 3 -C 6 alkynyloxycarbonyl, C 4 -C 7 cycloalkoxycarbonyl, C 2 -C 6 alkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy, C 4 -C 7 cycloalkoxycarbonyloxy, C 2 -C 6 alkylaminocarbonyloxy, C 2 -C 6 alkylcarbonylamino, C 2 -C 6 alkoxycarbonylamino or C 2 -C 6 alkylaminocarbonylamino, each optionally substituted with up to 3 substituents independently selected from R 19 . Embodiment 153. A compound of Embodiment 152 wherein each R 10 is independently cyano, halogen, C(=O)NR 14a R 14b or -U-V-Q; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 alkylsulfonylamino, C 2 -C 6 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 3 -C 6 alkenyloxycarbonyl, C 3 -C 6 alkynyloxycarbonyl, C 4 -C 6 cycloalkoxycarbonyl or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 19 . Embodiment 154. A compound of Embodiment 153 wherein each R 10 is independently halogen, C(=O)NR 14a R 14b or -U-V-Q; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 alkylsulfonylamino, C 2 -C 6 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 3 -C 6 alkenyloxycarbonyl, C 3 -C 6 alkynyloxycarbonyl, C 4 -C 6 cycloalkoxycarbonyl or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 19 . Embodiment 155. A compound of Embodiment 154 wherein each R 10 is independently halogen, C(=O)NR 14a R 14b or -U-V-Q; or C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkenyloxycarbonyl, C 3 -C 5 alkynyloxycarbonyl or C 4 -C 6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R 19 . Embodiment 156. A compound of Embodiment 155 wherein each R 10 is independently halogen, C(=O)NR 14a R 14b ; or C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkenyloxycarbonyl, C 3 -C 5 alkynyloxycarbonyl or C 4 -C 6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R 19 . Embodiment 157. A compound of Embodiment 156 wherein each R 10 is independently halogen, C(=O)NR 14a R 14b or C 2 -C 5 alkoxycarbonyl. Embodiment 157a. A compound of Embodiment 157 wherein each R 10 is independently halogen or C 2 -C 3 alkoxycarbonyl. Embodiment 158. A compound of Formula 1 or any one of Embodiments 1 through 157a wherein each R 11a and R 11b is independently H, halogen, cyano, C 1 -C 2 alkyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl, C 2 -C 3 alkoxycarbonyl or C 2 -C 3 haloalkoxycarbonyl. Embodiment 159. A compound of Embodiment 158 wherein each R 11a and R 11b is independently H, methyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 alkoxycarbonyl or C 2 -C 3 haloalkoxycarbonyl. Embodiment 160. A compound of Embodiment 159 wherein each R 11a and R 11b is independently H, methyl or C 2 -C 3 alkoxycarbonyl. Embodiment 161. A compound of Embodiment 160 wherein each R 11a and R 11b is independently H, methyl or EtOC(=O). Embodiment 161a. A compound of Embodiment 161 wherein each R 11a and R 11b is independently H or EtOC(=O). Embodiment 162. A compound of Embodiment 161 wherein each R 11a and R 11b is H. Embodiment 163. A compound of Formula 1 or any one of Embodiments 1 through 162 wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl. Embodiment 163a. A compound of Embodiment 163 wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy. Embodiment 163b. A compound of Embodiment 163a wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy. Embodiment 163c. A compound of Embodiment 163b wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy or C 4 -C 8 cycloalkylalkoxy. Embodiment 163d. A compound of Embodiment 163c wherein each R 12a is independently C 1 -C 3 haloalkoxy, C 2 -C 4 alkenyloxy or C 4 -C 5 cycloalkylalkoxy. Embodiment 164. A compound of Formula 1 or any one of Embodiments 1 through 163d wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy or C 4 -C 8 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl. Embodiment 165. A compound of Embodiment 164 wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy or C 4 -C 8 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl. Embodiment 166. A compound of Embodiment 165 wherein each R 12a is independently C 1 -C 4 haloalkoxy, C 2 -C 4 cyanoalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 2 -C 4 alkynyloxy, C 2 -C 4 haloalkynyloxy or C 4 -C 6 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl. Embodiment 167. A compound of Embodiment 166 wherein each R 12a is independently C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 2 -C 4 alkynyloxy or C 4 -C 6 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl. Embodiment 168. A compound of Embodiment 167 wherein each R 12a is independently C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 6 cycloalkylalkoxy or phenyl-CH 2 O. Embodiment 169. A compound of Embodiment 168 wherein each R 12a is independently C 1 -C 3 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy or phenyl-CH 2 O. Embodiment 170. A compound of Embodiment 165 wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 4 -C 8 cycloalkylalkoxy or phenyl-CH 2 O. Embodiment 170a. A compound of Embodiment 170 wherein each R 12a is independently C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy or C 4 -C 8 cycloalkylalkoxy. Embodiment 171. A compound of Embodiment 170 wherein each R 12a is independently C 1 -C 3 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 6 cycloalkylalkoxy or phenyl-CH 2 O. Embodiment 172. A compound of Embodiment 171 wherein each R 12a is independently C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 5 cycloalkylalkoxy or phenyl-CH 2 O. Embodiment 173. A compound of Formula 1 or any one of Embodiments 1 through 172 wherein each R 12b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl. Embodiment 174. A compound of Embodiment 173 wherein each R 12b is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl. Embodiment 175. A compound of Embodiment 174 wherein each R 12b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl. Embodiment 176. A compound of Embodiment 175 wherein each R 12b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl. Embodiment 177. A compound of Embodiment 176 wherein each R 12b is independently H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl. Embodiment 178. A compound of Embodiment 177 wherein each R 12b is independently H or methyl. Embodiment 179. A compound of Embodiment 178 wherein each R 12b is H. Embodiment 180. A compound of Formula 1 or any one of Embodiments 1 through 179 wherein when each R 12c is separate (i.e. not taken together with R 12d to form a ring), then each R 12c is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl. Embodiment 180a. A compound of Embodiment 180 wherein each R 12c is independently C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 180b. A compound of Embodiment 180a wherein each R 12c is independently C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 4 -C 5 cycloalkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 181. A compound of Embodiment 180 wherein each R 12c is independently H, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 182. A compound of Embodiment 181 wherein each R 12c is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 183. A compound of Embodiment 182 wherein each R 12c is independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 183a. A compound of Embodiment 183 wherein each R 12c is independently C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl. Embodiment 183a. A compound of Embodiment 183 wherein each R 12c is independently H or methyl. Embodiment 184. A compound of Embodiment 183 wherein each R 12c is independently H or C 1 -C 3 alkoxy. Embodiment 185. A compound of Embodiment 184 wherein each R 12c is methoxy. Embodiment 186. A compound of Embodiment 184 wherein each R 12c is H. Embodiment 187. A compound of Formula 1 or any one of Embodiments 1 through 186 wherein when each R 12d is separate (i.e. not taken together with R 12c to form a ring), then each R 12d is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl. Embodiment 188. A compound of Embodiment 187 wherein each R 12d is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl. Embodiment 189. A compound of Embodiment 188 wherein each R 12d is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl. Embodiment 190. A compound of Embodiment 189 wherein each R 12d is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl. Embodiment 191. A compound of Embodiment 190 wherein each R 12d is independently H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or cyclopropylmethyl. Embodiment 192. A compound of Embodiment 191 wherein each R 12d is independently H, methyl or cyclopropylmethyl. Embodiment 193. A compound of Embodiment 192 wherein each R 12d is methyl. Embodiment 194. A compound of Embodiment 192 wherein each R 12d is H. Embodiment 195. A compound of Formula 1 or any one of Embodiments 1 through 194 wherein when R 12c and R 12d are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 196. A compound of Embodiment 195 wherein R 12c and R 12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 197. A compound of Embodiment 196 wherein R 12c and R 12d are taken together to form an azetidinyl or pyrrolidinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 198. A compound of Formula 1 or any one of Embodiments 1 through 197 wherein each R 12e is independently NH 2 , C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 3 -C 8 alkoxyalkoxyalkyl, C 2 -C 6 alkylaminoalkyl, C 3 -C 8 dialkylaminoalkyl or C 3 -C 8 alkylcarbonyl. Embodiment 199. A compound of Embodiment 198 wherein each R 12e is independently C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 1 -C 6 hydroxyalkyl, C 2 -C 6 cyanoalkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 6 alkoxyalkyl or C 2 -C 6 haloalkoxyalkyl. Embodiment 200. A compound of Embodiment 199 wherein each R 12e is independently C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 5 cycloalkylalkoxy or C 2 -C 6 alkoxyalkyl. Embodiment 201. A compound of Embodiment 200 wherein each R 12e is independently C 2 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy. Embodiment 202. A compound of Embodiment 201 wherein each R 12e is independently C 2 -C 3 alkyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy. Embodiment 202a. A compound of Embodiment 202 wherein each R 12e is independently C 2 -C 3 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy. Embodiment 203. A compound of Embodiment 202 wherein each R 12e is independently C 2 -C 4 alkoxy or C 1 -C 3 haloalkoxy. Embodiment 204. A compound of Embodiment 203 wherein each R 12e is ethoxy. Embodiment 205. A compound of Formula 1 or any one of Embodiments 1 through 204 wherein each R 12f is independently hydroxy or NR 20a R 20b ; or C 1 -C 6 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from cyano and halogen. Embodiment 206. A compound of Embodiment 205 wherein each R 12f is independently C 1 -C 5 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen. Embodiment 206a. A compound of Embodiment 206 wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen. Embodiment 206b. A compound of Embodiment 206a wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy or C 2 -C 4 alkylcarbonyloxy. Embodiment 206b. A compound of Embodiment 206a wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or C 4 -C 5 cycloalkylalkoxy. Embodiment 207. A compound of Embodiment 206 wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or C 4 -C 6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen. Embodiment 208. A compound of Embodiment 207 wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen. Embodiment 209. A compound of Embodiment 208 wherein each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or cyclopropylmethoxy. Embodiment 209a. A compound of Embodiment 209 wherein each R 12f is independently C 1 -C 4 alkoxy. Embodiment 210. A compound of Embodiment 209 wherein each R 12f is independently C 3 -C 4 alkenyloxy. Embodiment 211. A compound of Formula 1 or any one of Embodiments 1 through 210 wherein when each R 12i and R 12j is separate (i.e. not taken together to form a ring), then each R 12i and R 12j is independently H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or C 2 -C 4 alkylcarbonyl. Embodiment 212. A compound of Embodiment 211 wherein each R 12i and R 12j is independently H, methyl or C 2 -C 3 alkylcarbonyl. Embodiment 213. A compound of Formula 1 or any one of Embodiments 1 through 212 wherein each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 alkylsufonyl or C 3 -C 6 cycloalkyl. Embodiment 214. A compound of Embodiment 213 wherein each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl. Embodiment 215. A compound of Embodiment 214 wherein each R 13 is independently halogen, cyano, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl. Embodiment 216. A compound of Embodiment 215 wherein each R 13 is independently Br, Cl, F, cyano, methoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 2 alkylthio or cyclopropyl. Embodiment 217. A compound of Embodiment 216 wherein each R 13 is independently Br, Cl, F, cyano, methoxy, CH 3 OC(=O), CH 3 S or cyclopropyl. Embodiment 218. A compound of Embodiment 217 wherein each R 13 is independently Br, Cl, F, cyano, methoxy, CH 3 OC(=O) or CH 3 S. Embodiment 219. A compound of Formula 1 or any one of Embodiments 1 through 218 wherein when each R 14a is separate (i.e. not taken together with R 14b to form a ring), then each R 14a is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 2 -C 4 haloalkynyl, C 2 -C 4 alkylcarbonyl, C 2 -C 5 alkoxycarbonyl or C 3 -C 5 dialkylaminocarbonyl. Embodiment 220. A compound of Embodiment 219 wherein each R 14a is independently H, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkylcarbonyl, C 2 -C 5 alkoxycarbonyl or C 3 -C 5 dialkylaminocarbonyl. Embodiment 221. A compound of Embodiment 220 wherein each R 14a is independently H, C 1 -C 2 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl. Embodiment 222. A compound of Embodiment 198 wherein each R 14a is independently H or C 1 -C 2 alkyl. Embodiment 223. A compound of Embodiment 222 wherein each R 14a is independently H or methyl. Embodiment 224. A compound of Embodiment 223 wherein each R 14a is H. Embodiment 225. A compound of Formula 1 or any one of Embodiments 1 through 224 wherein when each R 14b is separate (i.e. not taken together with R 14a to form a ring), then each R 14b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl. Embodiment 226. A compound of Embodiment 225 wherein each R 14b is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl. Embodiment 227. A compound of Embodiment 226 wherein each R 14b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl. Embodiment 228. A compound of Embodiment 227 wherein each R 14b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl. Embodiment 229. A compound of Embodiment 228 wherein each R 14b is independently H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or cyclopropylmethyl. Embodiment 300. A compound of Embodiment 229 wherein each R 14b is independently H, methyl or cyclopropylmethyl. Embodiment 301. A compound of Formula 1 or any one of Embodiments 1 through 300 wherein when R 14a and R 14b are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 302. A compound of Embodiment 301 wherein R 14a and R 14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 303. A compound of Embodiment 302 wherein R 14a and R 14b are taken together to form an azetidinyl or pyrrolidinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl. Embodiment 304. A compound of Formula 1 or any one of Embodiments 1 through 303 wherein each R 15 is independently H, cyano, halogen, methyl or methoxy. Embodiment 305. A compound of Embodiment 304 wherein each R 15 is independently H or methyl. Embodiment 306. A compound of Formula 1 or any one of Embodiments 1 through 305 wherein each R 16 is independently hydroxy, NR 20a R 20b , C 1 -C 2 alkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 4 alkoxycarbonyloxy. Embodiment 307. A compound of Embodiment 306 wherein each R 16 is independently hydroxy, NR 20a R 20b or C 1 -C 4 alkoxy. Embodiment 308. A compound of Embodiment 307 wherein each R 16 is independently hydroxy, NR 20a R 20b or methoxy. Embodiment 309. A compound of Embodiment 308 wherein each R 16 is hydroxy. Embodiment 310. A compound of Formula 1 or any one of Embodiments 1 through 309 wherein each R 17 is independently H or methyl. Embodiment 311. A compound of Embodiment 310 wherein each R 17 is H. Embodiment 312. A compound of Formula 1 or any one of Embodiments 1 through 311 wherein each R 18a and R 18b is independently H, methyl or ethyl. Embodiment 313. A compound of Embodiment 312 wherein each R 18a and R 18b is independently H or methyl. Embodiment 314. A compound of Formula 1 or any one of Embodiments 1 through 313 wherein each R 19 is independently cyano, halogen, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 2 -C 3 alkoxyalkoxy, C 1 -C 3 alkylthio, C 1 -C 3 alkylsulfinyl, C 1 -C 3 alkylsulfonyl, C 1 -C 3 haloalkylsulfonyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl, C 2 -C 3 alkoxycarbonyl, C 2 -C 3 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl. Embodiment 315. A compound of Embodiment 314 wherein each R 19 is independently cyano, halogen, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 2 alkoxy, C 1 -C 2 haloalkoxy, C 1 -C 2 alkylthio, C 1 -C 2 alkylsulfonyl, C 1 -C 2 haloalkylsulfonyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl, C 2 -C 3 alkoxycarbonyl or C 2 -C 3 alkylaminocarbonyl. Embodiment 316. A compound of Embodiment 315 wherein each R 19 is independently cyano, halogen, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 2 alkoxy, C 1 -C 2 haloalkoxy, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl or C 2 -C 3 alkoxycarbonyl. Embodiment 317. A compound of Embodiment 316 wherein each R 19 is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy or methoxycarbonyl. Embodiment 318. A compound of Embodiment 317 wherein each R 19 is independently cyano, halogen, cyclopropyl or methoxy. Embodiment 319. A compound of Embodiment 318 wherein each R 19 is independently halogen. Embodiment 320. A compound of Embodiment 319 wherein each R 19 is independently cyano, Cl, F, cyclopropyl or methoxy. Embodiment 321. A compound of Formula 1 or any one of Embodiments 1 through 320 wherein each U is independently a direct bond, C(=O)O or C(=O)N(R 25 ). Embodiment 322. A compound of Embodiment 321 wherein each U is independently a direct bond or C(=O)O. Embodiment 323. A compound of Embodiment 322 wherein each U is C(=O)O. Embodiment 324. A compound of Formula 1 or any one of Embodiments 1 through 323 wherein each V is independently a direct bond; or C 1 -C 6 alkylene, C 2 -C 6 alkenylene or C 3 -C 6 alkynylene, each optionally substituted with up to 2 substituents independently selected from halogen, cyano, nitro, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy. Embodiment 325. A compound of Embodiment 324 wherein each V is independently a direct bond; or C 1 -C 3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy. Embodiment 326. A compound of Embodiment 325 wherein each V is independently a direct bond or C 1 -C 3 alkylene. Embodiment 327. A compound of Embodiment 326 wherein each V is independently a direct bond or CH 2 . Embodiment 328. A compound of Embodiment 327 wherein each V is a direct bond. Embodiment 329. A compound of Embodiment 328 wherein each V is independently C 1 -C 2 alkylene. Embodiment 330. A compound of Embodiment 329 wherein each V is CH 2 . Embodiment 331. A compound of Formula 1 or any one of Embodiments 1 through 330 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R 27 ; or a 3- to 6-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(=O), C(=S), S(=O) and S(=O) 2 , each ring optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 332. A compound of Embodiment 331 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, thienyl, isoxazolinyl, piperidinyl, morpholinyl or piperazinyl, each optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 333. A compound of Embodiment 332 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 334. A compound of Embodiment 333 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or pyridinyl or pyrazolyl, each optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 335. A compound of Embodiment 334 wherein each Q is independently phenyl or pyridinyl, each optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 336. A compound of Embodiment 335 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 . Embodiment 337. A compound of Formula 1 or any one of Embodiments 1 through 336 wherein when each R 20a is separate (i.e. not taken together with R 20b to form a ring), then each R 20a is independently H, methyl or methylcarbonyl. Embodiment 338. A compound of Formula 1 or any one of Embodiments 1 through 337 wherein when each R 20b is separate (i.e. not taken together with R 20a to form a ring), then each R 20b is independently H, cyano, methyl, methylcarbonyl, methoxycarbonyl, methoxycarbonylmethyl, methylaminocarbonyl or dimethylaminocarbonyl. Embodiment 339. A compound of Formula 1 or any one of Embodiments 1 through 338 wherein when R 20a and R 20b are taken together to form a 5- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 methyl groups. Embodiment 340. A compound of Embodiment 339 wherein R 20a and R 20b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 methyl groups. Embodiment 341. A compound of Formula 1 or any one of Embodiments 1 through 247 wherein each R 21 and R 23 is independently H, cyano, halogen, methyl or methoxy. Embodiment 342. A compound of Formula 1 or any one of Embodiments 1 through 341 wherein each R 22 is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkylcarbonyl or C 2 -C 3 alkoxycarbonyl; or phenyl optionally substituted with up to 2 substituents independently selected halogen and methyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and methyl. Embodiment 343. A compound of Embodiment 342 wherein each R 22 is independently H or C 1 -C 2 alkyl. Embodiment 344. A compound of Formula 1 or any one of Embodiments 1 through 343 wherein each R 24 is independently H, cyano or C 1 -C 2 alkyl. Embodiment 345. A compound of Formula 1 or any one of Embodiments 1 through 344 wherein each R 25 and R 26 is independently H, cyano, hydroxy, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl. Embodiment 346. A compound of Embodiment 345 wherein each R 25 and R 26 is independently H, cyano, hydroxy or C 1 -C 2 alkyl. Embodiment 347. A compound of Formula 1 or any one of Embodiments 1 through 346 wherein each R 27 is independently halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy. Embodiment 348. A compound of Embodiment 347 wherein each R 27 is independently halogen, cyano, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or C 1 -C 2 alkoxy. Embodiment 349. A compound of Embodiment 348 wherein each R 27 is independently halogen, methyl or methoxy. Embodiment 350. A compound of Formula 1 or any one of Embodiments 1 through 349 wherein Z is a direct bond, O, NH, C(=O), C(=O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) 2 NH, NHS(=O) 2 or NHS(=O) 2 NH. Embodiment 351. A compound of Embodiment 350 wherein Z is a direct bond, O, NH, C(=O), C(=O)NH or NHC(=O). Embodiment 352. A compound of Embodiment 351 wherein Z is a direct bond, O, NH or C(=O). Embodiment 353. A compound of Embodiment 352 wherein Z is a direct bond. Embodiment 354. A compound of Formula 1 or any one of Embodiments 1 through 353 wherein each R 28 is independently H or C 1 -C 3 alkyl. Embodiment 355. A compound of Embodiment 354 wherein each R 28 is independently H or methyl. Embodiment 356. A compound of Formula 1 or any one of Embodiments 1 through 355 wherein p is 0 or 2. Embodiment 357. A compound of Embodiment 356 wherein p is 2. Embodiments of this invention, including Embodiments 1-357 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. In addition, embodiments of this invention, including Embodiments 1-357 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention. Combinations of Embodiments 1-357 are illustrated by: Embodiment A. A compound of Formula 1 wherein T is T-2 or T-3; R 1 is CF 3 ; X is O; Y is O; R 2a and R 2b are each independently H or C 1 -C 2 alkyl; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members; R 2c is methyl or ethyl; R 2d is H or methyl; A 1 is CR 5a R 5b or O; A 2 is a direct bond, CR 5a R 5b or O; each R 5a and R 5b is independently H or methyl; J is J-1, J-6 or J-14; each R 7 is independently F, Cl or methyl; q is 0, 1 or 2; each R 8a and R 8b is independently H, halogen or methyl; n is 0, 1 or 2; G is selected from the group consisting of:

wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3; and y is 0, 1, 2 or 3; each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); each m is independently 1 or 2; each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl or C 3 -C 8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 ; each R 10 is is independently halogen, C(=O)NR 14a R 14b or -U-V-Q; or C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkenyloxycarbonyl, C 3 -C 5 alkynyloxycarbonyl or C 4 -C 6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R 19 ; each R 11a and R 11b is independently H, methyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 alkoxycarbonyl or C 2 -C 3 haloalkoxycarbonyl; each R 12a is independently C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy or C 4 -C 8 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; each R 12b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; each R 12c is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; each R 12d is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; or R 12c and R 12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R 12e is independently C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 5 cycloalkylalkoxy or C 2 -C 6 alkoxyalkyl; each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 alkylsufonyl or C 3 -C 6 cycloalkyl; each R 14a is independently H, C 1 -C 2 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; each R 14b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl; or R 14a and R 14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R 19 is independently cyano, halogen, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 2 alkoxy, C 1 -C 2 haloalkoxy, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl or C 2 -C 3 alkoxycarbonyl; each U is independently a direct bond, C(=O)O or C(=O)N(R 25 ); each V is independently a direct bond; or C 1 -C 3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy; each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R 27 ; each R 25 is independently H, cyano, hydroxy or C 1 -C 2 alkyl; each R 27 is independently halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy; and Z is a direct bond, O, NH, C(=O), C(=O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) 2 NH, NHS(=O) 2 or NHS(=O) 2 NH. Embodiment B. A compound of Embodiment A wherein R 2a and R 2b are each independently H or methyl; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member; A 1 is O; A 2 is a direct bond, CH 2 or O; J is J-1; q is 0; each R 8a and R 8b is independently H or methyl; n is 0 or 1; G is G-1, G-3, G-12 or G-13; x is 1 or 2; y is 0 or 1; each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R 13 ; R 10 is halogen, C(=O)NR 14a R 14b ; or C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkenyloxycarbonyl, C 3 -C 5 alkynyloxycarbonyl or C 4 -C 6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R 19 ; each R 11a and R 11b is independently H, methyl or C 2 -C 3 alkoxycarbonyl; each R 12a is independently C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 2 -C 4 alkynyloxy or C 4 -C 6 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R 12b is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl; each R 12c is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; each R 12d is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl; each R 12e is independently C 2 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or C 4 -C 6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl; R 14a is H or C 1 -C 2 alkyl; R 14b is H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or cyclopropylmethyl; each R 19 is independently halogen; and Z is a direct bond, O, NH or C(=O). Embodiment C. A compound of Embodiment B wherein R 2a and R 2b are each H; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R 2c is ethyl; R 2d is H; A 2 is a direct bond; each R 8a and R 8b is H; n is 1; G is G-12; x is 1; y is 0; R 9 is -CH 2 R 9a , -CH 2 CH 2 R 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 ; R 12a is C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 6 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl; R 12c is H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; R 12d is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl; R 12e is C 2 -C 3 alkyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; R 12f is C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl; and Z is a direct bond. Embodiment D. A compound of Embodiment C wherein T is T-3; R 9 is -CH 2 R 9a , C(=O)NR 12a R 12b or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R 13 ; R 12a is C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 5 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; R 12c is H or C 1 -C 3 alkoxy; R 12d is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl; and each R 13 is independently Br, Cl, F, cyano, methoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 2 alkylthio or cyclopropyl. Embodiment E. A compound of Embodiment D wherein G is G-12 connected at the 1-position to Z and the 4-position is connected to R 9 ; or G is G-12 connected at the 1-position to Z and the 3-position is connected to R 9 ; or G is G-12 connected at the 1-position to Z and the 5-position is connected to R 9 ; R 9 is -CH 2 R 9a ; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy each optionally substituted with up to 1 substituent selected from R 13 ; R 12c is methoxy; R 12d is H, methyl or cyclopropylmethyl; and R 13 is Br, Cl, F, cyano, methoxy, CH 3 OC(=O), CH 3 S or cyclopropyl. Embodiment F. A compound of Embodiment C wherein T is T-2; R 9 is -CH 2 R 9a , C(=O)NR 12a R 12b or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 ; R 12a is C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 5 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; R 12c is H or C 1 -C 3 alkoxy; R 12d is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl; and each R 13 is independently Br, Cl, F, cyano, methoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 2 alkylthio or cyclopropyl. Embodiment G. A compound of Formula 1 wherein T is T-2 or T-3; R 1 is CF 3 ; X is O; Y is O; R 2a and R 2b are each H; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R 2c is methyl or ethyl; R 2d is H; A 1 is O; A 2 is a direct bond; each R 5a and R 5b is H; J is J-1, J-6 or J-14; each R 7 is F; q is 0, 1 or 2; each R 8a and R 8b is H; n is 1 or 2; G is selected from the group consisting of: wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring; x is 1; and y is 0 or 1; R 9 is -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); m is 1; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl or C 3 -C 8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 ; R 10 is halogen or C 2 -C 3 alkoxycarbonyl; each R 11a and R 11b is independently H, methyl or C 2 -C 3 alkoxycarbonyl; R 12a is C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy; or phenyl-CH 2 O, the phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; R 12b is H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; R 12c is H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; R 12d is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C3- C8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; or R 12c and R 12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; R 12e is C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkoxy, C 1- C 6 haloalkoxy, C 4 -C 5 cycloalkylalkoxy or C 2 -C 6 alkoxyalkyl; R 12f is C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 alkylsufonyl or C 3 -C 6 cycloalkyl; and Z is a direct bond, O, NH or C(=O). Embodiment H. A compound of Embodiment G wherein R 2c is ethyl; J is J-1; n is 1; G is G-12 or G-20; y is 0; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C4- C9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R 13 ; each R 11a and R 11b is independently H or EtOC(=O); R 12a is C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy; R 12b is H or methyl; R 12c is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 - C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl or C 2 -C 5 alkoxycarbonyl; R 12d is H or methyl; R 12e is C 2 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; R 12f is C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy or C 2 -C 4 alkylcarbonyloxy; each R 13 is independently halogen, cyano, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl; and Z is a direct bond. Embodiment I. A compound of Embodiment H wherein T is T-3; q is 0; G is G-12; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 3 -C 9 cycloalkoxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 3 -C 6 alkenyloxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 2 substituents independently selected from R 13 ; each R 11a and R 11b is H; R 12a is C 1 -C 6 haloalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 4 -C 8 cycloalkylalkoxy or C 2 -C 6 alkoxyalkoxy; R 12c is C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 4 -C 5 cycloalkylcarbonyl or C 2 -C 5 alkoxycarbonyl; R 12e is C 2 -C 3 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; R 12f is C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or C 4 -C 5 cycloalkylalkoxy; and R 13 is Br, Cl, F, cyano, methoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 2 alkylthio or cyclopropyl. Embodiment J. A compound of Embodiment I wherein R 9 is -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b or C(R 12e )=NR 12f ; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 6 alkoxycarbonylalkoxy or C 3 -C 6 alkenyloxycarbonyl, each optionally substituted with up to 2 substituents independently selected from R 13 ; R 12a is C 1 -C 6 haloalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy or C 4 -C 8 cycloalkylalkoxy; R 12b is H; R 12c is C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; R 12e is ethoxy; R 12f is C 1 -C 4 alkoxy; and R 13 is Br, Cl, F, cyano, methoxy, CH 3 OC(=O), CH 3 S or cyclopropyl. Specific embodiments include compounds of Formula 1 selected from the group consisting of: O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1- yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate (Compound 7); (Z)-(1-(4-((2-ethoxy-3,3,3-trifluoroprop-1-en-1-yl)oxy)benzy l)-1H-pyrazol-4- yl)methyl methoxy(methyl)carbamate (Compound 18); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl propanoate (Compound 21); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl acetate (Compound 22); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 2-methoxyacetate (Compound 23); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 3-methylbutanoate (Compound 27); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 2-methylpentanoate (Compound 30); 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-N- (phenylmethoxy)-1H-pyrazole-4-carboxamide (Compound 31); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 3,3,3-trifluoropropanoate (Compound 35); 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-N- (2,2,2-trifluoroethoxy)-1H-pyrazole-4-carboxamide (Compound 45); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 3-methylbutanoate (Compound 46); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 2,2-dimethylpropanoate (Compound 47); 1-[[1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy] phenyl]methyl]-1H- pyrazol-4-yl]methyl] 2-methyl ethanedioate (Compound 48); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl 3-(methylthio)propanoate (Compound 50); and 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-1H- pyrazol-4-yl]methyl methyl carbonate (Compound 52). Combinations of Embodiments 1-264 are also illustrated by: Embodiment AA. A compound of Formula 1 wherein T is T-2 or T-3; R 1 is CF 3 ; X is O; Y is O; R 2a and R 2b are each independently H or C 1 -C 2 alkyl; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(=O) and C(=S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members; R 2c is methyl or ethyl; R 2d is H or methyl; A 1 is CR 5a R 5b or O; A 2 is a direct bond, CR 5a R 5b or O; each R 5a and R 5b are independently H, cyano, hydroxy, Br, Cl, F or methyl; J is J-1, J-2, J-3, J-6 or J-14; each R 7 is independently F, Cl or methyl; q is 0, 1 or 2; each R 8a and R 8b is independently H, halogen or methyl; n is 0, 1 or 2; G is selected from the group consisting of G-1 through G-118, wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3; and y is 0, 1, 2 or 3; each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); each m is independently 1 or 2; each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkylsufonylalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylthio, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 5 -C 10 cycloalkylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl, C 5 -C 10 cycloalkylalkoxycarbonyl, C 3 -C 9 alkoxycarbonylcarbonyl or C 3 -C 8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R 13 ; each R 10 is independently halogen, C(=O)NR 14a R 14b or -U-V-Q; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 alkynyloxy, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 alkylsulfonylamino, C 2 -C 6 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 3 -C 6 alkenyloxycarbonyl, C 3 -C 6 alkynyloxycarbonyl, C 4 -C 6 cycloalkoxycarbonyl or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 19 ; each R 11a and R 11b is independently H, methyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 alkoxycarbonyl or C 2 -C 3 haloalkoxycarbonyl; each R 12a is independently C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkoxy, C 2 -C 6 cyanoalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy or C 4 -C 8 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; each R 12b is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; each R 12c is independently H, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 4 -C 7 cycloalkylcarbonyl, C 2 -C 5 alkoxycarbonyl, C 2 -C 5 alkylaminocarbonyl or C 3 -C 5 dialkylaminocarbonyl; each R 12d is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 cyanoalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 halocycloalkenyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 halocycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 2 -C 6 haloalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkylsulfonylalkyl, C 2 -C 6 alkylaminoalkyl or C 3 -C 8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; or R 12c and R 12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R 12e is independently C 2 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 4 -C 5 cycloalkylalkoxy or C 2 -C 6 alkoxyalkyl; each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 4 -C 6 cycloalkylalkoxy, C 2 -C 4 alkylcarbonyloxy or C 2 -C 5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio, C 1 -C 4 alkylsufonyl or C 3 -C 6 cycloalkyl; each R 14a is independently H, C 1 -C 2 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkylcarbonyl or C 2 -C 4 alkoxycarbonyl; each R 14b is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl; or R 14a and R 14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R 19 is independently cyano, halogen, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 2 alkoxy, C 1 -C 2 haloalkoxy, C 2 -C 3 alkylcarbonyl, C 2 -C 3 haloalkylcarbonyl or C 2 -C 3 alkoxycarbonyl; each U is independently a direct bond, C(=O)O or C(=O)N(R 25 ); each V is independently a direct bond; or C 1 -C 3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C 1 -C 2 alkyl, C 1 -C 2 alkoxy and C 1 -C 2 haloalkoxy; each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R 27 ; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R 27 ; each R 25 is independently H, cyano, hydroxy or C 1 -C 2 alkyl; each R 27 is independently halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy; and Z is a direct bond, O, NH, C(=O), C(=O)NH, NHC(=O), NHC(=O)NH, OC(=O)NH, NHC(=O)O, S(=O) 2 NH, NHS(=O) 2 or NHS(=O) 2 NH. Embodiment BB. A compound of Embodiment A wherein R 2a and R 2b are each independently H or methyl; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member; A 1 is O; A 2 is a direct bond, CH 2 or O; R 5a and R 5b are H; J is J-1, J-6 or J-14; q is 0; each R 8a and R 8b is independently H or methyl; n is 0 or 1; G is G-1, G-3, G-12 or G-13; x is 1 or 2; y is 0 or 1; each R 9 is independently -(CR 11a R 11b )mR 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); each R 9a is independently OC(=O)NR 12c R 12d ; or C 2 -C 8 alkylcarbonyloxy, C 3 -C 9 alkenylcarbonyloxy, C 3 -C 9 alkynylcarbonyloxy, C 4 -C 9 cycloalkylcarbonyloxy, C 2 -C 8 alkoxycarbonyloxy, C 4 -C 9 cycloalkylalkylcarbonyloxy, C 2 -C 8 alkenyloxy, C 2 -C 8 alkynyloxy, C 4 -C 10 cycloalkylalkoxy, C 2 -C 8 cyanoalkoxy, C 2 -C 8 alkoxycarbonylalkoxy, C 3 -C 9 alkoxycarbonylcarbonyloxy, C 2 -C 8 alkylcarbonylamino, C 3 -C 9 alkenylcarbonylamino, C 3 -C 9 alkynylcarbonylamino, C 2 -C 8 alkoxycarbonylamino, C 3 -C 6 alkenyloxycarbonyl or C 3 -C 9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R 13 ; R 10 is halogen, C(=O)NR 14a R 14b ; or C 2 -C 5 alkoxycarbonyl, C 3 -C 5 alkenyloxycarbonyl, C 3 -C 5 alkynyloxycarbonyl or C 4 -C 6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R 19 ; each R 11a and R 11b is independently H, methyl or C 2 -C 3 alkoxycarbonyl; each R 12a is independently C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 2 -C 4 alkynyloxy or C 4 -C 6 cycloalkylalkoxy; or phenyl-CH 2 O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R 12b is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl; each R 12c is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 5 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; each R 12d is independently H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 haloalkoxyalkyl, C 2 -C 4 alkylaminoalkyl or C 3 -C 5 dialkylaminoalkyl; each R 12e is independently C 2 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 3 alkenyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; each R 12f is independently C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or C 4 -C 6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl; R 14a is H or C 1 -C 2 alkyl; R 14b is H, C 1 -C 2 alkyl, C 1 -C 2 haloalkyl or cyclopropylmethyl; each R 19 is independently halogen; and Z is a direct bond, O, NH or C(=O). Embodiment CC. A compound of Embodiment B wherein R 2a and R 2b are each H; or R 2a and R 2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R 2c is ethyl; R 2d is H; A 2 is a direct bond; J is J-1; each R 8a and R 8b is H; n is 1; G is G-1, G-12 or G-13; x is 1; y is 0; R 9 is -CH 2 R 9a , -CH 2 CH 2 R 9a , C(=O)NR 12a R 12b , C(R 12e )=NR 12f or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 ; R 12a is C 1 -C 4 haloalkoxy, C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 6 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl; R 12c is H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl or C 2 -C 5 alkoxycarbonyl; R 12d is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 haloalkenyl, C 3 -C 5 cycloalkyl, C 4 -C 6 cycloalkylalkyl or C 2 -C 4 alkoxyalkyl; R 12e is C 2 -C 3 alkyl, C 2 -C 4 alkoxy, C 1 -C 3 haloalkoxy or C 4 -C 5 cycloalkylalkoxy; R 12f is C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R 13 is independently halogen, cyano, C 1 -C 4 alkoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 4 alkylthio or C 3 -C 5 cycloalkyl; and Z is a direct bond. Embodiment DD. A compound of Embodiment C wherein T is T-3; G is G-12; R 9 is -CH 2 R 9a , C(=O)NR 12a R 12b or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy, C 3 -C 6 alkenylcarbonyloxy, C 4 -C 6 cycloalkylcarbonyloxy, C 2 -C 6 alkoxycarbonyloxy or C 3 -C 6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 ; R 12a is C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 5 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; R 12c is H or C 1 -C 3 alkoxy; R 12d is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl; and each R 13 is independently Br, Cl, F, cyano, methoxy, C 2 -C 4 alkoxycarbonyl, C 1 -C 2 alkylthio or cyclopropyl. Embodiment EE. A compound of Embodiment D wherein G is G-12 connected at the 1-position to Z and the 4-position is connected to R 9 ; or G is G-12 connected at the 1-position to Z and the 3-position is connected to R 9 ; or G is G-12 connected at the 1-position to Z and the 5-position is connected to R 9 ; R 9 is -CH 2 R 9a ; R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy each optionally substituted with up to 1 substituent selected from R 13 ; R 12c is methoxy; R 12d is H, methyl or cyclopropylmethyl; and R 13 is Br, Cl, F, cyano, methoxy, CH 3 OC(=O), CH 3 S or cyclopropyl. Embodiment FF. A compound of Embodiment C wherein T is T-2; G is G-12; R 9 is -CH 2 R 9a , C(=O)NR 12a R 12b or C 2 -C 4 alkoxy(thiocarbonyl); R 9a is OC(=O)NR 12c R 12d ; or C 2 -C 6 alkylcarbonyloxy or C 2 -C 6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R 13 ; R 12a is C 2 -C 4 alkenyloxy, C 2 -C 4 haloalkenyloxy, C 4 -C 5 cycloalkylalkoxy or phenyl-CH 2 O; R 12b is H, C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; R 12c is H or C 1 -C 3 alkoxy; and R 12d is independently H, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropylmethyl or C 2 -C 4 alkoxyalkyl. In addition to the embodiments described above, this invention also provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, N-oxides, and salts thereof), and at least one other fungicide. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above. This invention also provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, N-oxides, and salts thereof) (i.e. in a fungicidally effective amount), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above. This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to a plant seed, a fungicidally effective amount of a compound of Formula 1 (including all stereoisomers, N-oxides, and salts thereof). Of note as embodiments of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments described above. Of particular note are embodiments where the compounds are applied as compositions of this invention. One or more of the following methods and variations as described in Schemes 1-23 can be used to prepare the compounds of Formula 1. The definitions of G, Z, L, A, A 1 , A 2 , J, T, X, Y, R 1 , R 2a , R 2b , R 2c , R 2d , R 5a and R 5b in the compounds of Formulae 1-23a below are as defined above in the Summary of the Invention unless otherwise noted. Compounds of Formulae 1a-1a1, 1b-1b4, 1c-1c1 and 1d-1d1 are various subsets of Formula 1, and all substituents for Formulae 1a- 1a1, 1b-1b 4 , 1c-1c 1 and 1d-1 d1 are as defined above for Formula 1 unless otherwise noted. As the synthetic literature includes many halomethyl ketone and hydrate-forming methods, which can readily be adapted to prepare compounds of the present invention, the following methods in Schemes 1-23 are representative examples of a wide variety of procedures useful for the preparation of compounds of Formula 1. For reviews of ketone and hydrate-forming methods, see, for example, Tetrahedron 1991, 47, 3207-3258 and Chem. Communications 2013, 49(95), 11133-11148, and references cited therein. Also see the methods outlined in U.S. Patent 6,350,892, and PCT publications WO 2018/080859, WO 2018/118781, WO 2018/187553, WO 2019/010192 and WO 2020/056090. Compounds of Formula 1 wherein G is a heterocyclic ring or ring system (e.g., pyrazole) linked to L via a nitrogen atom, and Z is a direct bond, can be prepared by displacement of an appropriate leaving group La of compounds of Formula 2 with nitrogen-containing heterocycles of Formula 3 in the presence of a base, as depicted in Scheme 1. Suitable bases include inorganic bases such as alkali or alkaline earth metal (e.g., lithium, sodium, potassium and cesium) hydrides, alkoxides, carbonates, phosphates and hydroxides. A variety of solvents are suitable for this method including, for example, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, acetonitrile and acetone. Particularly useful reaction conditions include using cesium carbonate or potassium carbonate as the base, and N,N-dimethylformamide or acetonitrile as the solvent at temperatures ranging between about 0 to 80 °C. Suitable leaving groups in the compounds of Formula 2 include bromide, chlorine, iodide, mesylate (OS(O) 2 CH 3 ), triflate (OS(O) 2 CF 3 ), and the like. For reaction conditions, see PCT publication WO 2018/187553 (Example 1, Step C, Examples 2-9, and Example 11, Step C). The method of Scheme 1 is also illustrated in present Example 1, Step F; Example 4, Step D; and Example 5, Step C. Scheme 1 Compounds of Formula 2 can be prepared by conversion of the corresponding alcohols of Formula 4 to an appropriate leaving group (i.e. La), as shown in Scheme 2. For example, alkyl chlorides of Formula 2 can be prepared by treating the corresponding alcohols with thionyl chloride, oxalyl chloride or phosphorus trichloride (for conditions, see present Example 5, Step B). Alkyl bromides can similarly be prepared using phosphorus tribromide or phosphorus oxybromide, or carbon tetrabromide or N-bromosuccinimide in the presence of triphenylphosphine (for conditions, see present Example 1, Step E and Example 4, Step C). Sulfonates can be prepared by reaction of a compound of Formula 4 with a sulfonating agent such as methanesulfonyl chloride, typically in the presence of a base, under conditions well known to one skilled in the art of organic synthesis. Scheme 2 General methods useful for preparing compounds of Formula 4 are well known in the literature. For example, as shown in Scheme 3, reduction of carboxylic esters of Formula 5 using a reducing agent such as lithium aluminum hydride or a borane/tetrahydrofuran complex in an aprotic solvent such as tetrahydrofuran or diethyl ether at temperatures from –78 °C to 25 °C provides compounds of Formula 4. For relevant literature references, see, for example, March and Smith, March’s Advanced Organic Chemistry, 5 th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 19; and Bulletin of the Chemical Society of Japan 1991, 64(9), 2730-2745. The method of Scheme 3 is also illustrated in present Example 1, Step D; and Example 4, Step B. Scheme 3 Alternatively, compounds of Formula 1 wherein G is an N-linked heterocycle can be prepared by reaction of primary or secondary alcohols of Formula 6 with nitrogen-containing heterocycles of Formula 3 using Mitsunobu coupling reaction conditions, as shown in Scheme 4. Mitsunobu reactions are typically run in tetrahydrofuran with triphenylphosphine and diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD) at room temperature. Polymer supported triphenylphosphine can be used to ease purification. For a review of the Mitsunobu reaction, see Mitsunobu, O. Comprehensive Organic Synthesis; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 6, pages 65-101. For reaction conditions, see PCT publication WO 2018/187553 (Example 12, Step C). Scheme 4 Compounds of Formula 1 can also be prepared by reaction of suitably functionalized compounds of Formula 7 with suitably functionalized compounds of Formula 8 as shown in Scheme 5. The functional groups Y 1 and Y 2 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amide oximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates (triflate), boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow for the construction of the various G rings. For example, reaction of a compound of Formula 7 where Y 1 is a chlorooxime moiety with a compound of Formula 8 where Y 2 is a vinyl or acetylene group in the presence of a base will give a compound of Formula 1 where G is an isoxazoline or isoxazole ring, respectively. For typical reaction conditions, see WO 2018/118781 (Examples 1, 2 and 6) and WO 2018/187553 (Example 13). The synthetic literature describes many general methods for forming heterocyclic rings and ring systems, such as those illustrated in G-1 through G-118 of Embodiment 106; see, for example, Comprehensive Heterocyclic Chemistry, Volumes 4-6, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984; Comprehensive Heterocyclic Chemistry II, Volumes 2-4, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996; and the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York. One skilled in the art knows how to select the appropriate functional groups Y 1 and Y 2 to construct the desired G rings. Scheme 5 As shown in Scheme 6, Compounds of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) wherein R 1 is CF 3 can be prepared by trifluoroacetylation of organometallic compounds of Formula 9. Typically, the ethyl ester of trifluoroacetic acid (i.e. ethyl trifluoroacetate) is used as the source of the trifluoroacetyl group in this method, but trifluoroacetonitrile and various trifluoroacetate salts can also be used. Depending on the reaction conditions, double addition on the trifluoroacetyl compound can occur. Conducting the reaction at –65 °C, or more preferably at –78 °C, can reduce the occurrence of double addition adducts to trace amounts, particularly when using organometallic species of Formula 9 wherein M is Li or MgBr. Many other organometallic species yield similar results. For reaction conditions useful in the method of Scheme 6, as well as other well-established routes for the synthesis of trifluoromethyl ketones see, for example, Journal of Organic Chemistry 1987, 52(22), 5026-5030; Chemical Communications 2013, 49(95), 11133-11148; and Journal of Fluorine Chemistry 1981, 18, 117-129. Conditions described in these references can easily be modified to prepare compounds of Formula 1a wherein R 1 is other than CF 3 (e.g., difluor- or trichloro-moieties). Scheme 6 Alternatively, compounds of Formula 1a can be prepared via alkylation of ethyl 4,4,4- trifluoroacetoacetate (ETFAA) with compounds of Formula 10 wherein La is a leaving group such as halogen (e.g., Cl, Br) or sulfonate (e.g., mesylate), and the like, as illustrated in Scheme 7. In this method ETFAA is first treated with a base such as sodium hydride in a polar aprotic solvent such as tetrahydrofuran, tetrahydrofuran/hexamethylphosphoramide (HMPA) or acetone. The ETFAA anion then displaces the leaving group in compounds of Formula 10 to give an intermediate ester which undergoes hydrolysis and decarboxylation in the presence of lithium chloride (LiCl) and N,N-dimethylformamide to provide ketones of Formula 1a. For reaction conditions see Journal of the Chemical Society, Chemical Communications 1989, (2), 83-84; Chemical Communications 2013, 49(95), 11133-11148; and Journal of Fluorine Chemistry 1989, 44, 377-394. Scheme 7 As shown in Scheme 8, compounds of Formula 1a can also be prepared by trifluoromethylation of an ester of Formula 11 with trifluoromethyltrimethylsilane (TMS-CF 3 ). The reaction is run in the presence of a fluoride initiator such as tetrabutylammonium fluoride, and in an anhydrous solvent such as toluene or dichloromethane at about –78 °C (for reaction conditions see, for example, Angew. Chem., Int. Ed.1998, 37(6), 820-821). Cesium fluoride can also be used as an initiator in a solvent such as 1,2-dimethoxyethane (glyme) at room temperature (for reaction conditions see, for example, J. Org. Chem.1999, 64, 2873). The reaction proceeds through a trimethylsilicate intermediate, which is hydrolyzed with aqueous acid to give the desired trifluoromethyl ketone compound of Formula 1a. Weinreb amides may also be used in place of the starting esters (for reaction conditions see, for example, Chem. Commun.2012, 48, 9610). Scheme 8 As shown in Scheme 9, compounds of Formula 1a1 (i.e. Formula 1a wherein A is A 1 -A 2 - CR 5a R 5b ) wherein R 1 is CF 3 and at least one R 5a or R 5b is H can be prepared by reacting acid chlorides of Formula 12 with trifluoroacetic anhydride (TFAA) and pyridine in a solvent such as dichloromethane or toluene at temperatures between about 0 to 80 °C, followed by aqueous hydrolysis (for reaction conditions see, for example, Tetrahedron 1995, 51, 2573-2584). Compounds of Formula 12 can be prepared from compounds of Formula 11 by ester hydrolysis to the corresponding carboxylic acid and treatment with oxalyl chloride, as known to one skilled in the art. Scheme 9 As shown in Scheme 10, compounds of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R 2a X and R 2b Y are OH can be prepared by reacting phenyl ketones of Formula 13 with trifluoroacetic esters (e.g., ethyl trifluoroacetate) in the presence of a base such as sodium hydride and in a solvent such as tetrahydrofuran, at a temperature between about 0 to 70 °C. The target compounds of Formula 1b are typically isolated as their ketone hydrates (i.e. dihydroxy) upon aqueous hydrolysis. For reaction conditions see, for example, Tetrahedron 2014, 70, 4668-4674; and Journal of Organic Chemistry 2013, 52, 4171-4176 Scheme 10 The method of Scheme 10 is also useful for preparing intermediates of Formula 5, which can subsequently be converted to compounds of Formula 1 using the methods of Schemes 1-3. Scheme 11 illustrates a specific example wherein a phenyl ketone of Formula 14 is reacted with ethyl trifluoroacetate in the presence of sodium hydride in tetrahydrofuran to provide a compound of Formula 5a (i.e. Formula 5 wherein A is OCH 2 , R 2a X and R 2b Y are OH and R 1 is CF 3 ). For reaction conditions, see present Example 1, Step B. Compounds of Formula 14 are available from commercial sources and can easily be prepared using commercial precursors and known methods. Present Example 1, Step A illustrates the preparation of a compound of Formula 14. Scheme 11 As shown in Scheme 12, compounds of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R 2a X and R 2b Y are OH can also be prepared by oxidation of alcohols of Formula 15 to the corresponding dihydroxy. The oxidation reaction can be performed by a variety of means, such as by treatment of the alcohols of Formula 15 with manganese dioxide, Dess-Martin periodinane, pyridinium chlorochromate or pyridinium dichromate. For typical reaction conditions, see PCT publication WO 2020/056090 (Example 6, Step F and Example 8, Step F). Scheme 12 As illustrated in Scheme 13, ketones of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) may exist in equilibrium with their corresponding ketone hydrates (i.e. dihydroxy) of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R 2a X and R 2b Y are OH. The predominance of Formula 1a or Formula 1b is dependent upon several factors, such as environment and structure. For example, in an aqueous environment ketones of Formula 1a can react with water to give ketone hydrates (also known as 1,1-geminal diols) of Formula 1b. Conversion back to the keto-form can usually be achieved by treatment with a dehydrating agent such as magnesium sulfate or molecular sieves. When the ketone moiety is in close proximity to an electron- withdrawing group, such as when R 1 is a trifluoromethyl group, the equilibrium typically favors the dihydrate form. In these cases, conversion back to the keto-form may require a strong dehydrating agent, such as phosphorus pentoxide (P 2 O 5 ). For reaction conditions see, for example, Eur. J. Org. Chem. 2013, 3658-3661; and Chemical Communications 2013, 49(95), 11133-11148, and references cited therein. Scheme 13 As shown in Scheme 14, ketones of Formula 1a may also exist in equilibrium with their hemiketals, hemithioketals and hemiaminals of Formula 1b 1 (i.e. Formula 1b wherein R 2b Y is OH and R 2a is other than H) along with their ketals, thioketals aminals of Formula 1b wherein R 2a and R 2b are other than H. Compounds of Formula 1b 1 can be prepared by reacting a compound of Formula 1a with a compound of formula R 2a X-H (e.g., alcohols for X being O, thiols for X being S or amines for X being NR 4a ), usually in the presence of a catalyst, such as a Bronsted (i.e. protic) acid or Lewis acid (e.g. BF 3 ), (see, for example, Master Organic Chemistry (Online), On Acetals and Hemiacetals, May 28, 2010, www.masterorganic- chemistry.com/2010/05/28/on-acetals-and-hemiacetals). In a subsequent step, compounds of Formula 1b1 can be treated with a compound of formula R 2b Y-H (e.g., alcohols for Y being O, thiols for Y being S or amines for Y being NR 4b ) under dehydrating conditions, or other means of water removal that will drive the equilibrium in the reaction to the right, to provide compounds of Formula 1b wherein R 2a and R 2b are other than H. Alternatively, ketones of Formula 1a can initially be treated with two equivalents (or an excess amount) of an alcohol, thiol or amine typically in the presence of a catalyst together with a dehydrating agent to provide compounds of Formula 1b directly (see, for example, the preparation of dimethylketals using methanol and trimethyl orthoformate in US 6,350,892). Scheme 14 As shown in Scheme 15, cyclic ketals of Formula 1b 2 (i.e. Formula 1b wherein X and Y are O, and R 2a and R 2b are taken together to form a 5- to 7-membered ring) can be prepared by treating the corresponding ketones of Formula 1a with haloalcohols (e.g., 2-chloroethanol or 2- bromopropanol) in the presence of a base such as potassium carbonate or potassium tert-butoxide and in as solvent such as acetonitrile or N,N-dimethylformamide. For reaction conditions see, Organic Letters 20068(17), 3745-3748, and PCT publication WO 2020/056090 (Example 2). Scheme 15 The method of Scheme 15 is also useful for preparing cyclic ketals starting from the corresponding ketone hydrate intermediate of Formula 5. Scheme 16 illustrates a specific example wherein the ketone hydrate of Formula 5a (i.e. Formula 5 wherein A is OCH 2 , R 2a X and R 2b Y are OH and R 1 is CF 3 ) is reacted with 2-chloroethanol in the presence of potassium carbonate in acetonitrile to provide a compound of Formula 5b (i.e. Formula 5 wherein A is OCH 2 , X and Y are O, R 2a and R 2b are taken together to form a 5-membered ring and R 1 is CF 3 ). The method of Scheme 16 is illustrated in present Example 1, Step C. Scheme 16 As shown in Scheme 17, Compounds of Formula 1b 3 (i.e. compounds of Formula 1b wherein A is A 1 -A 2 -CR 5a R 5b ) wherein A 1 is N(R 6 ), O or S and A 2 is a direct bond, or wherein A 1 is CR 5a R 5b and A 2 is N(R 6 ), O or S can be prepared by reacting compounds of Formula 16 wherein A 1 is O, S or N(R 6 ) and A 2 is a direct bond, or where A 1 is CR 5a R 5b and A 2 is O, S or N(R 6 ) with compounds of Formula 17 wherein L b is a leaving group (e.g., mesylate, triflate tosylate). The reaction is typically run in a solvent such as N,N-dimethylformamide or dimethyl sulfoxide with a base such as cesium or potassium carbonate or sodium hydride at temperatures between about 20 to 80 °C. The method of Scheme 17 is illustrated in PCT application WO 2020/056090 (Example 4, Step D). Scheme 17 Compounds of Formula 17 can be prepared using commercial precursors and known methods. For example, as shown in Scheme 18, compounds of Formula 17a (i.e. Formula 17 wherein R 5a and R 5b are H, X and Y are O and R 2a and R 2b are taken together to form a 5- membered ring) can be prepared by reacting compounds of Formula 18 with haloalcohols (e.g., 2-chloroethanol or 3-bromopropanol) under basic conditions (e.g., potassium tert-butoxide in a solvent such as N,N-dimethylformamide or tetrahydrofuran) to provide compounds of Formula 19. A variety of methods are disclosed in the chemical literature for the conversion of ketones to cyclic ketals and can be readily adapted to prepare compounds of Formula 19 (see, for example, G. Hilgetag and A. Martini, Ed., Preparative Organic Chemistry, pp 381-387: Wiley, New York, 1972, and references sited therein; also see PCT application WO 2020/056090, Example 4, Step A). The ester moiety of the resulting cyclic ketal of Formula 19 can be reduced to the corresponding alcohol of Formula 20 by standard methods known to one skilled in the art (PCT publication WO 2020/056090, Example 4, Step B illustrates a typical procedure). The hydroxy moiety in the compounds of Formula 20 can then be converted to a variety of L b groups to provide compounds of Formula 17a. For example, a mesylate or tosylate group can be installed by treating the alcohol with methanesulfonyl chloride (mesyl chloride) or 4-toluenesulfonyl chloride (tosyl chloride) in the presence of a base such as triethylamine at a temperature between about 0 to 40 °C and in a solvent such as dichloromethane. A triflate group can be installed by treating the alcohol with triflic anhydride (CF 3 SO 2 ) 2 O as illustrated in PCT publication WO 2020/056090 (Example 4, Step C). Compounds of Formula 18 are known and can be prepared by methods known to one skilled in the art. Scheme 18 Compounds of Formula 1c (i.e. Formula 1 wherein T is T-3 and X is O) can be prepared by reacting a compound of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) wherein A is A 1 -A 2 -CR 5a R 5b and at least one of R 5a and R 5b is H with a compound of Formula 21 in the presence of a base, as illustrated in Scheme 19. Suitable bases include cesium or potassium carbonate in a solvent such as N,N-dimethylformamide or dimethyl sulfoxide at temperatures from about 20 to 80 °C. In some cases, the method of Scheme 19 results in a mixture of O-alkylated product (typically as a mixture of (E)- and (Z)-isomers), along with C-alkylated product. Purification can be achieved using standard techniques such as column chromatography (see Magnetic Resonance in Chemistry 1991, 29, 675-678). Compounds of Formula 21 are commercially available and can be easily synthesized by general methods known to one skilled in the art. Scheme 19 The method of Scheme 19 is also useful for preparing compounds of Formula 1c starting from the corresponding ketone hydrates. Scheme 20 illustrates a specific example where a ketone hydrate of Formula 1b 4 (i.e. Formula 1b wherein L is CH 2 , J is phenyl, A is OCH 2 , R 2a X and R 2b Y are OH and R 1 is CF 3 ) is reacted with iodoethane in the presence of cesium carbonate in dimethyl sulfoxide at a temperature between about 25 to 75 °C to provide a compound of Formula 1c 1 (i.e. Formula 1c wherein L is CH 2 , J is phenyl, A is O, R 2d is H, XR 2c is OCH 2 CH 3 and R 1 is CF 3 ). PCT publication WO 2020/056090, Example 5, illustrates the method of Scheme 20. Scheme 20 The method of Scheme 20 can also be performed starting from the corresponding ketone hydrate of Formula 5a (i.e. Formula 5 wherein A is OCH 2 , R 2a X and R 2b Y are OH and R 1 is CF 3 ), as shown in Scheme 21. For reaction conditions, see present Example 4, Step A. Scheme 21 One skilled in the art will recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents. In particular, certain R 9 substituents attached to the G ring may be obtained via functional group interconversion reactions. For example, as shown in Scheme 22, compounds of Formula 1d (i.e. Formula 1 wherein the G ring is substituted with R 9 , and R 9 is -(CR 11a R 11b )mR 9a and R 9a is alkylcarbonyloxy, alkenylcarbonyloxy, cycloalkylcarbonyloxy, alkoxycarbonyloxy, and the like) can be prepared by reacting a carboxylic acid of Formula 22 with an alcohol of Formula 23. The reaction proceeds via activation of the carboxylic acid of Formula 22 followed by coupling with the alcohol of Formula 23. Activation of the carboxylic acid takes place with the aid of a coupling reagent, or alternatively by conversion of the carboxylic acid to the acid halide. For example, compounds of Formulae 23 and 22 can be reacted in the presence of a carbodiimide coupling reagent, such as N,N'-dicyclehexylcarbodiimide (DCC), N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide (EDC) or N,N'-diisopropylcarbodimide (DIC). In some instances, addition of a catalyst such as N,N-dimethyl-4-pyridinamine (DMAP) can aid in reducing the formation of undesired products (e.g., N-acylurea side products). A wide variety of other methods are available for formation of esters from carboxylic acids and alcohols, including use of coupling reagents such as benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP ®), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa- fluorophosphate (HBTU). The reaction is typically run in a polar aprotic solvent such as N,N-dimethylformamide, tetrahydrofuran or dichloromethane and in the presence of a base such as pyridine, triethylamine or N,N-diisopropylethylamine. In certain instances it can be advantageous to use polymer-supported coupling reagents, such as polymer bound dicyclohexyl carbodiimide (DCC). Alternatively, a carboxylic acid of Formula 22 can be reacted with a halogenating reagent such as thionyl chloride, oxalyl chloride, phosphorus trichloride, phosphorus oxychloride or phosphorus pentachloride in a solvent such as dichloromethane or toluene and optionally in the presence of a catalytic amount of N,N-dimethylformamide to provide the corresponding acid chloride. When using an acid chloride of Formula 22, the coupling step typically includes a base such as triethylamine, N,N-diisopropylethylamine and pyridine (for reaction conditions see Example 4, Step F). A wide variety of synthetic methods are known in the art to enable the formation of esters from carboxylic acids and alcohols; for an extensive review of coupling conditions, including solid-supported strategies, see Natural Product Reports 2015, 32(4), 605-632; Chemical Society Review 2009, 38, 606-631; Chemical Society Review 2014, 00, 1-29; Journal of Saudi Chemical Society 2012, 16, 97-116; Organic Letters 2011, 13(12), 2988-2991; and Tetrahedron 2005, 61, 10827-10852. Scheme 22 General methods useful for preparing compounds of Formula 23 are well known in the art. For example, reduction of ketones using a reducing agent such as lithium aluminum hydride or a borane/tetrahydrofuran complex in an aprotic solvent, analogous to the method described in Scheme 3. For reaction conditions, see present Example 1, Step G; Example 2, Step A; and Example 4, Step E. Carboxylic acids of Formula 22 are commercially available and can be prepared by known literature methods. Scheme 23 illustrates a specific example of the general method of Scheme 22 for the preparation of a compound of Formula 1d 1 (i.e. Formula 1d wherein G is pyrazole, L is CH 2 , J is phenyl and R 9 is cyclopentyl-C(=O)OCH 2 ). Present Example 1, Step H illustrates the method of Scheme 23. Scheme 23 T One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described above wherein W is O can be converted to the corresponding thiolates wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4- methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson’s reagent). Reactions of this type are well-known in the chemistry literature, see, for example, Heterocycles 1995, 40, 271- 278; Journal of Medicinal Chemistry 2008, 51, 8124-8134; Journal of Medicinal Chemistry 1990, 33, 2697-706; Synthesis 1989, (5), 396-3977; J. Chem. Soc., Perkin Trans. 1, 1988, 1663-1668; Tetrahedron 198844, 3025-3036; and Journal of Organic Chemistry 198853(6), 1323-1326. For relevant reaction conditions, see present Example 3. It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula 1. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other examples or steps. Ambient or room temperature is defined as about 20-25 °C. Unless otherwise indicated, the following examples are conducted under a nitrogen atmosphere with stirring. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. MPLC refers to medium pressure liquid chromatography on silica gel. 1H NMR spectra are reported in ppm downfield from tetramethylsilane; “s” means singlet, “d” means doublet, “t” means triplet, “q” means quartet, “m” means multiplet, “br s” means broad singlet, “br d” means broad doublet, “t d” means a triplet of doublets and “q d” means a quartet of doublets. 19 F NMR spectra are reported in ppm using trichlorofluoromethane as the reference. Mass spectra (MS) are reported as the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of H+ (molecular weight of 1) to the molecule, or (M-1) formed by the loss of H+ (molecular weight of 1) from the molecule, observed by using liquid chromatography coupled to a mass spectrometer (LCMS) using either atmospheric pressure chemical ionization (AP+) or electrospray ionization (ESI+). EXAMPLE 1 Preparation of [1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]pheny l]methyl]- 1H-pyrazol-4-yl]methyl cyclopentanecarboxylate (Compound 4) Step A: Preparation of ethyl 4-(2-oxo-2-phenylethoxy)benzoate To a mixture of ethyl 4-hydroxybenzoate (100 g, 0.60 mol) in acetone (3 L) was added portionwise 2-bromo-1-phenylethanone (132 g, 0.66 mol) and potassium carbonate (249 g, 1.80 mol). The reaction mixture was heated at 60 °C for 3 h, and then cooled and filtered, rinsing with acetone (250 mL). The filtrate was concentrated under reduced pressure and the resulting solid was triturated with pentane (500 mL) to provide the title compound as a white solid (159 g). 1 H NMR (CDCl 3 ): δ 8.00-7.99 (d, 4H), 7.64-7.62 (t, 1H), 7.54-7.50 (t, 2H), 6.97-6.94 (d, 2H), 5.35 (s, 2H), 4.37-4.32 (q, 2H), 1.39-1.36 (t, 3H). MS m/z: 284 [M+H] + Step B: Preparation of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate To a mixture of ethyl 2,2,2-trifluoroacetate (31.8 g, 0.22 mol) in tetrahydrofuran (750 mL) was added sodium hydride (60% in oil, 8.94 g, 0.22 mol). After 15 minutes, the reaction mixture was cooled to 0 °C, and then ethyl 4-(2-oxo-2-phenylethoxy)benzoate (i.e. the product of Step A) (53 g, 0.19 mol) was added portionwise. The reaction mixture was heated at 70 °C for 2.5 h, and then cooled to 0 °C and diluted with hydrochloric acid (1 N solution in water, 140 mL). After stirring for 15 minutes, saturated aqueous sodium bicarbonate solution (250 mL) was added, and the resulting mixture was extracted with ethyl acetate (2 x 380 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was triturated with pentane (100 mL) to provide the title compound as an off-white solid (43 g). 1H NMR (DMSO-d 6 ): δ 7.92-7.90 (d, 2H), 7.36 (s, 2H), 7.09-7.07 (d, 2H), 4.30-4.25 (q, 2H), 4.13 (s, 2H), 1.32-1.28 (t, 3H), MS m/z: 295 [M+H] + Step C: Preparation of ethyl 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzoate To a mixture of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate (i.e. the product of Step B) (42 g, 0.14 mol) in N,N-dimethylformamide (80 mL) was added potassium carbonate (58.9 g, 0.43 mol). After 10 minutes, 2-chloroethanol (34.5 g, 0.43 mol) was added dropwise to the reaction mixture and stirring was continued for 16 h. The reaction mixture was cooled to 0 °C and ice-cold water (250 mL) was added. The resulting mixture was extracted with ethyl acetate (2 x 300 mL), and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 1% ethyl acetate in petroleum ether) to provide the title compound as a colorless oil (31 g). 1 H NMR (CDCl 3 ): δ 8.02-7.98 (d, 2H), 6.98-6.94 (d, 2H), 4.38-4.33 (q, 2H), 4.29 (s, 2H), 4.21 (s, 4H), 1.40-1.36 (t, 3H). MS m/z: 321 [M+H] + Step D: Preparation of 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]- benzenemethanol To a mixture of ethyl 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzoate (i.e. the product of Step C) (25 g, 78.1 mmol) in tetrahydrofuran (120 mL) at 0 °C was added lithium aluminum hydride (2 M solution in tetrahydrofuran, 58.5 mL, 117 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 3 h, and then cooled to 0 °C and diluted with ethyl acetate (180 mL) and water (100 mL). The resulting mixture was filtered through a pad of Celite®, rinsing with ethyl acetate (100 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was triturated with petroleum ether to provide the title compound as an off-white solid (20 g). 1 H NMR (DMSO-d 6 ): δ 7.24-7-22 (d, 2H), 6.96-6.93 (d, 2H), 5.08-5.05 (t, 1H), 4.42-4.41 (d, 2H), 4.23-4.11 (m, 6H). Step E: Preparation of 2-[[4-(bromomethyl)phenoxy]methyl]-2-(trifluoromethyl)-1,3- dioxolane To a mixture of 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzenemet hanol (i.e. the product of Step D) (36 g, 0.13 mol) in dichloromethane (300 mL) at 0 °C was added tetrabromomethane (47.1 g, 0.14 mol) and triphenylphosphine (37.3 g, 0.14 mol). The reaction mixture was allowed to warm to room temperature and stirred for 2 h, and then cooled to 0 °C, diluted with ice-cold water (80 mL) and extracted with dichloromethane (2 x 150 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 5% ethyl acetate in petroleum ether) to provide the title compound as a pale-yellow oil (37.2 g). 1 H NMR (CDCl 3 ): δ 7.34-7.31 (d, 2H), 6.92-6.89 (d, 2H), 4.49-4.46 (s, 2H), 4.23-4.20 (m, 6H). Step F: Preparation of ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]- phenyl]methyl]-1H-pyrazole-4-carboxylate To a mixture of ethyl 1H-pyrazole-4-carboxylate (12.3 g, 87.9 mmol) in acetonitrile (220 mL) was added cesium carbonate (57.3 g, 0.18 mol). After 10 minutes, 2-[[4- (bromomethyl)phenoxy]methyl]-2-(trifluoromethyl)-1,3-dioxola ne (i.e. the product of Step E) (30 g, 87.9 mmol) was added to the reaction mixture and stirring was continued for 7 h. The reaction mixture was filtered through a frit funnel, rinsing with acetonitrile (50 mL), and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 15% ethyl acetate in petroleum ether) to provide the title compound as an off-white solid (26.2 g). 1 H NMR (CDCl 3 ): δ 7.92 (s, 1H), 7.81 (s, 1H), 7.22-7.19 (d, 2H), 6.95-6.93 (d, 2H), 5.24 (s, 2H), 4.28-4.26 (q, 2H), 4.23-4.20 (m, 6H), 1.34-1.31 (t, 3H). MS m/z: 401 [M+H] + Step G: Preparation of 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl ]- methyl]-1H-pyrazole-4-methanol To a mixture of ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl ]‐ methyl]-1H-pyrazole-4-carboxylate (i.e. the product of Step F) (30 g, 74.9 mmol) in tetrahydrofuran (200 mL) at 0 °C was added dropwise lithium aluminum hydride (1 M solution in tetrahydrofuran, 112 mL, 112 mmol). The reaction mixture was stirred at 0 °C for 2 h, and then diluted with ethyl acetate (300 mL) and water (200 mL). The resulting mixture was filtered through a pad of Celite®, rinsing with ethyl acetate (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 35% ethyl acetate in petroleum ether) to provide the title compound as a pale yellow solid (24.5 g). 1 H NMR (DMSO-d6): δ 7.53 (s, 1H), 7.35 (s, 1H), 7.20-7.18 (d, 2H), 6.93-6.91 (d, 2H), 5.21 (s, 2H), 4.56 (s, 2H), 4.22-4.20 (m, 6H). MS m/z: 359 [M+H] + Step H: Preparation of [1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]pheny l]- methyl]-1H-pyrazol-4-yl]methyl cyclopentanecarboxylate To a mixture of cyclopentanecarboxylic acid (111 mg, 0.97 mmol) in tetrahydrofuran (10 mL) at 0 °C was added N,N-dimethyl-4-pyridinamine (355 mg, 2.91 mmol), followed by 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (558 mg, 2.91 mmol). The reaction mixture was stirred at 0 °C for 10 minutes, and then 1-[[4-[[2-(trifluoromethyl)-1,3- dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-methanol (i.e. the product of Step G) (350 mg, 0.97 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for 16 h, and then diluted with water (10 mL). The resulting mixture was extracted with ethyl acetate (2 x 20 mL) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 20% ethyl acetate in petroleum ether) to provide the title compound, a compound of the present invention, as a colorless oil (210 mg). 1 H NMR (CDCl 3 ): δ 7.53 (s, 1H), 7.38 (s, 1H), 7.19-7.16 (d, 2H), 6.93-6.90 (d, 2H), 5.21 (s, 2H), 4.97 (s, 2H), 4.22-4.20 (m, 6H), 2.71-2.68 (m, 1H), 1.86-1.53 (m, 8H). MS m/z: 455 [M+H] + EXAMPLE 2 Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-N- methoxy-N-methyl-1H-pyrazole-4-acetamide (Compound 5) Step A: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-methanol To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]‐ methyl]-1H-pyrazole-4-carboxylate (10 g, 26.0 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in tetrahydrofuran (100 mL) at 0 °C was added dropwise lithium aluminum hydride (1 M solution in tetrahydrofuran, 31.2 mL, 31.2 mmol). The reaction mixture was stirred at 0 °C for 1 h, and then diluted with water (1.2 mL) and sodium hydroxide (10% aqueous solution, 2.4 mL), followed by more water (1.2 mL). After stirring for 15 minutes, the mixture was filtered through a pad of Celite® and the filtrate was concentrated under reduced pressure to provide the title compound as an oil (8 g). Step B: Preparation of 4-(chloromethyl)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-pro pen- 1-yl]oxy]phenyl]methyl]-1H-pyrazole To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-methanol (i.e. the product of Step A) (3.0 g, 8.8 mmol) in dichloromethane (30 mL) at 0 °C was added dropwise N,N-dimethylformamide (0.068 mL, 0.88 mmol) and thionyl chloride (1.28 mL, 17.53 mmol). The reaction mixture was heated at 45 °C for 1 h, cooled to room temperature, and then diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as an oil (3 g). 1 H NMR (CDCl 3 ): δ 7.54 (s, 1H), 7.40 (s, 1H), 7.23 (d, 2H), 7.02 (d, 2H), 6.76 (s, 1H), 5.23 (s, 2H), 4.51 (s, 2H), 4.17 (q, 2H), 1.33 (t, 3H) Step C: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-acetonitrile To a mixture of 4-(chloromethyl)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-pro pen-1- yl]oxy]phenyl]methyl]-1H-pyrazole (i.e. the product of Step B) (3.0 g, 8.3 mmol), and trimethylsilyl cyanide (1.66 mL, 12.47 mmol) in acetonitrile (40 mL) was added tetrabutylammonium fluoride solution (1 M solution in tetrahydrofuran, 12.5 mL, 12.5 mmol). After 16 h, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 50 to 55% ethyl acetate in hexanes) to provide the title compound as an oil (2 g). 1 H NMR (CDCl 3 ): δ 7.47 (s, 1H), 7.30 (s, 1H), 7.23 (m, 2H), 7.03 (m, 2H), 6.76 (s, 1H), 5.24 (s, 2H), 4.25-4.15 (m, 2H), 3.56 (s, 2H), 1.32 (t, 3H). MS m/z: 352 [M+H] + Step D: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-acetic acid To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-acetonitrile (i.e. the product of Step C) (1.0 g, 2.9 mmol) in water (5 mL) was added acetic acid (5 mL, 2.9 mmol) and sulfuric acid (5 mL, 2.9 mmol). The reaction mixture was heated at 100 °C for 4 h, and then cooled to room temperature and diluted with water. The resulting mixture was extracted with ethyl acetate, and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as an oil (0.7 g). MS m/z: 371 [M+H] + Step E: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-N-methoxy-N-methyl-1H-pyrazole-4-acetamide To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-acetic acid (i.e. the product of Step D) (150 mg, 0.41 mmol) and N,O- dimethylhydroxylamine hydrochloride (27 mg, 0.45 mmol) in dichloromethane (10 mL) was added propanephosphonic acid anhydride (T3P) (50% in ethyl acetate, 0.18 mL, 0.61 mmol) and triethylamine (0.11 mL, 0.81 mmol). The reaction mixture was stirred for 3 h, and then diluted with water and extracted with dichloromethane. The organic extract was dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 60 to 70% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as an oil (50 mg). 1 H NMR (CDCl 3 ): δ 7.47 (s, 1H), 7.41 (s, 1H), 7.22 (d, 2H), 6.99 (d, 2H), 6.74 (s, 1H), 5.21 (s, 2H), 4.15 (q, 2H), 3.67 (s, 3H), 3.60 (s, 2H), 3.17 (s, 3H), 1.32 (t, 3H). MS m/z: 414 [M+H] + EXAMPLE 3 Preparation of O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-carbothioate (Compound 7) To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-carboxylate (0.2 g, 0.52 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in xylenes (10 mL) was added 2,4-bis(4-methoxy- phenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson's reagent) (0.421 g, 1.04 mmol). The reaction mixture was heated at 150 °C for 16 h, cooled to room temperature and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 25 to 30% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a light yellow oil (0.1 g). 1 H NMR (CDCl 3 ): δ 7.97 (s, 1H), 7.93 (s, 1H), 7.27 (d, 2H), 7.04 (d, 2H), 6.76 (s, 1H), 5.25 (s, 2H), 4.64 (q, 2H), 4.17 (q, 2H), 1.44 (t, 3H), 1.34 (t, 3H). MS m/z: 401 [M+H] + EXAMPLE 4 Preparation of [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phe nyl]methyl]-1H- pyrazol-4-yl]methyl propanoate (Compound 21) Step A: Preparation of ethyl 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl] oxy]benzoate To a mixture of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate (i.e. the product of Example 1, Step B) (7.55 g, 25.7 mmol) in dimethyl sulfoxide (64 mL) was added cesium carbonate (16.8 g, 51.4 mmol) and iodoethane (27.2 g, 0.18 mol). The reaction mixture was heated at 50 °C for 3 h, cooled to room temperature, and then poured into ice-cold water (100 mL). The resulting mixture was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with saturated aqueous sodium chloride solution (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 10% ethyl acetate in hexanes) to give the title compound as a colorless oil (6.96 g). 1 H NMR (CDCl 3 ): δ 8.08-8.05 (m, 2H), 7.10-7.06 (m, 2H), 6.83 (s, 1H), 4.37 (q, 2H), 4.20 (q, 2H), 1.42-1.33 (m, 6H). 19 F NMR (CDCl 3 ): δ – 70.20 (s, 3F). Step B: Preparation of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzene- methanol To a mixture of ethyl 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzoate (i.e. the product of Step A) (12.3 g, 40.4 mmol) in tetrahydrofuran (202 mL) at 0 °C was added dropwise lithium aluminum hydride (2 M solution in tetrahydrofuran, 50.5 mL, 0.10 mol). The reaction mixture was stirred for 1 h, and then water (3.8 mL) was slowly added, followed by sodium hydroxide (15% aqueous solution, 3.8 mL), and more water (11.4 mL). To the resulting mixture was added magnesium sulfate, the mixture was stirred for 15 minutes and then filtered. The filtrate was concentrated under reduced pressure and the resulting material was purified by silica gel chromatography (eluting with 10-50% ethyl acetate in hexanes) to provide the title compound as a yellow oil (9.3 g). 1 H NMR (CDCl 3 ): δ 7.37-7.35 (m, 2H), 7.06-7.02 (m, 2H), 6.80-6.77 (m, 1H), 4.68-4.66 (m, 2H), 4.18 (q, 2H), 1.35 (t, 3H). 19 F NMR (CDCl 3 ): δ – 70.03(s, 3F). Step C: Preparation of 1-(bromomethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1 -yl] oxy]benzene A mixture of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzenem ethanol (i.e. the product of Step B) (9.3 g, 35.5 mmol) and triphenylphosphine (15.8 g, 60.3 mmol) in dichloromethane (236 mL) was cooled to 0 °C, and then N-bromosuccinimide (9.47 g, 53.2 mmol) was added portionwise over 5 minutes. After 30 minutes, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, and the aqueous layer was separated and extracted with dichloromethane. The combined organics were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 0-5% ethyl acetate in hexanes) to provide the title compound as a colorless oil (6.98 g). 1 H NMR (CDCl 3 ): δ 7.42-7.33 (m, 2H), 7.06-6.99 (m, 2H), 6.79-6.76 (m, 1H), 4.49 (s, 2H), 4.18 (q, 2H), 1.34 (t, 3H). 19 F NMR (CDCl 3 ): δ – 70.11(s, 3F). Step D: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]- phenyl]methyl]-1H-pyrazole-4-carboxylate To a mixture of 1-(bromomethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1 -yl]oxy] benzene (i.e. the product of Step C) (6.98 g, 21.5 mmol) in N,N-dimethylformamide (85.9 mL) was added ethyl 1H-pyrazole-4-carboxylate (3.61 g, 25.8 mmol) followed by cesium carbonate (17.5 g, 53.7 mmol). The reaction mixture was heated at 65 °C overnight, and then cooled to room temperature and diluted with water (100 mL) and ethyl acetate (200 mL). The aqueous layer was separated and extracted with ethyl acetate. The combined organics were washed with saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 0-50% ethyl acetate in hexanes) to provide the title compound as a white solid (5.96 g). 1 H NMR (CDCl 3 ): δ 7.94 (s, 1H), 7.86 (s, 1H), 7.29 (m, 2H), 7.05 (m, 2H), 6.78 (q, 1H), 5.28 (s, 2H), 4.27 (q, 2H), 4.17 (q, 2H), 1.30-1.40 (m, 6H). 19 F NMR (CDCl 3 ): δ – 70.13 (s, 3F). Step E: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]- phenyl]methyl]-1H-pyrazole-4-methanol To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]- phenyl]methyl]-1H-pyrazole-4-carboxylate (i.e. the product of Step D) (5.96 g, 15.5 mmol) in tetrahydrofuran (78 mL) at 0 °C was added dropwise lithium aluminum hydride (2 M in tetrahydrofuran, 15.5 mL, 31.0 mmol). The reaction mixture was stirred for 1 h, and then water (1.2 mL) was slowly added, followed by sodium hydroxide (15% aqueous solution, 1.2 mL) and more water (3.6 mL). The reaction mixture was allowed to warm to room temperature, stirred for 15 minutes, and then dried over magnesium sulfate, filtered and concentrated under reduce pressure. The resulting material was purified by silica gel column chromatography to provide the title compound as a white solid (4.52 g). 1 H NMR (CDCl 3 ): δ 7.53 (s, 1H), 7.27-7.22 (m, 3H), 7.03 (d, 2H), 6.75 (s, 1H), 5.25 (s, 2H), 4.57 (d, 2H), 4.17 (q, 2H), 1.58-1.46 (m, 1H), 1.34 (t, 3H). 19 F NMR (CDCl 3 ): δ – 70.09 (s, 3F). MS m/z: 343 [M+H] + Step F: Preparation of [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]- phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-methanol (i.e. the product of Step E) (0.15 g, 0.44 mmol) in dichloromethane (2.2 mL) at 0 °C was added pyridine (0.053 mL, 0.657 mmol) followed by propionyl chloride (0.057 mL, 0.657 mmol). The reaction mixture was stirred for 30 minutes, and then diluted with water and dichloromethane. The aqueous layer was separated and extracted with dichloromethane. The combined organics were washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 10% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a colorless oil (0.167 g). 1 H NMR (CDCl 3 ): δ 7.55 (s, 1H), 7.42 (s, 1H), 7.27-7.22 (m, 2H), 7.03 (d, 2H), 6.76 (q, 1H), 5.24 (s, 2H), 4.98 (s, 2H), 4.17 (q, 2H), 2.31 (q, 2H), 1.34 (t, 3H), 1.12 (t, 3H). 19 F NMR (CDCl 3 ): δ –70.11 (s, 3F). MS m/z: 399 [M+H] + EXAMPLE 5 Preparation of ethyl α-(acetyloxy)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-prope n-1- yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetate (Compound 54) Step A: Preparation of ethyl 2-oxo-2-(1H-pyrazol-4-yl)acetate A mixture of 4-bromo-1H-pyrazole (1.0 g, 6.80 mmol) in tetrahydrofuran (15 mL) was cooled to –78 °C, and then n-butyllithium (1.6 M in hexanes, 6.4 mL, 10.2 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 1 h, and then cooled to –78 °C, and diethyl oxalate (1.4 mL, 10.2 mmol) was added. After 30 minutes, the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 45 to 50% ethyl acetate in hexanes) to provide the title compound as an oil (0.3 g). 1 H NMR (CDCl 3 ): δ 8.40 (s, 2H), 4.41 (q, 2H), 1.42 (t, 3H). MS m/z: 169 [M+H] + Step B: Preparation of 1-(chloromethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen- 1-yl] oxy]benzene A mixture of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzenem ethanol (i.e. the product of Example 4, Step B) (7.0 g, 26.7 mmol) in dichloromethane (70 mL) at 0 °C was added N,N-dimethylformamide (0.21 mL, 2.67 mmol) and thionyl chloride (3.90 mL, 53.39 mmol). The reaction mixture was heated at 45 °C for 1 h, and then cooled to room temperature and diluted with saturated aqueous sodium bicarbonate solution. The resulting mixture was extracted with ethyl acetate (100 mL x 2) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 5-10% ethyl acetate in hexanes) to provide the title compound as a yellow oil (6 g). 1 H NMR (CDCl 3 ): δ 7.33-7.49 (m, 2H), 7.01-7.13 (m, 2H), 6.79 (s, 1H), 4.58 (s, 2H), 4.06-4.30 (m, 2 H), 1.24-1.44 (m, 3H). Step C: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1- yl]oxy]phenyl]methyl]-α-oxo-1H-pyrazole-4-acetate To a mixture 1-(chloromethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen- 1-yl]oxy] benzene (i.e. the product of Step B) (0.50 g, 1.78 mmol) and ethyl 2-oxo-2-(1H-pyrazol-4-yl) acetate (i.e. the product of Step A) (0.359 g, 2.14 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.369 g, 2.67 mmol). The reaction mixture was heated at 70 °C for 4 h, cooled to room temperature, and then diluted with water. The resulting mixture was extracted with ethyl acetate, and the organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 25-30% ethyl acetate in hexanes) to provide the title compound as an oil (0.5 g). 1 H NMR (CDCl 3 ): δ 8.25 (s, 1H), 8.21 (s, 1H), 7.29 (d, 2H), 7.06 (d, 2H), 6.76 (s, 1H), 5.33-5.30 (m, 2H), 4.37 (q, 2H), 4.17 (q, 2H), 1.40 (t, 3H), 1.33 (t, 3H). MS m/z: 413 [M+H] + Step D: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1- yl]oxy]phenyl]methyl]-α-hydroxy-1H-pyrazole-4-acetate To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]‐ methyl]-α-oxo-1H-pyrazole-4-acetate (i.e. the product of Step C) (150 mg, 0.364 mmol) in methanol (10 mL) at 0 °C was added sodium borohydride (0.021 g, 0.546 mmol). After 3 h, the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 50-55% ethyl acetate in hexanes) to provide the title compound as an oil (0.08 g). 1 H NMR (CDCl 3 ): δ 7.53 (s, 1H), 7.40 (s, 1H), 7.21 (d, 2H), 7.00 (d, 2H), 6.75 (s, 1H), 5.21 (s, 2H), 5.18-5.13 (m, 1H), 4.25 (q, 2H), 4.16 (q, 2H), 3.44 (br d, 1H), 1.32 (t, 3H), 1.25 (t, 3H). MS m/z: 415 [M+H] + Step E: Preparation of ethyl α-(acetyloxy)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1- propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetate To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-α-hydroxy-1H-pyrazole-4-acetate (i.e. the product of Step D) (0.10 g, 0.24 mmol) in dichloromethane (10 mL) at 0 °C was added triethylamine (0.05 mL, 0.36 mmol) and acetyl chloride (0.023 g, 0.29 mmol). The reaction mixture was allowed to warm to room temperature, stirred for 1 h, and then diluted with water and extracted with dichloromethane. The organic extracts were dried over sodium sulphate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 20-25% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as an oil (55 mg). 1 H NMR (CDCl 3 ): δ 7.58 (s, 1H), 7.46 (s, 1H), 7.24 (d, 2H), 7.02 (d, 2H), 6.75 (s, 1H), 5.91 (s, 1H), 5.24 (s, 2H), 4.31-4.10 (m, 4H), 2.13 (s, 3H), 1.32 (t, 3H), 1.23 (t, 3H). MS m/z: 457 [M+H] + EXAMPLE 6 Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-N- (2-propen-1-yloxy)-1H-pyrazole-4-carboxamide (Compound 55) Step A: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-carboxylic acid To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-1H-pyrazole-4-carboxylate (1.35 g, 3.51 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in ethanol (12 mL) and tetrahydrofuran (35 mL) was added lithium hydroxide (1 M in water, 6.30 mL, 6.30 mmol). After 2 days, the reaction mixture was concentrated under reduce pressure. The resulting mixture was diluted with water and saturated aqueous sodium bicarbonate solution, and then washed with ethyl acetate (3 x 5 mL). The resulting aqueous layer was acidified with hydrochloric acid (1N) to a pH of about 2, and then extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to provide the title compound as a white solid (1.22 g). 1 H NMR (DMSO-d6): δ 12.33 (br s, 1H), 8.37 (d, 1H), 7.81 (d, 1H), 7.34 (d, 2H), 7.26 (d, 1H), 7.20 (d, 2H), 5.34 (s, 2H), 4.11 (q, 2H), 1.24 (t, 3H). Step B: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]- phenyl]methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboxamid e To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]- 1H-pyrazole-4-carboxylic acid (i.e. the product of Step B) (1.30 g, 3.65 mmol) in N,N- dimethylformamide (10 mL) was added hydroxy-1H-benzotriazole (HOBT) (0.542 g, 4.01 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (0.77 g, 4.01 mmol), triethylamine (0.66 mL, 4.74 mmol) and O-2-propenylhydroxylamine (0.32 g, 4.38 mmol). The reaction mixture was stirred overnight, and then diluted with water (30 mL), and extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were dried over sodium sulfate and filtered. To the filtrate was added Celite® and the resulting mixture was concentrated under reduce pressure, then purified by MPLC (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a solid (1.17 g). 1 H NMR (CDCl 3 ): δ 7.90 (s, 1H), 7.87 (br s, 1H), 7.28-7.26 (m, 2H), 7.05 (d, 2H), 6.76 (d, 1H), 6.04-5.92 (m, 1H), 5.43-5.32 (m, 2H), 5.28 (s, 2H), 4.43 (d, 2H), 4.17 (q, 2H), 1.34 (t, 3H). EXAMPLE 7 Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-N- (2-propen-1-yloxy)-1H-pyrazole-4-carboximidate (Compound 40) A mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]- methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboxamide (i.e. the product of Example 6) (300 mg, 0.73 mmol), triphenylphosphine (0.21 g, 0.80 mmol) and ethanol (0.047 mL, 0.80 mmol) in tetrahydrofuran (1.2 mL) was cooled to 0 °C, and then diethyl azodicarboxylate (DEAD) (0.13 mL, 0.80 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 3 h, and then dichloromethane and Celite® (5 g) were added. The resulting mixture was concentrated under reduce pressure, and then purified by MPLC using a RediSep Gold® column (eluting with a gradient of 10 to 40% ethyl acetate in heptane over 16 minutes) to afford the title compound, a compound of the present invention, as a colorless oil (0.18 g). 1 H NMR (CDCl 3 ): δ 7.71 (s, 1H), 7.59 (s, 1H), 7.26- 7.23 (m, 2H), 7.04-7.02 (m, 2H), 6.76 (d, 1H), 6.06-5.98 (m, 1H), 5.31 (q d, 1H), 5.25 (s, 2H), 5.21 (q d, 1H), 4.50 (t d, 2H), 4.33 (q, 2H), 4.17 (q, 2H), 1.35-1.32 (m, 6H). MS m/z: 440 [M+H] + Formulation/Utility A compound of Formula 1 of this invention (including N-oxides and salts thereof), or a mixture (i.e. composition) comprising the compound with at least one additional fungicidal compound as described in the Summary of the Invention, will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serve as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature. A compound of Formula 1, or mixture thereof, can be formulated in a number of ways, including: (i) the compound of Formula 1 and optionally one or more other biologically active compounds or agents can be formulated separately and applied separately or applied simultaneously in an appropriate weight ratio, e.g., as a tank mix; or (ii) the compound of Formula 1 and optionally one or more other biologically active compounds or agents can be formulated together in the proper weight ratio. Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in-water emulsions, flowable concentrates and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil-in-water emulsion, flowable concentrate and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion. The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (“wettable”) or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or “overcoated”). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation. Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water, but occasionally another suitable medium like an aromatic or paraffinic hydrocarbon or vegetable oil. Spray volumes can range from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake. The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight. Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey. Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N- dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N- methylpyrrolidinone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2- heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and γ- butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2- ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C6-C22), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950. The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as “surface-active agents”) generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents. Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides. Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as N,N-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts. Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides. Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon’s Emulsifiers and Detergents, annual American and International Editions published by McCutcheon’s Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987. Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon’s Volume 2: Functional Materials, annual International and North American editions published by McCutcheon’s Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222. The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, “Agglomeration”, Chemical Engineering, December 4, 1967, pp 147-48, Perry’s Chemical Engineer’s Handbook, 4th Ed., McGraw-Hill, New York, 1963, pp 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S.4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S.3,299,566. One embodiment of the present invention relates to a method for controlling fungal pathogens, comprising diluting the fungicidal composition of the present invention (a compound of Formula 1 formulated with surfactants, solid diluents and liquid diluents or a formulated mixture of a compound of Formula 1 and at least one other fungicide) with water, and optionally adding an adjuvant to form a diluted composition, and contacting the fungal pathogen or its environment with an effective amount of said diluted composition. Although a spray composition formed by diluting with water a sufficient concentration of the present fungicidal composition can provide sufficient efficacy for controlling fungal pathogens, separately formulated adjuvant products can also be added to spray tank mixtures. These additional adjuvants are commonly known as “spray adjuvants” or “tank-mix adjuvants”, and include any substance mixed in a spray tank to improve the performance of a pesticide or alter the physical properties of the spray mixture. Adjuvants can be anionic or nonionic surfactants, emulsifying agents, petroleum-based crop oils, crop-derived seed oils, acidifiers, buffers, thickeners or defoaming agents. Adjuvants are used to enhancing efficacy (e.g., biological availability, adhesion, penetration, uniformity of coverage and durability of protection), or minimizing or eliminating spray application problems associated with incompatibility, foaming, drift, evaporation, volatilization and degradation. To obtain optimal performance, adjuvants are selected with regard to the properties of the active ingredient, formulation and target (e.g., crops, insect pests). The amount of adjuvants added to spray mixtures is generally in the range of about 0.1 % to 2.5% by volume. The application rates of adjuvants added to spray mixtures are typically between about 1 to 5 L per hectare. Representative examples of spray adjuvants include: Adigor ® (Syngenta) 47% methylated rapeseed oil in liquid hydrocarbons, Silwet® (Helena Chemical Company) polyalkyleneoxide modified heptamethyltrisiloxane and Assist® (BASF) 17% surfactant blend in 83% paraffin based mineral oil. One method of seed treatment is by spraying or dusting the seed with a compound of the invention (i.e. as a formulated composition) before sowing the seeds. Compositions formulated for seed treatment generally comprise a film former or adhesive agent. Therefore typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1 and a film former or adhesive agent. Seeds can be coated by spraying a flowable suspension concentrate directly into a tumbling bed of seeds and then drying the seeds. Alternatively, other formulation types such as wetted powders, solutions, suspoemulsions, emulsifiable concentrates and emulsions in water can be sprayed on the seed. This process is particularly useful for applying film coatings on seeds. Various coating machines and processes are available to one skilled in the art. Suitable processes include those listed in P. Kosters et al., Seed Treatment: Progress and Prospects, 1994 BCPC Mongraph No. 57, and references listed therein. For further information regarding the art of formulation, see T. S. Woods, “The Formulator’s Toolbox – Product Forms for Modern Agriculture” in Pesticide Chemistry and Bioscience, The Food–Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. Also see U.S.3,235,361, Col.6, line 16 through Col.7, line 19 and Examples 10-41; U.S.3,309,192, Col.5, line 43 through Col.7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S.2,891,855, Col.3, line 66 through Col.5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, UK, 2000. In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Active ingredient refers to the compounds in Index Table A disclosed herein. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be constructed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Water-soluble and water-dispersible formulations are typically diluted with water to form aqueous compositions before application. Aqueous compositions for direct applications to the plant or portion thereof (e.g., spray tank compositions) typically contain at least about 1 ppm or more (e.g., from 1 ppm to 100 ppm) of the compound(s) of this invention. Seed is normally treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (i.e. from about 0.0001 to 1% by weight of the seed before treatment). A flowable suspension formulated for seed treatment typically comprises from about 0.5 to about 70% of the active ingredient, from about 0.5 to about 30% of a film-forming adhesive, from about 0.5 to about 20% of a dispersing agent, from 0 to about 5% of a thickener, from 0 to about 5% of a pigment and/or dye, from 0 to about 2% of an antifoaming agent, from 0 to about 1% of a preservative, and from 0 to about 75% of a volatile liquid diluent. The compounds of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Ascomycota, Basidiomycota, Zygomycota phyla, and the fungal-like Oomycota class. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include but are not limited to those listed in Table 1-1. For Ascomycetes and Basidiomycetes, names for both the sexual/teleomorph/perfect stage as well as names for the asexual/anamorph/imperfect stage (in parentheses) are listed where known. Synonymous names for pathogens are indicated by an equal sign. For example, the sexual/teleomorph/perfect stage name Phaeosphaeria nodorum is followed by the corresponding asexual/anamorph/imperfect stage name Stagnospora nodorum and the synonymous older name Septoria nodorum. Table 1-1 In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and other related species. By controlling harmful microorganisms, the compounds of the invention are useful for improving (i.e. increasing) the ratio of beneficial to harmful microorganisms in contact with crop plants or their propagules (e.g., seeds, corms, bulbs, tubers, cuttings) or in the agronomic environment of the crop plants or their propagules. Compounds of the invention are useful in treating all plants, plant parts and seeds. Plant and seed varieties and cultivars can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants or seeds (transgenic plants or seeds) are those in which a heterologous gene (transgene) has been stably integrated into the plant's or seed’s genome. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event. Genetically modified plant cultivars which can be treated according to the invention include those that are resistant against one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, cold temperature, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits of, for example, herbicide tolerance, insect-resistance, modified oil profiles or drought tolerance. Treatment of genetically modified plants and seeds with compounds of the invention may result in super-additive or enhanced effects. For example, reduction in application rates, broadening of the activity spectrum, increased tolerance to biotic/abiotic stresses or enhanced storage stability may be greater than expected from just simple additive effects of the application of compounds of the invention on genetically modified plants and seeds. Compounds of this invention are useful in seed treatments for protecting seeds from plant diseases. In the context of the present disclosure and claims, treating a seed means contacting the seed with a biologically effective amount of a compound of this invention, which is typically formulated as a composition of the invention. This seed treatment protects the seed from soil- borne disease pathogens and generally can also protect roots and other plant parts in contact with the soil of the seedling developing from the germinating seed. The seed treatment may also provide protection of foliage by translocation of the compound of this invention or a second active ingredient within the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants genetically transformed to express specialized traits will germinate. Representative examples include those expressing proteins toxic to invertebrate pests, such as Bacillus thuringiensis toxin or those expressing herbicide resistance such as glyphosate acetyltransferase, which provides resistance to glyphosate. Seed treatments with compounds of this invention can also increase vigor of plants growing from the seed. Compounds of this invention and their compositions, both alone and in combination with other fungicides, nematicides and insecticides, are particularly useful in seed treatment for crops including, but not limited to, maize or corn, soybeans, cotton, cereal (e.g., wheat, oats, barley, rye and rice), potatoes, vegetables and oilseed rape. Furthermore, the compounds of this invention are useful in treating postharvest diseases of fruits and vegetables caused by fungi, oomycetes and bacteria. These infections can occur before, during and after harvest. For example, infections can occur before harvest and then remain dormant until some point during ripening (e.g., host begins tissue changes in such a way that infection can progress or conditions become conducive for disease development); also infections can arise from surface wounds created by mechanical or insect injury. In this respect, the compounds of this invention can reduce losses (i.e. losses resulting from quantity and quality) due to postharvest diseases which may occur at any time from harvest to consumption. Treatment of postharvest diseases with compounds of the invention can increase the period of time during which perishable edible plant parts (e.g., fruits, seeds, foliage, stems, bulbs, tubers) can be stored refrigerated or un-refrigerated after harvest, and remain edible and free from noticeable or harmful degradation or contamination by fungi or other microorganisms. Treatment of edible plant parts before or after harvest with compounds of the invention can also decrease the formation of toxic metabolites of fungi or other microorganisms, for example, mycotoxins such as aflatoxins. Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruits, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants. Control of postharvest pathogens which infect the produce before harvest is typically accomplished by field application of a compound of this invention, and in cases where infection occurs after harvest the compounds can be applied to the harvested crop as dips, sprays, fumigants, treated wraps and box liners. The compounds can also be applied using an unmanned aerial vehicle (UAV) for the dispension of the compositions disclosed herein over a planted area. In some embodiments the planted area is a crop-containing area. In some embodiments, the crop is selected from a monocot or dicot. In some embodiments, the crop is selected form rice, corn, barley, sobean, wheat, vegetable, tobacco, tea tree, fruit tree and sugar cane. In some embodiments, the compositions disclosed herein are formulated for spraying at an ultra-low volume. Products applied by drones may use water or oil as the spray carrier. Typical spray volume (including product) used for drone applications globally is 5.0 liters/ha – 100 liters/ha (approximately 0.5-10 gpa). This includes the range of ultra low spray volume (ULV) to low spray volume (LV). Although not common there may be situations where even lower spray volumes could be used as low as 1.0 liter/ha (0.1 gpa). Suitable rates of application for the compounds of this invention (i.e. a fungicidally effective amount) can be influenced by factors such as the plant diseases to be controlled, the plant species to be protected, the population structure of the pathogen to be controlled, ambient moisture and temperature and should be determined under actual use conditions. One skilled in the art can easily determine through simple experimentation the fungicidally effective amount necessary for the desired level of plant disease control. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed. One skilled in the art can easily determine through simple experimentation the application rates for the compounds of this invention, and compositions thereof, needed to provide the desired spectrum of plant protection and control of plant diseases and optionally other plant pests. Compounds of the present invention may also be useful for increasing vigor of a crop plant. This method comprises contacting the crop plant (e.g., foliage, flowers, fruit or roots) or the seed from which the crop plant is grown with a compound of Formula 1 in amount sufficient to achieve the desired plant vigor effect (i.e. biologically effective amount). Typically the compound of Formula 1 is applied in a formulated composition. Although the compound of Formula 1 is often applied directly to the crop plant or its seed, it can also be applied to the locus of the crop plant, i.e. the environment of the crop plant, particularly the portion of the environment in close enough proximity to allow the compound of Formula 1 to migrate to the crop plant. The locus relevant to this method most commonly comprises the growth medium (i.e. medium providing nutrients to the plant), typically soil in which the plant is grown. Treatment of a crop plant to increase vigor of the crop plant thus comprises contacting the crop plant, the seed from which the crop plant is grown or the locus of the crop plant with a biologically effective amount of a compound of Formula 1. Increased crop vigor can result in one or more of the following observed effects: (a) optimal crop establishment as demonstrated by excellent seed germination, crop emergence and crop stand; (b) enhanced crop growth as demonstrated by rapid and robust leaf growth (e.g., measured by leaf area index), plant height, number of tillers (e.g., for rice), root mass and overall dry weight of vegetative mass of the crop; (c) improved crop yields, as demonstrated by time to flowering, duration of flowering, number of flowers, total biomass accumulation (i.e. yield quantity) and/or fruit or grain grade marketability of produce (i.e. yield quality); (d) enhanced ability of the crop to withstand or prevent plant disease infections and arthropod, nematode or mollusk pest infestations; and (e) increased ability of the crop to withstand environmental stresses such as exposure to thermal extremes, suboptimal moisture or phytotoxic chemicals. The compounds of the present invention may increase the vigor of treated plants compared to untreated plants by preventing and/or curing plant diseases caused by fungal plant pathogens in the environment of the plants. In the absence of such control of plant diseases, the diseases reduce plant vigor by consuming plant tissues or sap, or transmiting plant pathogens such as viruses. Even in the absence of fungal plant pathogens, the compounds of the invention may increase plant vigor by modifying metabolism of plants. Generally, the vigor of a crop plant will be most significantly increased by treating the plant with a compound of the invention if the plant is grown in a nonideal environment, i.e. an environment comprising one or more aspects adverse to the plant achieving the full genetic potential it would exhibit in an ideal environment. Of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment comprising plant diseases caused by fungal plant pathogens. Also of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment not comprising plant diseases caused by fungal plant pathogens. Also of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment comprising an amount of moisture less than ideal for supporting growth of the crop plant. Compounds of this invention can also be mixed with one or more other biologically active compounds or agents including fungicides, insecticides, nematicides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Thus the present invention also pertains to a composition comprising a compound of Formula 1 (in a fungicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount) and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of the present invention, one or more other biologically active compounds or agents can be formulated together with a compound of Formula 1, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1, and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession. As mentioned in the Summary of the Invention, one aspect of the present invention is a fungicidal composition comprising (i.e. a mixture or combination of) a compound of Formula 1, an N-oxide, or a salt thereof (i.e. component a), and at least one other fungicide (i.e. component b). Of note is such a combination where the other fungicidal active ingredient has different site of action from the compound of Formula 1. In certain instances, a combination with at least one other fungicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise a fungicidally effective amount of at least one additional fungicidal active ingredient having a similar spectrum of control but a different site of action. Of note is a composition which in addition to the Formula 1 compound of component (a), includes as component (b) at least one fungicidal compound selected from the group consisting of the FRAC-defined mode of action (MOA) classes, including (A) nucleic acids metabolism, (B) cytoskeleton and motor protein, (C) respiration, (D) amino acids and protein synthesis, (E) signal transduction, (F) lipid synthesis or transport and membrane integrity or function, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis, (I) melanin synthesis in cell wall, (P) host plant defense induction, (U) unknown mode of action, (M) chemicals with multi-site activity and (BM) biologicals with multiple modes of action. FRAC-recognized or proposed target sites of action along with their FRAC target site codes belonging to the above MOA classes are (A1) RNA polymerase I, (A2) adenosine deaminase, (A3) DNA/RNA synthesis (proposed), (A4) DNA topoisomerase type II (gyrase), (B1)-(B3) ß- tubulin assembly in mitosis, (B4) cell division (unknown site), (B5) delocalization of spectrin- like proteins, (B6) actin/myosin/fimbrin function, (C1) complex I NADH odxido-reductase, (C2) complex II: succinate dehydrogenase, (C3) complex III: cytochrome bc1 (ubiquinol oxidase) at Qo site, (C4) complex III: cytochrome bc1 (ubiquinone reductase) at Qi site, (C5) uncouplers of oxidative phosphorylation, (C6) inhibitors of oxidative phosphorylation, ATP synthase, (C7) ATP production (proposed), (C8) complex III: cytochrome bc1 (ubiquinone reductase) at Qo site, stigmatellin binding sub-site (D1) methionine biosynthesis (proposed), (D2) protein synthesis (ribosome, termination step), (D3) protein synthesis (ribosome, initiation step), (D4) protein synthesis (ribosome, initiation step), (D5) protein synthesis (ribosome, elongation step), (E1) signal transduction (mechanism unknown), (E2)-(E3) MAP/histidine kinase in osmotic signal transduction, (F2) phospholipid biosynthesis, methyl transferase, (F3) cell peroxidation (proposed), (F4) cell membrane permeability, fatty acids (proposed), (F6) microbial disrupters of pathogen cell membranes, (F7) cell membrane disruption, (F8) ergosterol binding, (F9) lipid homeostasis and transfer/storage, (G1) C14-demethylase in sterol biosynthesis, (G2) ∆14- reductase and ∆8→∆7-isomerase in sterol biosynthesis, (G3) 3-keto reductase, C4-demethylation, (G4) squalene epoxidase in sterol biosynthesis, (H4) chitin synthase, (H5) cellulose synthase, (I1) reductase in melanin biosynthesis, (I2) dehydratase in melanin biosynthesis, (I3) polyketide synthase in melanin biosynthesis, (P1)-(P3) salicylate-related, (P4) polysaccharide elicitors, (P5) anthraquinone elicitors, (P6) microbial elicitors, (P7) phosphonates, (BM01) plant extract, and (BM02) microbial, living microbes or extract, metabolites. Of note is a composition which in addition to the Formula 1 compound of component (a), includes as component (b) at least one fungicidal compound selected from the group consisting of the classes (b1) methyl benzimidazole carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide (PA) fungicides; (b5) amine/morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine (AP) fungicides; (b10) N-phenyl carbamate fungicides; (b11) quinone outside inhibitor (QoI) fungicides; (b12) phenylpyrrole (PP) fungicides; (b13) azanaphthalene fungicides; (b14) cell peroxidation inhibitor fungicides; (b15) melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; (b16a) melanin biosynthesis inhibitor- dehydratase (MBI-D) fungicides; (b16b) melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides; (b17) keto reductase inhibitor (KRI) fungicides; (b18) squalene-epoxidase inhibitor fungicides; (b19) polyoxin fungicides; (b20) phenylurea fungicides; (b21) quinone inside inhibitor (QiI) fungicides; (b22) benzamide and thiazole carboxamide fungicides; (b23) enopyranuronic acid antibiotic fungicides; (b24) hexopyranosyl antibiotic fungicides; (b25) glucopyranosyl antibiotic: protein synthesis fungicides; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamideoxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupling fungicides; (b30) organo tin fungicides; (b31) carboxylic acid fungicides; (b32) heteroaromatic fungicides; (b33) phosphonate fungicides; (b34) phthalamic acid fungicides; (b35) benzotriazine fungicides; (b36) benzene-sulfonamide fungicides; (b37) pyridazinone fungicides; (b38) thiophene-carboxamide fungicides; (b39) complex I NADH oxido-reductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) quinone outside inhibitor, stigmatellin binding (QoSI) fungicides; (b46) plant extract fungicides; (b47) cyanoacrylate fungicides; (b48) polyene fungicides; (b49) oxysterol binding protein inhibitor (OSBPI) fungicides; (b50) aryl-phenyl- ketone fungicides; (b51) host plant defense induction fungicides; (b52) multi-site activity fungicides; (b53) biologicals with multiple modes of action; (b54) fungicides other than fungicides of component (a) and components (b1) through (b53); and salts of compounds of (b1) through (b54). Also of note are embodiments wherein component (b) comprises at least one fungicidal compound from each of two different groups selected from (b1) through (b54). Further descriptions of groups (b1) through (b54) are as follows. (b1) “Methyl benzimidazole carbamate (MBC) fungicides” (FRAC code 1) inhibit mitosis by binding to β-tubulin during microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Methyl benzimidazole carbamate fungicides include benzimidazole and thiophanate fungicides. The benzimidazoles include benomyl, carbendazim, fuberidazole and thiabendazole. The thiophanates include thiophanate and thiophanate-methyl. (b2) “Dicarboximide fungicides” (FRAC code 2) inhibit a mitogen-activated protein (MAP)/histidine kinase in osmotic signal transduction. Examples include chlozolinate, dimethachlone, iprodione, procymidone and vinclozolin. (b3) “Demethylation inhibitor (DMI) fungicides” (FRAC code 3) (Sterol Biosynthesis Inhibitors (SBI): Class I) inhibit C14-demethylase, which plays a role in sterol production. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. DMI fungicides are divided between several chemical classes: piperazines, pyridines, pyrimidines, imidazoles, triazoles and triazolinthiones. The piperazines include triforine. The pyridines include buthiobate, pyrifenox, pyrisoxazole and (αS)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4- isoxazolyl]-3- pyridinemethanol. The pyrimidines include fenarimol, nuarimol and triarimol. The imidazoles include econazole, imazalil, oxpoconazole, pefurazoate, prochloraz and triflumizole. The triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, uniconazole-P, α-(1-chlorocyclopropyl)-α-[2-(2,2- dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2- (2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)- 2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2 ,4-triazole-3-thione and rel-1- [[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiran yl]methyl]-5-(2-propen-1-ylthio)- 1H-1,2,4-triazole. The triazolinthiones include prothioconazole. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides - Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258. (b4) “Phenylamide fungicides” (FRAC code 4) are specific inhibitors of RNA polymerase in Oomycete fungi. Sensitive fungi exposed to these fungicides show a reduced capacity to incorporate uridine into rRNA. Growth and development in sensitive fungi is prevented by exposure to this class of fungicide. Phenylamide fungicides include acylalanine, oxazolidinone and butyrolactone fungicides. The acylalanines include benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl and metalaxyl-M (also known as mefenoxam). The oxazolidinones include oxadixyl. The butyrolactones include ofurace. (b5) “Amine/morpholine fungicides” (FRAC code 5) (SBI: Class II) inhibit two target sites within the sterol biosynthetic pathway, Δ 8 →Δ 7 isomerase and Δ14 reductase. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Amine/morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine and spiroketal-amine fungicides. The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin and piperalin. The spiroketal-amines include spiroxamine. (b6) “Phospholipid biosynthesis inhibitor fungicides” (FRAC code 6) inhibit growth of fungi by affecting phospholipid biosynthesis. Phospholipid biosynthesis fungicides include phophorothiolate and dithiolane fungicides. The phosphorothiolates include edifenphos, iprobenfos and pyrazophos. The dithiolanes include isoprothiolane. (b7) “Succinate dehydrogenase inhibitor (SDHI) fungicides” (FRAC code 7) inhibit complex II fungal respiration by disrupting a key enzyme in the Krebs Cycle (TCA cycle) named succinate dehydrogenase. Inhibiting respiration prevents the fungus from making ATP, and thus inhibits growth and reproduction. SDHI fungicides include phenylbenzamide, phenyloxoethylthiophene amide, pyridinylethylbenzamide, furan carboxamide, oxathiin carboxamide, thiazole carboxamide, pyrazole-4-carboxamide, N-cyclopropyl-N-benzyl-pyrazole carboxamide, N-methoxy-(phenyl-ethyl)-pyrazole carboxamide, pyridine carboxamide and pyrazine carboxamide fungicides. The phenylbenzamides include benodanil, flutolanil and mepronil. The phenyloxoethylthiophene amides include isofetamid. The pyridinylethylbenzamides include fluopyram. The furan carboxamides include fenfuram. The oxathiin carboxamides include carboxin and oxycarboxin. The thiazole carboxamides include thifluzamide. The pyrazole-4-carboxamides include benzovindiflupyr, bixafen, flubeneteram (provisional common name, Registry Number 1676101-39-5), fluindapyr, fluxapyroxad, furametpyr, inpyrfluxam, isopyrazam, penflufen, penthiopyrad, pyrapropoyne (provisional common name, Registry Number 1803108-03-3), sedaxane and N-[2-(2,4-dichlorophenyl)-2- methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazo le-4-carboxamide. The N- cyclopropyl-N-benzyl-pyrazole carboxamides include isoflucypram. The N-methoxy-(phenyl- ethyl)-pyrazole carboxamides include pydiflumetofen. The pyridine carboxamides include boscalid. The pyrazine carboxamides include pyraziflumid. (b8) “Hydroxy-(2-amino-)pyrimidine fungicides” (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol and ethirimol. (b9) “Anilinopyrimidine fungicides” (FRAC code 9) are proposed to inhibit biosynthesis of the amino acid methionine and to disrupt the secretion of hydrolytic enzymes that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil. (b10) “N-Phenyl carbamate fungicides” (FRAC code 10) inhibit mitosis by binding to β- tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Examples include diethofencarb. (b11) “Quinone outside inhibitor (QoI) fungicides” (FRAC code 11) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Oxidation of ubiquinol is blocked at the “quinone outside” (Qo) site of the cytochrome bc 1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone outside inhibitor fungicides include methoxyacrylate, methoxyacetamide, methoxycarbamate, oximinoacetate, oximinoacetamide and dihydrodioxazine fungicides (collectively also known as strobilurin fungicides), and oxazolidinedione, imidazolinone and benzylcarbamate fungicides. The methoxyacrylates include azoxystrobin, coumoxystrobin, enoxastrobin (also known as enestroburin), flufenoxystrobin, picoxystrobin and pyraoxystrobin. The methoxyacetamides include mandestrobin. The methoxy- carbamates include pyraclostrobin, pyrametostrobin and triclopyricarb. The oximinoacetates include kresoxim-methyl and trifloxystrobin. The oximinoacetamides include dimoxystrobin, fenaminstrobin, metominostrobin and orysastrobin. The dihydrodioxazines include fluoxastrobin. The oxazolidinediones include famoxadone. The imidazolinones include fenamidone. The benzylcarbamates include pyribencarb. (b12) “Phenylpyrrole fungicides” (FRAC code 12) inhibit a MAP/histidine kinase associated with osmotic signal transduction in fungi. Fenpiclonil and fludioxonil are examples of this fungicide class. (b13) “Azanaphthalene fungicides” (FRAC code 13) are proposed to inhibit signal transduction by a mechanism which is as yet unknown. They have been shown to interfere with germination and/or appressorium formation in fungi that cause powdery mildew diseases. Azanaphthalene fungicides include aryloxyquinolines and quinazolinones. The aryloxyquinolines include quinoxyfen. The quinazolinones include proquinazid. (b14) “Lipid peroxidation inhibitor fungicides” (FRAC code 14) are proposed to inhibit lipid peroxidation which affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes such as respiration and melanin biosynthesis. Cell peroxidation fungicides include aromatic hydrocarbon and 1,2,4-thiadiazole fungicides. The aromatic hydrocarboncarbon fungicides include biphenyl, chloroneb, dicloran, quintozene, tecnazene and tolclofos-methyl. The 1,2,4-thiadiazoles include etridiazole. (b15) “Melanin biosynthesis inhibitors-reductase (MBI-R) fungicides” (FRAC code 16.1) inhibit the naphthal reduction step in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-reductase fungicides include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. The isobenzofuranones include fthalide. The pyrroloquinolinones include pyroquilon. The triazolobenzothiazoles include tricyclazole. (b16a) “Melanin biosynthesis inhibitors-dehydratase (MBI-D) fungicides” (FRAC code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-dehydratase fungicides include cyclopropanecarboxamide, carboxamide and propionamide fungicides. The cyclopropanecarboxamides include carpropamid. The carboxamides include diclocymet. The propionamides include fenoxanil. (b16b) “Melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides” (FRAC code 16.3) inhibit polyketide synthase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-polyketide synthase fungicides include trifluoroethylcarbamate fungicides. The trifluoroethylcarbamates include tolprocarb. (b17) “Sterol Biosynthesis Inhibitor (SBI): Class III fungicides (FRAC code 17) inhibit 3- keto reductase during C4-demethylation in sterol production. Keto reductase inhibitor fungicides (also known as Sterol Biosynthesis Inhibitors (SBI): Class III) include hydroxyanilides and amino-pyrazolinones. Hydroxyanilides include fenhexamid. Amino-pyrazolinones include fenpyrazamine. Quinofumelin (provisional common name, Registry Number 861647-84-9) and ipflufenoquin (provisional common name, Registry Number 1314008-27-9) are also believed to be keto reductase inhibitor fungicides. (b18) “Squalene-epoxidase inhibitor fungicides” (FRAC code 18) (SBI: Class IV) inhibit squalene-epoxidase in the sterol biosynthesis pathway. Sterols such as ergosterol are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include thiocarbamate and allylamine fungicides. The thiocarbamates include pyributicarb. The allylamines include naftifine and terbinafine. (b19) “Polyoxin fungicides” (FRAC code 19) inhibit chitin synthase. Examples include polyoxin. (b20) “Phenylurea fungicides” (FRAC code 20) are proposed to affect cell division. Examples include pencycuron. (b21) “Quinone inside inhibitor (QiI) fungicides” (FRAC code 21) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. Reduction of ubiquinone is blocked at the “quinone inside” (Qi) site of the cytochrome bc 1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone inside inhibitor fungicides include cyanoimidazole, sulfamoyltriazole and picolinamide fungicides. The cyanoimidazoles include cyazofamid. The sulfamoyltriazoles include amisulbrom. The picolinamides include fenpicoxamid (Registry Number 517875-34-2). (b22) “Benzamide and thiazole carboxamide fungicides” (FRAC code 22) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. The benzamides include toluamides such as zoxamide. The thiazole carboxamides include ethylaminothiazole carboxamides such as ethaboxam. (b23) “Enopyranuronic acid antibiotic fungicides” (FRAC code 23) inhibit growth of fungi by affecting protein biosynthesis. Examples include blasticidin-S. (b24) “Hexopyranosyl antibiotic fungicides” (FRAC code 24) inhibit growth of fungi by affecting protein biosynthesis. Examples include kasugamycin. (b25) “Glucopyranosyl antibiotic: protein synthesis fungicides” (FRAC code 25) inhibit growth of fungi by affecting protein biosynthesis. Examples include streptomycin. (b26) “Glucopyranosyl antibiotic fungicides” (FRAC code U18, previously FRAC code 26 reclassified to U18) are proposed to inhibit trehalase and inositol biosynthesis. Examples include validamycin. (b27) “Cyanoacetamideoxime fungicides (FRAC code 27) include cymoxanil. (b28) “Carbamate fungicides” (FRAC code 28) are considered multi-site inhibitors of fungal growth. They are proposed to interfere with the synthesis of fatty acids in cell membranes, which then disrupts cell membrane permeability. Iodocarb, propamacarb and prothiocarb are examples of this fungicide class. (b29) “Oxidative phosphorylation uncoupling fungicides” (FRAC code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibiting respiration prevents normal fungal growth and development. This class includes 2,6-dinitroanilines such as fluazinam, and dinitrophenyl crotonates such as dinocap, meptyldinocap and binapacryl. (b30) “Organo tin fungicides” (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide. (b31) “Carboxylic acid fungicides” (FRAC code 31) inhibit growth of fungi by affecting deoxyribonucleic acid (DNA) topoisomerase type II (gyrase). Examples include oxolinic acid. (b32) “Heteroaromatic fungicides” (FRAC code 32) are proposed to affect DNA/ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazoles and isothiazolones. The isoxazoles include hymexazole and the isothiazolones include octhilinone. (b33) “Phosphonate fungicides” (FRAC code P07, previously FRAC code 33 reclassified to P07) include phosphorous acid and its various salts, including fosetyl-aluminum. (b34) “Phthalamic acid fungicides” (FRAC code 34) include teclofthalam. (b35) “Benzotriazine fungicides” (FRAC code 35) include triazoxide. (b36) “Benzene-sulfonamide fungicides” (FRAC code 36) include flusulfamide. (b37) “Pyridazinone fungicides” (FRAC code 37) include diclomezine. (b38) “Thiophene-carboxamide fungicides” (FRAC code 38) are proposed to affect ATP production. Examples include silthiofam. (b39) “Complex I NADH oxidoreductase inhibitor fungicides” (FRAC code 39) inhibit electron transport in mitochondria and include pyrimidinamines such as diflumetorim, pyrazole- 5-carboxamides such as tolfenpyrad, and quinazoline such as fenazaquin. (b40) “Carboxylic acid amide (CAA) fungicides” (FRAC code 40) inhibit cellulose synthase which prevents growth and leads to death of the target fungus. Carboxylic acid amide fungicides include cinnamic acid amide, valinamide carbamate and mandelic acid amide fungicides. The cinnamic acid amides include dimethomorph, flumorph and pyrimorph. The valinamide carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, tolprocarb and valifenalate (also known as valiphenal). The mandelic acid amides include mandipropamid, N- [2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxypheny l]ethyl]-3-methyl-2- [(methylsulfonyl)amino]butanamide and N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3- methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butana mide. (b41) “Tetracycline antibiotic fungicides” (FRAC code 41) inhibit growth of fungi by affecting protein synthesis. Examples include oxytetracycline. (b42) “Thiocarbamate fungicides” (FRAC code M12, previously FRAC code 42 reclassified to M12) include methasulfocarb. (b43) “Benzamide fungicides” (FRAC code 43) inhibit growth of fungi by delocalization of spectrin-like proteins. Examples include pyridinylmethyl benzamides such as fluopicolide and fluopimomide. (b44) “Microbial fungicides” (FRAC code BM02, previously FRAC code 44 reclassified to BM02) disrupt fungal pathogen cell membranes. Microbial fungicides include Bacillus species such as Bacillus amyloliquefaciens strains AP-136, AP-188, AP-218, AP-219, AP-295, QST713, FZB24, F727, MB1600, D747, TJ100 (also called strain 1 BE; known from EP2962568), and the fungicidal lipopeptides which they produce. (b45) “Quinone outside inhibitor, stigmatellin binding (QoSI) fungicides” (FRAC code 45) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase at the “quinone outside” (Qo) site, stigmatellin binding sub-site, of the cytochrome bc 1 complex. Inhibiting mitochondrial respiration prevents normal fungal growth and development. QoSI fungicides include triazolopyrimidylamines such as ametoctradin. (b46) “Plant extract fungicides” (FRAC code 46) cause cell membrane disruption. Plant extract fungicides include terpene hydrocarbons, terpene alcohols and terpen phenols such as the extract from Melaleuca alternifolia (tea tree) and plant oils (mixtures) such as eugenol, geraniol and thymol. (b47) “Cyanoacrylate fungicides” (FRAC code 47) bind to the myosin motor domain and effect motor activity and actin assembly. Cyanoacrylates include fungicides such as phenamacril. (b48) “Polyene fungicides” (FRAC code 48) cause disruption of the fungal cell membrane by binding to ergosterol, the main sterol in the membrane. Examples include natamycin (pimaricin). (b49) “Oxysterol binding protein inhibitor (OSBPI) Fungicides” (FRAC code 49) bind to the oxysterol-binding protein in oomycetes causing inhibition of zoospore release, zoospore motility and sporangia germination. Oxysterol binding fungicides include piperdinylthiazoleisoxazolines such as oxathiapiprolin and fluoxapiprolin. (b50) “Aryl-phenyl-ketone fungicides” (FRAC code 50, previously FRAC code U8 reclassified to 50) inhibit the growth of mycelium in fungi. Aryl-phenyl ketone fungicides include benzophenones such as metrafenone, and benzoylpyridines such as pyriofenone. (b51) “Host plant defense induction fungicides” induce host plant defense mechanisms. Host plant defense induction fungicides include benzothiadiazole (FRAC code P01), benzisothiazole (FRAC code P02), thiadiazole carboxamide (FRAC code P03), polysaccharide (FRAC code P04), plant extract (FRAC code P05), microbial (FRAC code P06) and phosphonate fungicides (FRAC code P07, see (b33) above). The benzothiadiazoles include acibenzolar-S- methyl. The benzisothiazoles include probenazole. The thiadiazole carboxamides include tiadinil and isotianil. The polysaccharides include laminarin. The plant extracts include extract from Reynoutria sachalinensis (giant knotweed). The microbials include Bacillus mycoides isolate J and cell walls of Saccharomyces cerevisiae strain LAS117. (b52) “Multi-site activity fungicides” inhibit fungal growth through multiple sites of action and have contact/preventive activity. Multi-site activity fungicides include copper fungicides (FRAC code M01), sulfur fungicides (FRAC code M02), dithiocarbamate fungicides (FRAC code M03), phthalimide fungicides (FRAC code M04), chloronitrile fungicides (FRAC code M05), sulfamide fungicides (FRAC code M06), multi-site contact guanidine fungicides (FRAC code M07), triazine fungicides (FRAC code M08), quinone fungicides (FRAC code M09), quinoxaline fungicides (FRAC code M10), maleimide fungicides (FRAC code M11) and thiocarbamate (FRAC code M12, see (b42) above) fungicides. Copper fungicides are inorganic compounds containing copper, typically in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). Sulfur fungicides are inorganic chemicals containing rings or chains of sulfur atoms; examples include elemental sulfur. Dithiocarbamate fungicides contain a dithiocarbamate molecular moiety; examples include ferbam, mancozeb, maneb, metiram, propineb, thiram, zinc thiazole, zineb and ziram. Phthalimide fungicides contain a phthalimide molecular moiety; examples include folpet, captan and captafol. Chloronitrile fungicides contain an aromatic ring substituted with chloro and cyano; examples include chlorothalonil. Sulfamide fungicides include dichlofluanid and tolyfluanid. Multi-site contact guanidine fungicides include, guazatine, iminoctadine albesilate and iminoctadine triacetate. Triazine fungicides include anilazine. Quinone fungicides include dithianon. Quinoxaline fungicides include quinomethionate (also known as chinomethionate). Maleimide fungicides include fluoroimide. (b53) “Biologicals with multiple modes of action” include agents from biological origins showing multiple mechanisms of action without evidence of a dominating mode of action. This class of fungicides includes polypeptide (lectin), phenol, sesquiterpene, tritepenoid and coumarin fungicides (FRAC code BM01) such as extract from the cotyledons of lupine plantlets. This class also includes momicrobial fungicides (FRAC code BM02, see (b44) above). (b54) “Fungicides other than fungicides of component (a) and components (b1) through (b53)”; include certain fungicides whose mode of action may be unknown. These include: (b54.1) “phenyl-acetamide fungicides” (FRAC code U06), (b54.2) “guanidine fungicides” (FRAC code U12), (b54.3) “thiazolidine fungicides” (FRAC code U13), (b54.4) “pyrimidinone-hydrazone fungicides” (FRAC code U14), (b54.5) “4-quinolylacetate fungicides” (FRAC code U16), (54.6) “tetrazolyloxime fungicides” (FRAC code U17) and “glucopyranosyl antibiotic fungicides” (FRAC code U18, see (b26) above). The phenyl-acetamides include cyflufenamid. The guanidines include dodine. The thiazolidines include flutianil. The pyrimidinonehydrazones include ferimzone. The 4-quinolylacetates include tebufloquin. The tetrazolyloximes include picarbutrazox. The (b54) class also includes bethoxazin, dichlobentiazox (provisional common name, Registry Number 957144-77-3), dipymetitrone (provisional common name, Registry Number 16114-35-5), flometoquin, neo-asozin (ferric methanearsonate), pyrrolnitrin, tolnifanide (Registry Number 304911-98-6), N'-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphen yl]-N- ethyl-N-methylmethanimidamide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine and 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbam ate. Additional “Fungicides other than fungicides of classes (b1) through (b54)” whose mode of action may be unknown, or may not yet be classified include a fungicidal compound selected from components (b54.7) through (b54.12), as shown below. Component (54.7) relates to (1S)-2,2-bis(4-fluorophenyl)-1-methylethyl N-[[3-(acetyloxy)- 4-methoxy-2-pyridinyl]carbonyl]-L-alaninate (provisional common name florylpicoxamid, Registry Number 1961312-55-9) which is believed to be a Quinone inside inhibitor (QiI) fungicide (FRAC code 21) inhibiting the Complex III mitochondrial respiration in fungi. Component (54.8) relates to 1-[2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-3- methylphenyl]-1,4-dihydro-4-methyl-5H-tetrazol-5-one (provisional common name metyltetraprole, Registry Number 1472649-01-6), which is believed to be a quinone outside inhibitor (QoI) fungicide (FRAC code 45) inhibiting the Complex III mitochondrial respiration in fungi, and is effective against QoI resistant strains. Component (54.9) relates to 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine (provisional common name pyridachlometyl, Registry Number 1358061-55-8), which is believed to be promoter tubulin polymerization, resulting antifungal activity against fungal species belonging to the phyla Ascomycota and Basidiomycota. Component (54.10) relates to (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3- carboxylate (provisional common name aminopyrifen, Registry Number 1531626-08-0) which is believed to inhibit GWT-1 protein in glycosylphosphatidylinositol-anchor biosynthesis in Neurospora crassa. Component (b54.11) relates a compound of Formula b54.11

wherein R b1 and R b3 are each independently halogen; and R b2 is H, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl. Examples of compounds of Formula b54.11 include (b54.11a) methyl N-[[5-[1-(2,6-difluoro-4- formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl] methyl]carbamate, (b54.11b) methyl N-[[5-[1- (4-cyclopropyl-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methyl phenyl]methyl]carbamate, (b54.11c) methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-me thylphenyl]- methyl]carbamate, (b54.11d) methyl N-[[5-[1-(4-cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3- yl]-2-methylphenyl]methyl]carbamate, (b54.11e) methyl N-[[5-[1-[2,6-difluoro-4-(1- methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]c arbamate and (b54.11f) methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol -3-yl]-2- methylphenyl]methyl]carbamate. Compounds of Formula b54.11, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publications WO 2008/124092, WO 2014/066120 and WO 2020/097012. Component (b54.12) relates to a compound of Formula b54.12 wherein R b4 is R b6 is C 2 -C 4 alkoxycarbonyl or C 2 -C 4 haloalkylaminocarbonyl; L is CH 2 or CH 2 O, wherein the atom to the right is connected to the phenyl ring in Formula b54.12; R b5 is ; and R b7 is C 1 -C 3 alkyl, wherein the wavy bond indicates the adjacent double bond is either (Z)- or (E)-configuration, or a mixture thereof. Examples of compounds of Formula b54.12 include (b54.12a) N-(2,2,2-trifluoroethyl)-2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxaz olecarboxamide, (b54.12b) ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]meth yl]-1H-pyrazole-4-carboxylate, (b54.12c) ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phen yl]methyl]-1H- pyrazole-4-carboxylate and (b54.12d) ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2- yl]methoxy]phenyl]methyl]-1H-pyrazole-4-carboxylate. Compounds of Formula b54.12, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publications WO 2008/187553 and WO 2020/056090. Therefore of note is a mixture (i.e. composition) comprising a compound of Formula 1 and at least one fungicidal compound selected from the group consisting of the aforedescribed classes (b1) through (b54), including (b54.7) through (b54.12). Also of note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of particular note is a mixture (i.e. composition) comprising a compound of Formula 1 and at least one fungicidal compound selected from the group of specific compounds listed above in connection with classes (b1) through (b54). Also of particular note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional surfactant selected from the group consisting of surfactants, solid diluents and liquid diluents. Examples of component (b) fungicides include acibenzolar-S-methyl, aldimorph, ametoctradin, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl- M), benodanil, benomyl, benthiavalicarb (including benthiavalicarb-isopropyl), benzovindiflupyr, bethoxazin, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, buthiobate, captafol, captan, carbendazim, carboxin, carpropamid, chloroneb, chlorothalonil, chlozolinate, clotrimazole, copper hydroxide, copper oxychloride, copper sulfate, coumoxystrobin, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole (including diniconazole-M), dinocap, dithianon, dithiolanes, dodemorph, dodine, dipymetitrone, econazole, edifenphos, enoxastrobin (also known as enestroburin), epoxiconazole, etaconazole, ethaboxam, ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenaminstrobin, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, flometoquin, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, flumorph, fluopicolide, fluopimomide, fluopyram, flouroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fthalide, fuberidazole, furalaxyl, furametpyr, guazatine, hexaconazole, hymexazole, imazalil, imibenconazole, iminoctadine albesilate, iminoctadine triacetate, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isofetamid, isoprothiolane, isoflucypram, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandepropamid, mandestrobin, maneb, mepanipyrim, mepronil, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), mefentrifluconazole, metconazole, methasulfocarb, metiram, metominostrobin, metrafenone, miconazole, myclobutanil, naftifine, neo-asozin, nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxathiapiprolin, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, pefurazoate, penconazole, pencycuron, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picarbutrazox, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinconazole, quinofumelin (Registry Number 861647-84-9) quinomethionate, quinoxyfen, quintozene, sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquin, teclofthalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolnifanide, tolprocarb, tolyfluanid, triadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole, triclopyricarb, tridemorph, trifloxystrobin, triflumizole, triforine, trimorphamide, uniconazole, uniconazole-P, validamycin, valifenalate (also known as valiphenal), vinclozolin, zineb, ziram, zoxamide, N-[2-(1S,2R)-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromet hyl)-1- methyl-1H-pyrazole-4-carboxamide, α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)- ethyl]-1H-1,2,4-triazole-1-ethanol, (αS)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4- isoxazolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2- oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)- 2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, rel-1-[[(2R,3S)-3-(2-chlorophenyl)- 2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylth io)-1H-1,2,4-triazole, N-[2-[4-[[3- (4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3 -methyl-2-[(methylsulfonyl)- amino]butanamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphe nyl]ethyl]- 3-methyl-2-[(ethylsulfonyl)amino]butanamide, N'-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5- dimethylphenyl]-N-ethyl-N-methylmethanimidamide, N-[[(cyclopropylmethoxy)amino][6- (difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetam ide, N-[2-(2,4-dichlorophenyl)- 2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyra zole-4-carboxamide, N-(3',4'- difluoro[1,1'-biphenyl]-2-yl)-3-(trifluoromethyl)-2-pyrazine carboxamide, 3-(difluoromethyl)-N- (2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyra zole-4-carboxamide, 5,8-di- fluoro-N-[2-[3-methoxy-4-[[4-(trifluoromethyl)-2-pyridinyl]o xy]phenyl]ethyl]-4-quinazo- linamine, 1-[4-[4-[5R-[(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isox azolyl]-2-thiazolyl]-1- piperdinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] ethanone, 4-fluorophenyl N-[1- [[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)- methoxy]-4-pyrimidinamine, α-(methoxyimino)-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl ]- ethoxy]imino]methyl]benzeneacetamide, and [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2- methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan -3-yl]amino]carbonyl]-3- pyridinyl]oxy]methyl 2-methylpropanoate. Therefore of note is a fungicidal composition comprising as component (a) a compound of Formula 1 (or an N-oxide or salt thereof) and as component (b) at least one fungicide selected from the preceding list. Of particular note are combinations of compounds of Formula 1 (or an N-oxide or salt thereof) (i.e. Component (a) in compositions) with aminopyrifen (Registry Number 1531626-08- 0), azoxystrobin, benzovindiflupyr, bixafen, captan, carpropamid, chlorothalonil, copper hydroxide, copper oxychloride, copper sulfate, cymoxanil, cyproconazole, cyprodinil, dichlobentiazox (Registry Number 957144-77-3), diethofencarb, difenoconazole, dimethomorph, dipymetitrone, epoxiconazole, ethaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapyr, fluopyram, flusilazole, flutianil, flutriafol, fluxapyroxad, folpet, ipflufenoquin (Registry Number 1314008-27-9), iprodione, isofetamid, isoflucypram, isopyrazam, kresoxim- methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl- M/mefenoxam), mefentrifluconazole, metconazole, metrafenone, metyltetraprole (Registry Number 1472649-01-6), myclobutanil, oxathiapiprolin, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyridachlometyl (Registry Number 1358061-55-8), pyraclostrobin, pyrapropoyne (Registry Number 1803108-03-3), pyrimethanil, sedaxane spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, α-(1-chlorocyclopropyl)-α-[2-(2,2- dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, N-[2-(2,4-dichlorophenyl)-2-methoxy- 1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-car boxamide, 3-(difluoromethyl)-N- (2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyra zole-4-carboxamide, 1-[4-[4-[5R- (2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]- 1-piperidinyl]-2-[5-methyl-3- (trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1,1-dimethylethyl N-[6-[[[[(1-methyl-1H-tetrazol- 5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate , 5-fluoro-2-[(4-fluorophenyl)- methoxy]-4-pyrimidinamine, (αS)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4- isox- azolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2- ox- iranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2- oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, and rel-1-[[(2R,3S)-3-(2-chloro- phenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-prope n-1-ylthio)-1H-1,2,4-triazole (i.e. as Component (b) in compositons). Generally preferred for better control of plant diseases caused by fungal plant pathogens (e.g., lower use rate or broader spectrum of plant pathogens controlled) or resistance management are mixtures of a compound of Formula 1, an N-oxide, or salt thereof, with a fungicidal compound selected from the group: amisulbrom, azoxystrobin, boscalid, carbendazim, carboxin, cymoxanil, cyproconazole, difenoconazole, dimethomorph, dimoxystrobin, fenpropimorph, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, fluquinconazole, fluopicolide, fluoxastrobin, flutriafol, fluxapyroxad, ipconazole, ipfentrifluconazole, iprodione, kresoxim-methyl, metalaxyl, mefenoxam, mefentrifluconazole, metconazole, metominostrobin, myclobutanil, paclobutrazole, penflufen, picoxystrobin, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone, sedaxane, silthiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole. Examples of other biologically active compounds or agents with which compounds of this invention can be formulated are: invertebrate pest control compounds or agents such as abamectin, acephate, acetamiprid, acrinathrin, afidopyropen ([(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)o xy]-1,3,4,4a,5,6,6a,12,12a,12b- decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyri dinyl)-2H,11H-naphtho[2,1- b]pyrano[3,4-e]pyran-4-yl]methyl cyclopropanecarboxylate), amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyantraniliprole (3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2- methyl-6-[(methylamino)carbonyl]phenyl]-1H-pyrazole-5-carbox amide), cyclaniliprole (3- bromo-N-[2-bromo-4-chloro-6-[[(1-cyclopropylethyl)amino]carb onyl]phenyl]-1-(3-chloro-2- pyridinyl)-1H-pyrazole-5-carboxamide), cycloxaprid ((5S,8R)-1-[(6-chloro-3-pyridinyl)methyl]- 2,3,5,6,7,8-hexahydro-9-nitro-5,8-epoxy-1H-imidazo[1,2-a]aze pine), cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, flufenoxystrobin (methyl (αE)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-α-(me thoxymethylene)benzene- acetate), fluensulfone (5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]thiazole ), flupiprole (1- [2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methyl-2-prop en-1-yl)amino]-4-[(trifluoro- methyl)sulfinyl]-1H-pyrazole-3-carbonitrile), flupyradifurone (4-[[(6-chloro-3-pyridinyl)- methyl](2,2-difluoroethyl)amino]-2(5H)-furanone), tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, heptafluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)- phenyl]methyl 2,2-dimethyl-3-[(1Z)-3,3,3-trifluoro-1-propen-1-yl]cycloprop anecarboxylate), hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, meperfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl (1R,3S)-3-(2,2-dichloro- ethenyl)-2,2-dimethylcyclopropanecarboxylate), metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, methoxyfenozide, metofluthrin, milbemycin oxime, momfluorothrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl-3-(2- cyano-1-propen-1-yl)-2,2-dimethylcyclopropanecarboxylate), monocrotophos, nicotine, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, pyflubumide (1,3,5- trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[ 2,2,2-trifluoro-1-methoxy-1- (trifluoromethyl)ethyl]phenyl]-1H-pyrazole-4-carboxamide), parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriminostrobin (methyl (αE)- 2-[[[2-[(2,4-dichlorophenyl)amino]-6-(trifluoromethyl)-4-pyr imidinyl]oxy]methyl]-α-(methoxy- methylene)benzeneacetate), pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulfoxaflor, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon and triflumuron; and biological agents including entomopathogenic bacteria, such as Bacillus thuringiensis subsp. aizawai, Bacillus thuringiensis subsp. kurstaki, and the encapsulated delta- endotoxins of Bacillus thuringiensis (e.g., Cellcap, MPV, MPVII); entomopathogenic fungi, such as green muscardine fungus; and entomopathogenic virus including baculovirus, nucleopolyhedro virus (NPV) such as HzNPV, AfNPV; and granulosis virus (GV) such as CpGV. One embodiment of biological agents for mixing with compounds of this disclosure include entomopathogenic bacteria such as Bacillus thuringiensis, and the encapsulated delta-endotoxins of Bacillus thuringiensis such as MVP® and MVPII® bioinsecticides prepared by the CellCap® process (CellCap®, MVP® and MVPII® are trademarks of Mycogen Corporation, Indianapolis, Indiana, USA); entomopathogenic fungi such as green muscardine fungus; and entomopathogenic (both naturally occurring and genetically modified) viruses including baculovirus, nucleopolyhedro virus (NPV) such as Helicoverpa zea nucleopolyhedrovirus (HzNPV), Anagrapha falcifera nucleopolyhedrovirus (AfNPV); and granulosis virus (GV) such as Cydia pomonella granulosis virus (CpGV). General references for these agricultural protectants (i.e. insecticides, fungicides, nematocides, acaricides, herbicides and biological agents) include The Pesticide Manual, 13th Edition, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and The BioPesticide Manual, 2nd Edition, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001. For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1:3000 to about 3000: 1, and more typically between about 1:500 and about 500:1. Of note are compositions where in the weight ratio of component (a) to component (b) is from about 125:1 to about 1:125. With many fungicidal compounds of component (b), these compositions are particularly effective for controlling plant diseases caused by fungal plant pathogens. Of particular note are compositions wherein the weight ratio of component (a) to component (b) is from about 25:1 to about 1:25, or from about 5:1 to about 1:5. One skilled in the art can easily determine through simple experimentation the weight ratios and application rates of fungicidal compounds necessary for the desired spectrum of fungicidal protection and control. It will be evident that including additional fungicidal compounds in component (b) may expand the spectrum of plant diseases controlled beyond the spectrum controlled by component (a) alone. In certain instances, combinations of a compound of this invention with other biologically active (particularly fungicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. When synergism of fungicidal active ingredients occurs at application rates giving agronomically satisfactory levels of fungal control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load. Also in certain instances, combinations of a compound of the invention with other biologically active compounds or agents can result in a less-than-additive (i.e. safening) effect on organisms beneficial to the agronomic environment. For example, a compound of the invention may safen a herbicide on crop plants or protect a beneficial insect species (e.g., insect predators, pollinators such as bees) from an insecticide. Fungicides of note for formulation with compounds of Formula 1 to provide mixtures useful in seed treatment include but are not limited to amisulbrom, azoxystrobin, boscalid, carbendazim, carboxin, cymoxanil, cyproconazole, difenoconazole, dimethomorph, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluquinconazole, fluopicolide, fluoxastrobin, flutriafol, fluxapyroxad, ipconazole, iprodione, metalaxyl, mefenoxam, mefentrifluconazole, metconazole, myclobutanil, paclobutrazole, penflufen, picoxystrobin, prothioconazole, pyraclostrobin, sedaxane, silthiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole. Invertebrate pest control compounds or agents with which compounds of Formula 1 can be formulated to provide mixtures useful in seed treatment include but are not limited to abamectin, acetamiprid, acrinathrin, afidopyropen, amitraz, avermectin, azadirachtin, bensultap, bifenthrin, buprofezin, cadusafos, carbaryl, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorpyrifos, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta- cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenothiocarb, fenoxycarb, fenvalerate, fipronil, flonicamid, flubendiamide, fluensulfone, flufenoxuron, flufiprole, flupyradifurone, fluvalinate, formetanate, fosthiazate, heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, lufenuron, meperfluthrin, metaflumizone, methiocarb, methomyl, methoprene, methoxyfenozide, momfluorothrin, nitenpyram, nithiazine, novaluron, oxamyl, pyflubumide, pymetrozine, pyrethrin, pyridaben, pyriminostrobin, pyridalyl, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor, tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumuron, Bacillus thuringiensis delta-endotoxins, strains of Bacillus thuringiensis and strains of Nucleo polyhydrosis viruses. Compositions comprising compounds of Formula 1 useful for seed treatment can further comprise bacteria and fungi that have the ability to provide protection from the harmful effects of plant pathogenic fungi or bacteria and/or soil born animals such as nematodes. Bacteria exhibiting nematicidal properties may include but are not limited to Bacillus firmus, Bacillus cereus, Bacillius subtiliis and Pasteuria penetrans. A suitable Bacillus firmus strain is strain CNCM I- 1582 (GB-126) which is commercially available as BioNem TM . A suitable Bacillus cereus strain is strain NCMM I-1592. Both Bacillus strains are disclosed in US 6,406,690. Other suitable bacteria exhibiting nematicidal activity are B. amyloliquefaciens IN937a and B. subtilis strain GB03. Bacteria exhibiting fungicidal properties may include but are not limited to B. pumilus strain GB34. Fungal species exhibiting nematicidal properties may include but are not limited to Myrothecium verrucaria, Paecilomyces lilacinus and Purpureocillium lilacinum. Seed treatments can also include one or more nematicidal agents of natural origin such as the elicitor protein called harpin which is isolated from certain bacterial plant pathogens such as Erwinia amylovora. An example is the Harpin-N-Tek seed treatment technology available as N- Hibit TM Gold CST. Seed treatments can also include one or more species of legume-root nodulating bacteria such as the microsymbiotic nitrogen-fixing bacteria Bradyrhizobium japonicum. These inocculants can optionally include one or more lipo-chitooligosaccharides (LCOs), which are nodulation (Nod) factors produced by rhizobia bacteria during the initiation of nodule formation on the roots of legumes. For example, the Optimize® brand seed treatment technology incorporates LCO Promoter Technology TM in combination with an inocculant. Seed treatments can also include one or more isoflavones which can increase the level of root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by enhancing the root uptake of nutrients such as water, sulfates, nitrates, phosphates and metals. Examples of isoflavones include, but are not limited to, genistein, biochanin A, formononetin, daidzein, glycitein, hesperetin, naringenin and pratensein. Formononetin is available as an active ingredient in mycorrhizal inocculant products such as PHC Colonize® AG. Seed treatments can also include one or more plant activators that induce systemic acquired resistance in plants following contact by a pathogen. An example of a plant activator which induces such protective mechanisms is acibenzolar-S-methyl. The following TESTS demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Table A below for compound descriptions. The abbreviation “Cmpd.” stands for “Compound”, and the abbreviation “Ex.” stands for “Example” and is followed by a number indicating in which example the compound is prepared. 19 F NMR spectra are reported in ppm relative to trichlorofluoromethane in CDCl 3 solution unless indicated otherwise. The numerical value reported in the column “MS” is the molecular weight of the highest isotopic abundance positively charged parent ion (M+1) formed by addition of H+ (molecular weight of 1) to the molecule having the highest isotopic abundance, or the highest isotopic abundance negatively charged ion (M–1) formed by loss of H+ (molecular weight of 1). The presence of molecular ions containing one or more higher atomic weight isotopes of lower abundance (e.g., 37Cl, 81Br) is not reported. The reported MS peaks were observed by mass spectrometry using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). INDEX TABLE A

INDEX TABLE Al INDEX TABLE B INDEX TABLE C INDEX TABLE D INDEX TABLE E BIOLOGICAL EXAMPLES OF THE INVENTION General protocol for preparing test suspensions for Test A: the test compounds were first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant PEG400 (polyhydric alcohol esters). The resulting test suspensions were then used in Test A. TEST A The test solution was sprayed to the point of run-off on soybean seedlings. The following day the seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi (the causal agent of Asian soybean rust) and incubated in a saturated atmosphere at 22 °C for 24 h and then moved to a growth chamber at 22 °C for 8 days, after which time visual disease ratings were made. In addition to Test A, some compounds of this invention were also sprayed on wheat seedlings inoculated with a spore suspension of Puccinia recondita f. sp. tritici (the causal agent of wheat leaf rust) 24 h after treatment. The wheat seedlings were incubated in a saturated atmosphere at 20 °C for 24 h, and then moved to a growth chamber at 20 °C for 7 days, after which time disease ratings were made. The compounds tested did not show noticeable activity against this pathogen under the test conditions at the application rates tested. Results for Test A are given in Table A below. A rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls). TABLE A




 
Previous Patent: COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION

Next Patent: PULSE-ECHO GUIDED ULTRASOUND ABLATION; AN ACOUSTIC METHOD FOR SENSING ULTRASOUND ABLATION CATHETER O...